<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004514.pub2" GROUP_ID="DEMENTIA" ID="707703041409415658" MERGED_FROM="" MODIFIED="2008-12-01 16:45:35 +0100" MODIFIED_BY="Helen Collins" REVIEW_NO="127" REVMAN_SUB_VERSION="5.0.17" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2008-12-01 16:45:35 +0100" MODIFIED_BY="Helen Collins">
<TITLE MODIFIED="2008-05-13 10:59:29 +0100" MODIFIED_BY="Helen Collins">Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people</TITLE>
<CONTACT MODIFIED="2008-12-01 16:45:35 +0100" MODIFIED_BY="Helen Collins"><PERSON ID="13050" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Reem</FIRST_NAME><LAST_NAME>Malouf</LAST_NAME><POSITION>Systematic Reviewer and Clinical Trials Coding Specialist</POSITION><EMAIL_1>reemmalouf@yahoo.com</EMAIL_1><ADDRESS><ORGANISATION>Cochrane Dementia and Cognitive Improvement Group</ORGANISATION><ADDRESS_1>John Radcliffe Hospital (4th Floor, Room 4401C)</ADDRESS_1><ADDRESS_2>Headington</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01865 234306</PHONE_1><FAX_1>01865 221354</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-12-01 16:45:35 +0100" MODIFIED_BY="Helen Collins"><PERSON ID="13050" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Reem</FIRST_NAME><LAST_NAME>Malouf</LAST_NAME><POSITION>Systematic Reviewer and Clinical Trials Coding Specialist</POSITION><EMAIL_1>reemmalouf@yahoo.com</EMAIL_1><ADDRESS><ORGANISATION>Cochrane Dementia and Cognitive Improvement Group</ORGANISATION><ADDRESS_1>John Radcliffe Hospital (4th Floor, Room 4401C)</ADDRESS_1><ADDRESS_2>Headington</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01865 234306</PHONE_1><FAX_1>01865 221354</FAX_1></ADDRESS></PERSON><PERSON ID="7556" ROLE="AUTHOR"><PREFIX>Sir</PREFIX><FIRST_NAME>John</FIRST_NAME><LAST_NAME>Grimley Evans</LAST_NAME><POSITION>Professor Emeritus</POSITION><EMAIL_1>john.grimleyevans@green.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Division of Clinical Geratology, Nuffield Department of Clinical Medicine</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Infirmary</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6HE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><FAX_1>+44 1865 224815</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-12-01 15:38:55 +0000" MODIFIED_BY="Helen Collins">
<UP_TO_DATE>
<DATE DAY="22" MONTH="7" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="10" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="19" MONTH="7" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2008-12-01 15:40:51 +0000" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-12-01 15:40:51 +0000" MODIFIED_BY="Helen Collins">
<DATE DAY="1" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>Published note added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-12-01 15:39:23 +0000" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-12-01 15:39:23 +0000" MODIFIED_BY="Helen Collins">
<DATE DAY="19" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>March 2008 update: Five new trials were included. Three conducted among healthy older people, one in Alzheimer's patients, and one in mixed dementia. There is no adequate evidence of folic acid supplementation alone or with vitamin B12, on cognition function in both normal people or those with impaired cognitive function.</P>
<P>One trial showed a benefit of folic acid in cognition function after three years in healthy elderly with high homocysteine levels.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-03-19 10:43:46 +0000" MODIFIED_BY="Helen Collins">
<DATE DAY="25" MONTH="1" YEAR="2006"/>
<DESCRIPTION>
<P>minor update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-03-19 10:46:07 +0000" MODIFIED_BY="Helen Collins">
<DATE DAY="15" MONTH="2" YEAR="2005"/>
<DESCRIPTION>
<P>reply to feedback added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-03-19 10:44:35 +0000" MODIFIED_BY="Helen Collins">
<DATE DAY="4" MONTH="12" YEAR="2004"/>
<DESCRIPTION>
<P>feedback added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-07-23 14:37:41 +0100" MODIFIED_BY="Helen Collins">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Division of Clinical Geratology, Nuffield Department of Clinical Medicine, University of Oxford</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Alzheimer's Society</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2008-07-23 14:37:41 +0100" MODIFIED_BY="Helen Collins">
<SOURCE>
<NAME>National Health Service, Research and Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2008-07-23 14:37:41 +0100" MODIFIED_BY="Helen Collins">
<NAME>Alzheimer's Society</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-12-01 15:41:06 +0000" MODIFIED_BY="Helen Collins">
<SUMMARY MODIFIED="2008-07-22 16:53:56 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-07-22 16:52:50 +0100" MODIFIED_BY="[Empty name]">No evidence that folic acid with or without vitamin B12 improves cognitive function of unselected elderly people with or without dementia. Long-term supplementation may benefit cognitive function of healthy older people with high homocysteine levels</TITLE>
<SUMMARY_BODY MODIFIED="2008-07-22 16:53:56 +0100" MODIFIED_BY="[Empty name]">
<P>In the economically developed world, folate deficiency is one of the commonest vitamin deficiencies. Several reports suggest a higher prevalence of various psychiatric disorders in elderly people with folate deficiency. There is interest in whether dietary supplements of folic acid (an artificial chemical analogue of naturally occurring folates) can improve cognitive function of people at risk of cognitive decline associated with ageing or dementia, whether by affecting homocysteine metabolism or through other mechanisms. Eight trials met the criteria for inclusion. It was not possible to pool the data because the trials studied different populations, tested folic acid in different doses, and used different outcome measures. There were two trials of folic acid in conjunction with B12. The analysis showed significant benefit of folic acid over placebo in some measures of cognition in a long-term trial recruiting elderly people with high homocysteine levels from a general population. In one pilot trial, 1 mg/day of folic acid was associated with significant improvement in behavioural response to cholinesterase inhibitors in people with Alzheimer's disease. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-07-22 16:49:09 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-07-22 16:45:30 +0100" MODIFIED_BY="[Empty name]">
<P>Folate deficiency can result in congenital neural tube defects and megaloblastic anaemia. Low folate levels may be due to insufficient dietary intake or inefficient absorption, but impaired metabolic utilization also occurs.</P>
<P>Because B12 deficiency can produce a similar anaemia to folate deficiency, there is a risk that folate supplementation can delay the diagnosis of B12 deficiency, which can cause irreversible neurological damage.  Folic acid supplements may sometimes therefore include vitamin B12 supplements with simultaneous administration of vitamin B12.</P>
<P>Lesser degrees of folate inadequacy are associated with high blood levels of the amino acid homocysteine which has been linked with the risk of arterial disease, dementia and Alzheimer's disease. There is therefore interest in whether dietary supplementation can improve cognitive function in the elderly.</P>
<P>However, any apparent benefit from folic acid which was given in combination with B12 needs to be "corrected" for any effect of vitamin B12 alone. A separate Cochrane review of vitamin B12 and cognitive function has therefore been published.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To examine the effects of folic acid supplementation, with or without vitamin B12, on elderly healthy or demented people, in preventing cognitive impairment or retarding its progress.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-07-22 16:46:11 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were identified from a search of the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 10 October 2007 using the terms: folic acid, folate, vitamin B9, leucovorin, methyltetrahydrofolate, vitamin B12, cobalamin and cyanocobalamin. This Register contains references from all major health care databases and many ongoing trials databases. In addition MEDLINE, EMBASE, CINAHL, PsychINFO and LILACS were searched (years 2003-2007) for additional trials of folate with or without vitamin B12 on healthy elderly people.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-07-22 16:46:47 +0100" MODIFIED_BY="[Empty name]">
<P>All double-blind, placebo-controlled, randomized trials, in which supplements of folic acid with or without vitamin B12 were compared with placebo for elderly healthy people or people with any type of dementia or cognitive impairment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>The reviewers independently applied the selection criteria and assessed study quality. One reviewer extracted and analysed the data. In comparing intervention with placebo, weighted mean differences and standardized mean difference or odds ratios were estimated.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-07-22 16:49:09 +0100" MODIFIED_BY="[Empty name]">
<P>Eight randomized controlled trials fulfilled the inclusion criteria for this review. Four trials enrolled healthy older people, and four recruited participants with mild to moderate cognitive impairment or dementia with or without diagnosed folate deficiency. Pooling the data was not possible owing to heterogeneity in sample selections, outcomes, trial duration, and dosage. Two studies involved a combination of folic acid and vitamin B12.</P>
<P>There is no adequate evidence of benefit from folic acid supplemententation with or without vitamin B12 on cognitive function and mood of unselected healthy elderly people. However, in one trial enrolling a selected group of healthy elderly people with high homocysteine levels, 800 mcg/day folic acid supplementation over three years was associated with significant benefit in terms of global functioning (WMD 0.05, 95% CI 0.004 to 0.096, P = 0.033); memory storage (WMD 0.14, 95% CI 0.04 to 0.24, P = 0.006) and information-processing speed (WMD 0.09, 95% CI 0.02 to 0.16, P = 0.016). </P>
<P>Four trials involved people with cognitive impairment. In one pilot trial enrolling people with Alzheimer's disease, the overall response to cholinesterase inhibitors significantly improved with folic acid at a dose of 1mg/day (odds ratio: 4.06, 95% CI 1.22 to 13.53; P = 0.02) and there was a significant improvement in scores on the Instrumental Activities of Daily Living and the Social Behaviour subscale of the Nurse's Observation Scale for Geriatric Patients (WMD 4.01, 95% CI 0.50 to 7.52, P = 0.02). Other trials involving people with cognitive impairment did not show any benefit in measures of cognitive function from folic acid, with or without vitamin B12. </P>
<P>Folic acid plus vitamin B12 was effective in reducing serum homocysteine concentrations (WMD -5.90, 95% CI -8.43 to -3.37, P &lt; 0.00001). Folic acid was well tolerated and no adverse effects were reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-07-22 16:11:06 +0100" MODIFIED_BY="[Empty name]">
<P>The small number of studies which have been done provide no consistent evidence either way that folic acid, with or without vitamin B12, has a beneficial effect on cognitive function of unselected healthy or cognitively impaired older people. In a preliminary study, folic acid was associated with improvement in the response of people with Alzheimer's disease to cholinesterase inhibitors. In another, long-term use appeared to improve the cognitive function of healthy older people with high homocysteine levels.  More studies are needed on this important issue.<BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-07-23 16:18:57 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-07-01 10:07:17 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2008-07-22 16:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Dementia is a syndrome characterized by an acquired global impairment of memory and other cognitive functions sufficient to interfere with normal life (<LINK REF="REF-Gottfries-1998" TYPE="REFERENCE">Gottfries 1998</LINK>). There are many causes of the syndrome including Alzheimer's disease and cerebrovascular disorders, and most are progressive. Worldwide, 24·3 million people have dementia, with 4·6 million new cases of dementia every year (one new case every seven seconds) (<LINK REF="REF-Ferri-2005" TYPE="REFERENCE">Ferri 2005</LINK>). In Western populations, Alzheimer's disease accounts for more than 70% of cases of dementia. Approximately 6 to 8% of all older people over the age of 65 years have the disease (<LINK REF="REF-Small-1997" TYPE="REFERENCE">Small 1997</LINK>), and the prevalence increases steeply with age (<LINK REF="REF-Jorm-1987" TYPE="REFERENCE">Jorm 1987</LINK>). There are promising developments in treatment of the established disease, but it is more important to find means of preventing its onset. This requires observational studies to identify risk factors and so generate hypotheses on pathogenesis to be tested in intervention trials. The possible involvement of nutritional factors in the aetiology (causes) or pathogenesis (mechanisms of brain damage) of dementia has been widely considered. In particular, dietary deficiency of folates has been postulated as contributing to the aetiology of both Alzheimer's disease and vascular dementia.</P>
<P>Folates are essential components of the human diet, and are synthesized by microorganisms and plants. They occur widely as polyglutamates in dihydrofolate or tetrahydrofolate forms. Leafy vegetables, fruits, mushrooms, yeast and animal protein are all rich sources of folates (<LINK REF="REF-Antony-1995" TYPE="REFERENCE">Antony 1995</LINK>). Prolonged cooking (more than 15 minutes) destroys 60 to 90% of a food's content of folates. The minimum daily requirement is 50 micrograms and the recommended daily intake is 100 micrograms for adults but in pregnancy this rises to 500 micrograms. The body's storage of the vitamin is adequate for about four months of dietary deficiency (<LINK REF="REF-Herbert-1985" TYPE="REFERENCE">Herbert 1985</LINK>; <LINK REF="REF-Chanarin-1979" TYPE="REFERENCE">Chanarin 1979</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-07-22 16:55:25 +0100" MODIFIED_BY="[Empty name]">
<P>Folate is absorbed in the upper jejunum in monoglutamate form and converted to methyltetrahydrofolate which is the main form in serum. The primary mechanism of folate absorption across the small intestine is passive diffusion (<LINK REF="REF-Rosenberg-1985" TYPE="REFERENCE">Rosenberg 1985</LINK>), but absorption is influenced by genotypic variation in the enzyme methylenetetrahydrofolate reductase (MTHFR). One identified genotype is the 677 C-&gt;T mutation. People with the 677 TT (thymine/thymine) genotype absorb folate less efficiently than people with the CT (cytosine/thymine) or CC (cytosine/cytosine) variants. The C677T mutation is associated with decreased MTHFR activity, low plasma and red cell folate concentrations, and high plasma homocysteine levels. It occurs at above general population frequency in mothers of spina bifida offspring (<LINK REF="REF-Whitehead-1995" TYPE="REFERENCE">Whitehead 1995</LINK>). Two thirds of the folate in the plasma is free and one third nonspecifically bound to albumin and possibly other proteins. Folate concentration in the cerebrospinal fluid (CSF) is three times that in the serum (<LINK REF="REF-Botez-1979" TYPE="REFERENCE">Botez 1979</LINK>), and concentrations decline with age (<LINK REF="REF-Bottiglieri-2000" TYPE="REFERENCE">Bottiglieri 2000</LINK>).</P>
<P>Folic acid and folinic acid are artificial compounds that can substitute for the naturally occurring folates. Folic acid is well tolerated, and adverse effects are rare and limited to hypersensitivity reactions (<LINK REF="REF-Smith-2002" TYPE="REFERENCE">Smith 2002</LINK>). Folinic acid is more stable than folic acid and has a longer half-life in the body. Folinic acid also crosses the blood-brain barrier and is cleared more slowly than folic acid which is poorly transported into the brain and rapidly cleared from the central nervous system. <LINK REF="REF-Smith-2008" TYPE="REFERENCE">Smith 2008</LINK> has published an important review on this subject.</P>
</INTERVENTION>
<THEORY MODIFIED="2008-05-13 11:15:47 +0100" MODIFIED_BY="Helen Collins">
<P>Folate is particularly important during the early development of the brain, and in later life is involved in methylation processes that are essential for the maintenance of normal brain function. Folate acts as a donor of methyl groups in a reaction catalysed by the enzyme methionine synthase to produce methylcobalamin needed for methylation of homocysteine to methionine (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Folate deficiency therefore leads to an increase in blood and intracellular levels of homocysteine. Homocysteine is a specific chemical compound, but is readily and partly reversibly transformed into other compounds. It has become conventional for the term "total homocysteine" (tHcy) to be used for the sum of these inter-related forms as measured chemically. High intraneuronal levels of homocysteine are one mechanism whereby inadequate methylation could disturb brain metabolism, and cause cognitive impairment (<LINK REF="REF-La-Rue-1997" TYPE="REFERENCE">La Rue 1997</LINK>), but high blood homocysteine levels are also a risk factor for atherosclerosis and cerebrovascular disease. In addition to lack of folate activity, other causes of elevated total homocysteine levels are deficiency of vitamins B12 or B6, and renal impairment.</P>
<P>In addition to its effect in lowering homocysteine levels, folate improves nitric oxide availability in the brain. It also plays a number of other crucial roles in the brain, as coenzyme in the synthesis of serotonin and catecholamine neurotransmitters and also of S-adenosylmethionine, which has antidepressant properties (<LINK REF="REF-Levitt-1989" TYPE="REFERENCE">Levitt 1989</LINK>; <LINK REF="REF-Shane-1985" TYPE="REFERENCE">Shane 1985</LINK>). Folate deficiency impairs DNA repair in neurons, and sensitizes neurons to oxidative damage and the toxicity of amyloid beta-peptide (Abeta) (<LINK REF="REF-Kruman-2002" TYPE="REFERENCE">Kruman 2002</LINK>).</P>
<P>Low folate levels can be the result of inadequate dietary intake, diminished absorption from the gastrointestinal tract or increased utilization. Folate deficiency is common in economically less developed countries (<LINK REF="REF-Cooper-1986" TYPE="REFERENCE">Cooper 1986</LINK>), as a consequence of malnutrition, poverty, ethnic diets, cooking techniques and chronic illness. In more developed countries, dietary deficiency associated with alcoholism is the most common cause, but slimming diets have also been incriminated. Some medications interact with folate metabolism and can cause deficiency; examples include anti-convulsant medications (such as dilantin, phenytoin and primidone), metformin (sometimes prescribed to control blood sugar in type 2 diabetes), sulfasalazine (used to control inflammation associated with Crohn's disease and ulcerative colitis), triamterene (a diuretic), methotrexate (used for cancer and other diseases such as rheumatoid arthritis), pyrimethamine, trimethoprim and barbiturates (used as sedatives).</P>
</THEORY>
<IMPORTANCE MODIFIED="2008-07-22 17:06:23 +0100" MODIFIED_BY="[Empty name]">
<P>Folate deficiency can cause megaloblastic anaemia, congestive heart failure, pigmentation, premature greying of hair, infertility, cervical dysplasia, uterine dysplasia, neuropathy, psychiatric disorders, cognitive dysfunction and dementia. Behavioural abnormalities have been noted in folate-deficient mice (<LINK REF="REF-Gospe-1995" TYPE="REFERENCE">Gospe 1995</LINK>). Other studies have found an association between folate deficiency and psychiatric diseases including schizophrenia and organic psychosis (<LINK REF="REF-Reynolds-1976" TYPE="REFERENCE">Reynolds 1976</LINK>; <LINK REF="REF-Ortega-1996" TYPE="REFERENCE">Ortega 1996</LINK>). Prospective studies on folate intake in the<SUP> </SUP>United States (<LINK REF="REF-Corrada-2005" TYPE="REFERENCE">Corrada 2005</LINK> ), and on serum folate concentrations in Italy (<LINK REF="REF-Ravaglia-2005" TYPE="REFERENCE">Ravaglia 2005</LINK>) have produced evidence of low folate intake or status as<SUP> </SUP>a risk factor for dementia.</P>
<P>Folate status is assessed by measuring plasma and blood red cell folate concentrations and plasma or serum total homocysteine levels. Red cell folate is more stable than serum folate levels and better correlated with the tissue stores (<LINK REF="REF-Chanarin-1989" TYPE="REFERENCE">Chanarin 1989</LINK>; <LINK REF="REF-Shane-1985" TYPE="REFERENCE">Shane 1985</LINK>). Serum total homocysteine concentration is a sensitive but non-specific indicator of folate deficiency (<LINK REF="REF-Ueland-1993" TYPE="REFERENCE">Ueland 1993</LINK>).</P>
<P>In observational studies, hyperhomocysteinaemia is a risk factor for coronary heart disease (<LINK REF="REF-Mayer-1996" TYPE="REFERENCE">Mayer 1996</LINK>; <LINK REF="REF-Nygard-1997" TYPE="REFERENCE">Nygard 1997</LINK>), extracranial carotid artery stenosis (<LINK REF="REF-Aronow-1997" TYPE="REFERENCE">Aronow 1997</LINK>) and stroke (<LINK REF="REF-Perry-1995" TYPE="REFERENCE">Perry 1995</LINK>). High homocysteine levels are associated with a decrease in cognitive function and dementia (<LINK REF="REF-Breteler-1994" TYPE="REFERENCE">Breteler 1994</LINK>; <LINK REF="REF-Hofman-1997" TYPE="REFERENCE">Hofman 1997</LINK>). Individuals with Alzheimer's disease have been found to have higher plasma homocysteine levels than age-matched controls (<LINK REF="REF-McCaddon-1998" TYPE="REFERENCE">McCaddon 1998</LINK>), and it has been reported that elevation of plasma homocysteine levels precedes clinical manifestations of Alzheimer's disease (<LINK REF="REF-Seshadri-2002" TYPE="REFERENCE">Seshadri 2002</LINK>). The underlying mechanisms of homocysteine as a risk factor for both vascular and Alzheimer's dementia are still uncertain, but there are many ways in which homocysteine could damage neurons, including impairment of blood supply through endothelial dysfunction in arteries, cerebral microangiopathy. Increased oxidative stress may also be relevant. In rats, homocysteine induces apoptosis in hippocampal neurons, and in vivo it increases excitotoxicity and oxidative damage (<LINK REF="REF-Kruman-2002" TYPE="REFERENCE">Kruman 2002</LINK>). Folate supplementation causes a significant decline in blood total homocysteine levels (<LINK REF="REF-Stabler-1986" TYPE="REFERENCE">Stabler 1986</LINK>; <LINK REF="REF-Stabler-1988" TYPE="REFERENCE">Stabler 1988</LINK>), and many studies are in progress to assess the effects of reducing homocysteine levels by dietary supplements of folic acid alone or in combination with vitamins B12 and B6.</P>
<P>Serum total homocysteine levels vary between population groups. High blood levels are more common in the Netherlands than in the United States, probably because of greater use of folic acid supplementation and food fortification in the USA (<LINK REF="REF-Stehouwer-1998" TYPE="REFERENCE">Stehouwer 1998</LINK>). The US government has legislated for all flour to be fortified with folic acid at a level of 140 mcg per 100 g in order to reduce the incidence of congenital neural tube defects. Such mandatory fortification has not yet been adopted in Europe, although some manufacturers are adding folic acid to breakfast cereals, and may introduce it into spreadable fats. Fortification of milk with folic acid has been shown to be acceptable and sufficient for preventing folate deficiency among older people (<LINK REF="REF-Keane-1998" TYPE="REFERENCE">Keane 1998</LINK>). The prevalence of low folate and high homocysteine concentrations in the USA declined from 22.0 to18.7% respectively before the fortification programme was introduced to 1.7% and 9.8% respectively afterwards (<LINK REF="REF-Jacques-1999" TYPE="REFERENCE">Jacques 1999</LINK>).</P>
<P>Giving folic acid to someone who has unrecognized deficiency of vitamin B12 will prevent the anaemia of that condition but not the irreversible neurological damage that may occur as the deficiency continues. Thus by "masking" the early signs and symptoms of vitamin B12 deficiency, folic acid may increase the incidence of neuropathy. There is also concern, based on observations in the 1940s when pernicious anaemia was treated with high doses of folic acid, that giving folic acid to someone who is deficient in vitamin B12 may make the neurological consequences of that deficiency more rapid and more severe. For these reasons doctors do not prescribe high doses of folic acid for patients whose vitamin B12 status is unknown. The prevalence of vitamin B12 deficiency in the general population is uncertain but is known to be significantly common in later life (<LINK REF="REF-Clarke-2007" TYPE="REFERENCE">Clarke 2007</LINK>). This is one concern raised by the possibility of a folic acid fortification programme in the United Kingdom. A prospective study was performed after six months of the Chilean government fortification programme of 220 microgram of folic acid per 100 gram of wheat flour. One hundred and eight elderly people who consumed fortified flour showed a moderate decline in their homocysteine levels, but one third of the participants had subclinical vitamin B12 deficiency (<LINK REF="REF-Hirsch-2002" TYPE="REFERENCE">Hirsch 2002</LINK>).</P>
<P>Folate deficiency is one of the commonest forms of vitamin deficiency, occurring in about 10% of the USA population (<LINK REF="REF-Senti-1985" TYPE="REFERENCE">Senti 1985</LINK>). Folate deficiency is common in geriatric patients: approximately 30 to 35% have metabolic evidence of deficiency (elevated homocysteine) (<LINK REF="REF-Selhub-1993" TYPE="REFERENCE">Selhub 1993</LINK>). In one study, low serum and red cell folate concentrations were found in 42% of healthy older people (<LINK REF="REF-Bottiglieri-1994" TYPE="REFERENCE">Bottiglieri 1994</LINK>). Several reports suggest a higher prevalence of psychiatric disorders in elderly patients with folate deficiency (<LINK REF="REF-Bottiglieri-1994" TYPE="REFERENCE">Bottiglieri 1994</LINK>).</P>
<P>Older people with low folate status are more likely to be demented, institutionalized or depressed (<LINK REF="REF-Ebly-1998" TYPE="REFERENCE">Ebly 1998</LINK>). In observational studies, low serum folate levels have been associated with Alzheimer's disease and with all types of dementia (<LINK REF="REF-Meindok-1970" TYPE="REFERENCE">Meindok 1970</LINK>; <LINK REF="REF-Sneath-1973" TYPE="REFERENCE">Sneath 1973</LINK>; <LINK REF="REF-Renvall-1989" TYPE="REFERENCE">Renvall 1989</LINK>; <LINK REF="REF-Clarke-1998" TYPE="REFERENCE">Clarke 1998</LINK>; <LINK REF="REF-Ebly-1998" TYPE="REFERENCE">Ebly 1998</LINK>). It has been noted that low serum folate levels were associated with atrophy of the cerebral cortex (<LINK REF="REF-Snowdon-2000" TYPE="REFERENCE">Snowdon 2000</LINK>). The Mini Mental State Examination (MMSE) scores of people with high serum and erythrocyte folic acid concentrations were significantly greater than those of people with lower concentrations (<LINK REF="REF-Ortega-1996" TYPE="REFERENCE">Ortega 1996</LINK>). A correlation has been reported between low serum levels of folate and specific cognitive functions such as recall and recognition (<LINK REF="REF-Hassing-1999" TYPE="REFERENCE">Hassing 1999</LINK>; <LINK REF="REF-Wahlin-1996" TYPE="REFERENCE">Wahlin 1996</LINK>). Red cell folate and CSF folate levels are lower in patients with Alzheimer's disease than in controls (<LINK REF="REF-Abalan-1996" TYPE="REFERENCE">Abalan 1996</LINK>). Insomnia, fatigue and forgetfulness after a four-month folate-deficient diet were reported by <LINK REF="REF-Herbet-1961" TYPE="REFERENCE">Herbet 1961</LINK>. Older people with low levels of folate are twice as likely to develop Alzheimer's disease as are those with normal levels (<LINK REF="REF-Wang-2001" TYPE="REFERENCE">Wang 2001</LINK>). In an open clinical study three patients with dementia and folate deficiency recovered completely after taking 50 mg folic acid daily for 21 days (<LINK REF="REF-Brocker-1986" TYPE="REFERENCE">Brocker 1986</LINK>).</P>
<P>It is not yet clear to what extent these associations between folate deficiency and cognitive impairment represent cause or effect. Low intakes of folate could be a consequence of mental dysfunction. In particular demented patients may be anorexic and can suffer from agnosia (impairment of interpretation of sense data) and apraxia (inability to carry out feeding behaviour) that can impair dietary intake (<LINK REF="REF-Marcus-1998" TYPE="REFERENCE">Marcus 1998</LINK>). Conversely, as reviewed above, folate deficiency may be a cause of cognitive deficits. It is therefore important to review the evidence from randomized clinical trials on whether supplements of folic acid can prevent or retard cognitive impairment in older people with or without diagnosed dementia. Because of the possibility of folic acid supplements harming people with unrecognized deficiency of vitamin B12, trials may involve simultaneous administration of vitamin B12 with folic acid. Apparent benefit from folic acid given in combination would therefore need to be "corrected" for any effect of vitamin B12 alone. A separate Cochrane review of vitamin B12 and cognitive function has been published (<LINK REF="REF-Malouf-2003-a" TYPE="REFERENCE">Malouf 2003 a</LINK>).</P>
<P>Apart from its possible risk for people with deficiency of vitamin B12 activity discussed above, folic acid produces few documented adverse effects. However, there has recently been concern that introducing folic acid into the food chain in North America may have caused an increase in colorectal cancer (<LINK REF="REF-Cole-2007" TYPE="REFERENCE">Cole 2007</LINK>; <LINK REF="REF-Mason-2007" TYPE="REFERENCE">Mason 2007</LINK>). This might reflect an increase in the growth rate of pre-existing cancers. However, for various reasons, levels of folic acid intake in North American populations is higher than was envisaged in fortification programmes. High levels of folic acid in the diet can saturate the biochemical processes that convert it into naturally occurring folate derivatives, and little is known of possible effects of unmetabolized folic acid circulating in the body. </P>
<P>In contrast to the earlier reports that folate might improve cognitive function, a prospective study in the United States, conducted after fortification, has reported that a high intake of folic acid was associated with an increased risk of cognitive decline in older people, especially in those who took vitamin supplements containing &gt; 400 µg folic acid/day (<A HREF="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=707703041409415658&amp;versionPK1=C6E6DBB382E26AA2011884394E4DF993&amp;versionPK2=DE2ADE1F82E26AA2014753DAACF14BA2#REF-Morris-2005#REF-Morris-2005">Morris 2005</A>). A later study found that this relationship was restricted to older people with impaired vitamin B12 status (<A HREF="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=707703041409415658&amp;versionPK1=C6E6DBB382E26AA2011884394E4DF993&amp;versionPK2=DE2ADE1F82E26AA2014753DAACF14BA2#REF-Morris-2007#REF-Morris-2007">Morris 2007</A>).  Furthermore, in those without low B12, high folate levels were associated with better cognitive function.  This raises the possibility that a subclinical form of the neurological damage which can the affect spinal cord might also affect the brain in those with low B2 and high folate.<BR/>
</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>The aim of the review is to examine the effects of folic acid supplementation, with or without vitamin B12, on elderly healthy or demented people in preventing cognitive impairment or retarding its progress.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-07-23 13:32:13 +0100" MODIFIED_BY="Helen Collins">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomized double-blind, placebo-controlled trials in which folic acid with or without vitamin B12 was compared with placebo.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-07-22 17:06:52 +0100" MODIFIED_BY="[Empty name]">
<P>Healthy older people or people with cognitive impairment or any type of dementia, Alzheimer's disease, vascular, mixed dementia and others. Patients should be diagnosed with dementia using accepted criteria such as those of the International Classification of Diseases (<LINK REF="REF-ICD_x002d_10-1992" TYPE="REFERENCE">ICD-10 1992</LINK>), DSM American Psychiatric Association (<LINK REF="REF-APA-1987" TYPE="REFERENCE">APA 1987</LINK>) and the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA) (<LINK REF="REF-McKhann-1984" TYPE="REFERENCE">McKhann 1984</LINK>). The diagnosis of cognitive impairment is made according to the results of reliable and valid rating scales.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-05-13 11:23:08 +0100" MODIFIED_BY="Helen Collins">
<P>Folic acid with or without vitamin B12 at any dose and by any route of administration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-03-19 11:08:51 +0000" MODIFIED_BY="Helen Collins">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-03-19 11:09:10 +0000" MODIFIED_BY="Helen Collins">
<UL>
<LI>Cognitive measurements</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-06-05 13:50:48 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Blood folate levels</LI>
<LI>Serum or plasma levels of total homocysteine</LI>
<LI>Mood changes</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-23 13:32:13 +0100" MODIFIED_BY="Helen Collins">
<P>See <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/dementia/frame.html">Cochrane Dementia and Cognitive Improvement Group</A> methods used in reviews.</P>
<P>The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG) was searched on 10 October 2007 for all years up to December 2005. This register contains records from the major healthcare databases, <I>The Cochrane Library</I>, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS, and many ongoing trial databases and other grey literature sources. The following search terms were used: folic, folinic, folate, "vitamin B9", VITAMIN-B9, leucovorin, methyltetrahydrofolate.</P>
<P>
<I>The Cochrane Library</I>, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS were searched separately on 10 October 2007 to identify randomized controlled trials with healthy elderly people for the years 2003 to 2007. The search terms used to identify relevant controlled trials on cognition and dementia for the Group's Specialized Register can be found in the Group's module on <I>The Cochrane Library</I>. These search terms were combined with the following search terms and adapted for each database, where appropriate: folic, folinic, folate, "vitamin B9", VITAMIN-B9, leucovorin, methyltetrahydrofolate.</P>
<P>On 10 October 2007, the Register consisted of records from the following databases:</P>
<SUBSECTION>
<HEADING LEVEL="3">Healthcare databases</HEADING>
<UL>
<LI>CENTRAL: (The Cochrane Library 2006, Issue 1);</LI>
<LI>MEDLINE (1966 to 2006/07, week 5);</LI>
<LI>EMBASE (1980 to 2006/07);</LI>
<LI>PsycINFO (1887 to 2006/08, week 1);</LI>
<LI>CINAHL (1982 to 2006/06);</LI>
<LI>SIGLE (Grey Literature in Europe) (1980 to 2005/03);</LI>
<LI>LILACS: Latin American and Caribbean Health Science Literature (http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&amp;base=LILACS&amp;lang=i&amp;form=F) (last searched 29 August 2006).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Conference proceedings</HEADING>
<UL>
<LI>ISTP (http://portal.isiknowledge.com/portal.cgi) (Index to Scientific and Technical Proceedings) (to 29 August 2006);</LI>
<LI>INSIDE (BL database of Conference Proceedings and Journals) (to June 2000).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Theses</HEADING>
<UL>
<LI>Index to Theses (formerly ASLIB) (http://www.theses.com/) (UK and Ireland theses) (1716 to 11 August 2006);</LI>
<LI>Australian Digital Theses Program (http://adt.caul.edu.au/): (last update 24 March 2006);</LI>
<LI>Canadian Theses and Dissertations (http://www.collectionscanada.ca/thesescanada/index-e.html): 1989 to 28 August 2006);</LI>
<LI>DATAD - Database of African Theses and Dissertations (http://www.aau.org/datad/backgrd.htm);</LI>
<LI>Dissertation Abstract Online (USA) (http://wwwlib.umi.com/dissertations/gateway) (1861 to 28 August 2006).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing trials</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">UK</HEADING>
<UL>
<LI>National Research Register (http://www.update-software.com/projects/nrr/) (last searched issue 3/2006);</LI>
<LI>ReFeR (http://www.refer.nhs.uk/ViewWebPage.asp?Page=Home) (last searched 30 August 2006);</LI>
<LI>Current Controlled trials: Meta Register of Controlled trials (mRCT) (http://www.controlled-trials.com/) (last searched 30 August 2006) :</LI>
<LI>ISRCTN Register - trials registered with a unique identifier</LI>
<LI>Action medical research</LI>
<LI>Kings College London</LI>
<LI>Laxdale Ltd</LI>
<LI>Medical Research Council (UK)</LI>
<LI>NHS Trusts Clinical Trials Register</LI>
<LI>National Health Service Research and Development Health Technology Assessment Programme (HTA)</LI>
<LI>National Health Service Research and Development Programme 'Time-Limited' National Programmes</LI>
<LI>National Health Service Research and Development Regional Programmes</LI>
<LI>The Wellcome Trust</LI>
<LI>Stroke Trials Registry (http://www.strokecenter.org/trials/index.aspx) (last searched 31 August 2006).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Netherlands</HEADING>
<P>"Nederlands Trial Register (http://www.trialregister.nl/trialreg/index.asp) (last searched 31 August 2006).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">USA/International</HEADING>
<UL>
<LI>ClinicalTrials.gov (http://www.ClinicalTrials.gov) (last searched 31 August 2006) (contains all records from http://clinicalstudies.info.nih.gov/);</LI>
<LI>IPFMA Clinical trials Register: www.ifpma.org/clinicaltrials.html. The Ongoing Trials database within this Register searches http://www.controlled-trials.com/isrctn, http://www.ClinicalTrials.gov and http://www.centerwatch.com/. The ISRCTN register and Clinicaltrials.gov are searched separately. Centerwatch is very difficult to search for our purposes and no update searches have been done since 2003.</LI>
<LI>The IFPMA Trial Results databases searches a wide variety of sources among which are:</LI>
<LI>http://www.astrazenecaclinicaltrials.com (seroquel, statins)</LI>
<LI>http://www.centerwatch.com</LI>
<LI>http://www.clinicalstudyresults.org</LI>
<LI>http://clinicaltrials.gov</LI>
<LI>http://www.controlled-trials.com</LI>
<LI>http://ctr.gsk.co.uk</LI>
<LI>http://www.lillytrials.com (zyprexa)</LI>
<LI>http://www.roche-trials.com (anti-abeta antibody)</LI>
<LI>http://www.organon.com</LI>
<LI>http://www.novartisclinicaltrials.com (rivastigmine)</LI>
<LI>http://www.bayerhealthcare.com</LI>
<LI>http://trials.boehringer-ingelheim.com</LI>
<LI>http://www.cmrinteract.com</LI>
<LI>http://www.esteve.es</LI>
<LI>http://www.clinicaltrials.jp</LI>
</UL>
<P>
<BR/>This part of the IPFMA database is searched and was last updated on 4 September 2006;<BR/>
</P>
<UL>
<LI>Lundbeck Clinical Trial Registry (http://www.lundbecktrials.com) (last searched 15 August 2006);</LI>
<LI>Forest Clinical trial Registry (http://www.forestclinicaltrials.com/) (last searched 15 August 2006).</LI>
</UL>
<P>
<BR/>The search strategies used to identify relevant records in CENTRAL, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS can be found in the Group's module on <I>The Cochrane Library</I>.<BR/>
<BR/>The authors of trial reports were approached where necessary (<LINK REF="STD-Bryan-2002" TYPE="STUDY">Bryan 2002</LINK>; Sommer 1998; <LINK REF="STD-Clarke-2003" TYPE="STUDY">Clarke 2003</LINK>) and asked for additional data. We obtained no reply from Dr Sommer (Sommer 1998), but both Dr Eva Calvaresi (<LINK REF="STD-Bryan-2002" TYPE="STUDY">Bryan 2002</LINK>) and Dr Robert Clarke (<LINK REF="STD-Clarke-2003" TYPE="STUDY">Clarke 2003</LINK>) replied and provided the data requested.</P>
</SUBSECTION>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-07-23 11:40:48 +0100" MODIFIED_BY="Helen Collins">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>The abstracts of trial reports discovered in the search were read and selected for retrieval by the reviewers (RM and JGE) acting independently. Trial reports thought to be eligible were retrieved and any disagreements over eligibility for inclusion were resolved by discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment</HEADING>
<P>The reviewers assessed the methodological quality of randomization in each trial using one of the approaches described in the Cochrane Reviewers' Handbook (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>):<BR/>
</P>
<UL>
<LI>In category A (adequate), the report describes allocation of treatment by: (i) some form of centralized randomized scheme, such as having to provide details of an enrolled participant to an office by telephone to receive the treatment group allocation; (ii) some form of randomization scheme controlled by a pharmacy; (iii) numbered or coded containers, as in a pharmaceutical trial in which capsules from identical-looking numbered bottles are administrated sequentially to enrolled participants; (iv) an on-site or coded computer system, provided that the allocations were in a locked, unreadable file that could be accessed only after inputting the characteristics of an enrolled participants; or (v) if assignment envelopes were used, the report should at least specify that they were sequentially numbered, sealed, and opaque; (vi) other combinations of described elements of the process that provide assurance of adequate concealment.</LI>
<LI>Category B ( intermediate) is where the report describes allocation of treatment by: (i) use of a ''list'' of ''table'' to allocate assignments; (ii) use of ''envelopes'' or ''sealed envelopes''; (iii) stating the study as ''randomized'' without further detail.</LI>
<LI>Category C ( inadequate) is where the report describes allocation of treatment by: (i) alternation; (ii) reference to case record numbers, dates of birth, day of week, or any such approach; (iii) any allocation procedure that is transparent before assignment, such as an open list of random numbers or assignments. Empirical research has shown that lack of adequate allocation concealment is associated with bias. Trials with unclear concealment measures have been shown liable to yield more pronounced estimates of treatment effects than trials that have adequate measure to conceal allocation schedules, but the effect is less pronounced than inadequately concealed trials (<LINK REF="REF-Chalmers-1983" TYPE="REFERENCE">Chalmers 1983</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Trials were considered if they conformed to categories A or B, but those falling in category C were excluded. Other aspects of trial quality were not assessed by a scoring system but details of blinding, appropriateness of methods and the number of patients lost to follow-up were noted.</LI>
</UL>
<P>Only trials in which outcome assessments were made without knowledge of treatment allocation were eligible for inclusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>One reviewer (RM) extracted data from the published reports. The summary statistics required for each trial and each outcome for continuous data were the mean change from baseline, the standard deviation, and the number of patients for each treatment group at each assessment. Where changes from baseline were not reported, the mean, standard deviation and the number of patients for each treatment group at each time point were extracted if available.</P>
<P>For binary data the numbers in each treatment group and the numbers experiencing the outcome of interest were sought.</P>
<P>The baseline assessment is defined as the latest available assessment prior to randomization, but no longer than two months before.</P>
<P>For each outcome measure, data were sought on every patient assessed. To allow an intention-to-treat analysis, the data were sought irrespective of compliance, whether or not the patient was subsequently deemed ineligible, or otherwise excluded from treatment or follow-up. If intention-to-treat data were not available in the publications, "on-treatment" data of participants who completed the trial were sought and indicated as such.</P>
<P>In studies where a cross-over design was used, only data from the first treatment phase after randomization were eligible for inclusion. Data from titration phases prior to the randomized phase were not used to assess safety or efficacy because patients were usually not randomized, nor were treatments concealed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>The outcomes measured in clinical trials of dementia and cognitive impairment often arise from ordinal rating scales. Where the rating scales used in the trials have a reasonably large number of categories (more than 10) the data were treated as continuous outcomes arising from a normal distribution.</P>
<P>Summary statistics (n, mean and standard deviation) were required for each rating scale at each assessment time for each treatment group in each trial for change from baseline. For cross-over trials only the data from the first treatment period were used.</P>
<P>When change from baseline results were not reported, the required summary statistics would be calculated from the baseline and assessment time treatment group means and standard deviations. In this case, zero correlation between the measurements at baseline and assessment time was assumed. This method overestimates the standard deviation of the change from baseline, but this conservative approach is considered to be preferable for meta-analysis.</P>
<P>The meta-analysis requires the combination of data from the trials that may not use the same rating scale to assess an outcome. The measure of the treatment difference for any outcome was the weighted mean difference when the pooled trials use the same rating scale or test, and the standardized mean difference, which was the absolute mean difference divided by the standard deviation when different rating scales or tests had been used.</P>
<P>The duration of the trials may vary considerably. If the range was considered too great to combine all trials into one meta-analysis it was divided into smaller time periods and a separate meta-analysis conducted for each period. Some trials might contribute data to more than one time period if multiple assessments were made.</P>
<P>For binary outcomes, such as clinical improvement or no clinical improvement, the odds ratio was used to measure treatment effect. A weighted estimate of the typical treatment effect across trials was calculated.</P>
<P>Overall estimates of the treatment difference were sought. In all cases the overall estimate from a fixed-effects model was to be presented and a test for heterogeneity using a standard chi-square statistic performed. Where there was evidence of heterogeneity of the treatment effect between trials then either only homogeneous results were to be pooled, or a random-effects model be used (in which case the confidence intervals would be broader than those of a fixed-effects model).</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-07-23 16:18:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-07-23 15:31:58 +0100" MODIFIED_BY="[Empty name]">
<P>Four randomized double-blind controlled trials were identified that met the criteria for inclusion in this review. The trial reports were published between 1997 to 2003. <LINK REF="STD-Bryan-2002" TYPE="STUDY">Bryan 2002</LINK> enrolled healthy women and <LINK REF="STD-Fioravanti-1997" TYPE="STUDY">Fioravanti 1997</LINK>; Sommer 1998; <LINK REF="STD-Clarke-2003" TYPE="STUDY">Clarke 2003</LINK> enrolled cognitively impaired and demented participants.</P>
<P>
<LINK REF="STD-Bryan-2002" TYPE="STUDY">Bryan 2002</LINK>, enrolled 211 healthy women of various age groups in a multifactorial trial of randomized placebo-controlled design. Vitamin B6, vitamin B12 and folic acid were compared with placebo. The entry criteria were that participants should be non-smokers, not pregnant, not lactating, and not taking oral contraceptives or hormone replacement therapy or any medication likely to affect mood or mental function. In addition participants needed to have English as mother language or to be proficient in English as many assessments were language-dependent. Seventy-five participants aged 65 to 92 years comprised the older group eligible for this review; 19 received 750 &#956;g folic acid orally per day for five weeks and 21 were randomized to placebo.</P>
<P>
<LINK REF="STD-Fioravanti-1997" TYPE="STUDY">Fioravanti 1997</LINK> restricted enrolment to community-living people with a history of cognitive impairment over the previous two years, whose cognitive decline was diagnosed as very mild to moderately severe by the Global Deterioration Scale (GDS) and on the Mini-Mental State Examination (MMSE) between 16 to 24. Patients with clear diagnosis of dementia were excluded, as were people with serum folate levels above 3 ng/ml.</P>
<P>Sommer 1998, did not provide enough data for interpretation. Enrolment involved an unspecified small number of patients with dementia who received 10 mg of folic acid for an unspecified period, and measures of cognition and mood were not reported.</P>
<P>Participants eligible for the <LINK REF="STD-Clarke-2003" TYPE="STUDY">Clarke 2003</LINK> trial had either a clinical diagnosis of dementia (by DSM-IV) and MMSE scores between 12 and 26 inclusive, or mild cognitive impairment defined by symptoms of memory problems and a Modified Telephone Interview for Cognitive Status(TICS-M) score below 27 (<LINK REF="REF-Prince-1999" TYPE="REFERENCE">Prince 1999</LINK>). Eighty-four patients had Alzheimer's disease, 11 mixed dementia, 47 cognitive impairment, and 4 had unclassified memory deficits. Use of multivitamins containing less than 200&#956;g daily of folic acid and less than 100 mg daily of vitamin E was permitted. Drugs that affect cognitive function (donepezil, metrifonate, rivastigmine) were also permitted in this trial. Baseline serum homocysteine and folate levels were measured. Participants were living in the community.</P>
<P>The sample sizes of the included studies on cognitive impairment and demented patients were small and the number of participants ranged from 30 in <LINK REF="STD-Fioravanti-1997" TYPE="STUDY">Fioravanti 1997</LINK> to 147 in <LINK REF="STD-Clarke-2003" TYPE="STUDY">Clarke 2003</LINK>. No concomitant illnesses were reported in the trials.</P>
<SUBSECTION>
<HEADING LEVEL="3">2008 update</HEADING>
<P>The combined searches identified 98 articles. A total of four randomized trials published between 2003 and 2008 were retained for inclusion. Three trials, <LINK REF="STD-Eussen-2006" TYPE="STUDY">Eussen 2006</LINK>, <LINK REF="STD-Pathansali-2006" TYPE="STUDY">Pathansali 2006</LINK> and <LINK REF="STD-Durga-2007" TYPE="STUDY">Durga 2007</LINK> enrolled healthy elderly people and one <LINK REF="STD-Connelly-2008" TYPE="STUDY">Connelly 2008</LINK> recruited people with Alzheimer's disease. One preliminary trial on people with dementia (<A HREF="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=707703041409415658&amp;versionPK1=C6E6DBB382E26AA2011884394E4DF993&amp;versionPK2=DE2ADE1F82E26AA2014753DAACF14BA2#STD-Sommer-1998#STD-Sommer-1998">Sommer 1998</A>) had originally been included on the basis of a conference proceeding but has since been published more fully (<A HREF="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=707703041409415658&amp;versionPK1=C6E6DBB382E26AA2011884394E4DF993&amp;versionPK2=DE2ADE1F82E26AA2014753DAACF14BA2#STD-Sommer-2003#STD-Sommer-2003">Sommer 2003</A>). The trials were similar in their inclusion criteria with regard to previous history of vascular disease, hypertension, diabetes or smoking, normal kidney function, and not taking any supplements or any medications that might interfere with the metabolism of folic acid. <LINK REF="STD-Eussen-2006" TYPE="STUDY">Eussen 2006</LINK> enrolled healthy elderly people with mild vitamin B12 deficiency and compared combined folic acid and B12 with placebo. <LINK REF="STD-Pathansali-2006" TYPE="STUDY">Pathansali 2006</LINK> and <LINK REF="STD-Durga-2007" TYPE="STUDY">Durga 2007</LINK> enrolled healthy elderly people with normal folate levels and compared folic acid alone with placebo. <LINK REF="STD-Connelly-2008" TYPE="STUDY">Connelly 2008</LINK> recruited people with probable Alzheimer's disease and assessed the relationship between changes in homocysteine levels and the response to treatment with cholinesterase inhibitors.</P>
<P>
<LINK REF="STD-Eussen-2006" TYPE="STUDY">Eussen 2006</LINK> recruited 195 home-living and care-facility living elderly people. The objective of this trial was to assess the effect of vitamin B12 with or without folic acid supplements on cognitive function of healthy elderly people with mild vitamin B12 deficiency. Mild vitamin B12 deficiency was defined as serum vitamin B12 concentration 100 to 200 pmol/L or serum vitamin B12 concentration 200 to 300 pmol/L and MMA plasma &gt;32 mcmol/L. People scoring less than 19 on the MMSE were excluded. In a six-month, double-blind trial, folic acid (400 mcg/day) in combination with vitamin B12 (1000 mcg/day) was compared with vitamin B12 (1000 mcg/day) alone and with placebo.</P>
<P>
<LINK REF="STD-Pathansali-2006" TYPE="STUDY">Pathansali 2006</LINK> enrolled 24 healthy elderly people aged 73 (SD 5.6 years) (mean±SD) with normal folic acid levels (6.3 ± 2.4 mcg/l) and normal cognitive function defined as MMSE &gt; 27. A dose of 5 mg/day folic acid was compared with placebo in a four-week trial.</P>
<P>
<LINK REF="STD-Durga-2007" TYPE="STUDY">Durga 2007</LINK> recruited 818 people aged 50 to 70 years with normal serum vitamin B12 to a three-year double-blind trial of 800 mcg folic acid per day versus placebo. This study was part of the Folic Acid and Carotid Intimamedia Thickness Trial (FACIT) investigating the effect of folic acid supplementation on progression of atherosclerosis. The participants were selected to benefit from folic acid's homocysteine-lowering effect, and participants with plasma total homocysteine of less than 13 micmol/L were excluded. Adequate compliance in a six-week placebo run-in period was required before acceptance into the study. Participants were required to score 24 or more on the MMSE. Cognitive function was assessed as memory, sensorimotor speed, complex speed, information processing and word fluency.</P>
<P>
<LINK REF="STD-Sommer-2003" TYPE="STUDY">Sommer 2003</LINK>: Eleven people who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R) criteria for dementia and with normal or low serum folate levels (2 to 5 mcg/L) and normal vitamin B12 levels (&gt;200 ng/L) were randomized to 10 mg/day folic acid or placebo for 10 weeks. Baseline MMSE range (14 to 27). Seven participants completed the trial (three with probable AD, one with vascular dementia, one with Lewy body dementia, two with unspecified dementia).</P>
<P>
<LINK REF="STD-Connelly-2008" TYPE="STUDY">Connelly 2008</LINK> enrolled 57 people with probable Alzheimer's disease according to the NINCDS-ADRDA criteria and who scored 11 to 30 on MMSE, 0 or 1 on the Modified Hachinski Ischaemia Scale, and &lt; 2 on the Rosen scale (<LINK REF="REF-Rosen-1984" TYPE="REFERENCE">Rosen 1984</LINK>). In a six-month, double-blind trial participants received a cholinesterase inhibitor and were randomized to a daily dose of 1 mg of folic acid or to placebo. Outcomes were categorized according to criteria of the National Insitute of Clinical Excellence (<LINK REF="REF-NICE-2006a" TYPE="REFERENCE">NICE 2006a</LINK>). The primary outcome was the number of participants showing a good response (improvement or no deterioration in MMSE with global improvement on behavioural and/or functional assessment).</P>
<P>Baseline characteristics of the included studies were presented in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intervention</HEADING>
<P>The doses of folic acid compared with placebo varied from 750 microgram to 15 milligram orally per day. The durations of the trials ranged from five weeks to three years. <LINK REF="STD-Clarke-2003" TYPE="STUDY">Clarke 2003</LINK> compared a combination of folic acid and vitamin B12 with placebo as part of a 2 x 2 x 2 factorial design that also included vitamin C plus vitamin E against placebo and aspirin against placebo. In <LINK REF="STD-Bryan-2002" TYPE="STUDY">Bryan 2002</LINK> the four arms in a parallel group study were vitamin B12, vitamin B6, folic acid and placebo. <LINK REF="STD-Connelly-2008" TYPE="STUDY">Connelly 2008</LINK> compared 1 mg/day of folic acid against placebo for people with Alzheimer's disease who also took a cholinesterase inhibitor. <LINK REF="STD-Eussen-2006" TYPE="STUDY">Eussen 2006</LINK>, compared the combination of folic acid and Vitamin B12 with Vitamin B12 alone or placebo. A dose of 5 mg/day of folic acid was used in <LINK REF="STD-Pathansali-2006" TYPE="STUDY">Pathansali 2006</LINK>. <LINK REF="STD-Durga-2007" TYPE="STUDY">Durga 2007</LINK> compared 800 mcg/day folic acid against placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dietary assessment</HEADING>
<P>Daily dietary intake was assessed only in three trials (<LINK REF="STD-Bryan-2002" TYPE="STUDY">Bryan 2002</LINK>, <LINK REF="STD-Eussen-2006" TYPE="STUDY">Eussen 2006</LINK>; <LINK REF="STD-Durga-2007" TYPE="STUDY">Durga 2007</LINK>) using a self-reported food frequency questionnaire.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome measures</HEADING>
<P>The following cognitive and mood measures were involved in assessing the outcome on healthy people:</P>
<SUBSECTION>
<HEADING LEVEL="4">Speed of processing</HEADING>
<UL>
<LI>Boxes test (<LINK REF="REF-Earles-1995" TYPE="REFERENCE">Earles 1995</LINK>) is a paper-and-pencil test to assess sensory-motor speed; it comprises 100 three-sided boxes with a requirement to draw lines to complete each box. The score represents the number of boxes completed correctly in 30 seconds.</LI>
<LI>Digit Symbol Coding Task (<LINK REF="REF-Wechsler-1997" TYPE="REFERENCE">Wechsler 1997</LINK>) is a symbol substitution task measuring the ability of participants to complete 133 substitutions on a printed sheet. The score is the number of correct substitutions completed in 120 seconds.</LI>
<LI>Symbol Search Task (<LINK REF="REF-Wechsler-1997" TYPE="REFERENCE">Wechsler 1997</LINK>) is a subtest of the Wechsler Adult Intelligence Scale III measuring perceptual speed. Two columns of symbols are presented and the participants required to scan the columns and indicate if a symbol of one column appears also in the other. Final score represents the number of symbols identified correctly in 60 seconds.</LI>
<LI>Continuous Attention Test (CAT) (<LINK REF="REF-Kalra-1993" TYPE="REFERENCE">Kalra 1993</LINK>; <LINK REF="REF-Bryant-1998" TYPE="REFERENCE">Bryant 1998</LINK>). This test assesses attention, visuo-spatial memory, and response speed. A series of 240 geometric shapes with 40 repetitions build up from a random pattern of four light and five dark squares arranged in a 3 x 3 grid. The duration of each stimulation was 0.1 second, and the interval between successive stimuli was 2 to 4 seconds. The task was to touch the response box with a touching pen whenever two patterns were the same. The number of repetitions identified correctly (cat-c) and incorrect responses was scored (cat-i). The error index was measured by expressing the total number of false negative and false positive responses as a proportion of the total response speed.</LI>
<LI>Four-Choice Reaction Time (FCRT) (<LINK REF="REF-Kalra-1993" TYPE="REFERENCE">Kalra 1993</LINK>; <LINK REF="REF-Bryant-1998" TYPE="REFERENCE">Bryant 1998</LINK>). This test assessed attention, reaction time, and visuomotor coordination. Four circles could be arranged in the shape of a square. The task was to place the touch pen on an equivalent series of circles arranged in a square below on the same screen. At random intervals one of the circles was illuminated and the correct response was to touch the equivalent circle on the lower part of the screen as fast as possible. Three measures of accuracy and reaction time needed to be obtained: response to random stimuli, to fixed stimuli and the transition between the two. The results were the correct (fc-c) and incorrect response (fc-i) and the mean reaction time of the correct (fc-rtc) and the incorrect reaction responses (fc-rti).</LI>
<LI>Digit-Symbol substitution (DSS). This test assessed attention, associative memory, and reaction time. A series of 10 digits appeared on top of the screen with corresponding symbols. A digit and a symbol were then projected on to the screen and the task was to touch a yes or no button depending on whether the combination was correct or not. The task was to idenitfy as many combinations as possible in 90 seconds. The score was the total number of correct (dsyn-c) and incorrect responses (dsyn-i). The mean correct reaction time (dsyn-rtc) and incorrect reaction time (dsyn-irtc) were scored.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Working memory</HEADING>
<UL>
<LI>Digit Span-Backwards (<LINK REF="REF-Wechsler-1997" TYPE="REFERENCE">Wechsler 1997</LINK>). This is the digit span test used in the intelligence and memory scales of the Wechsler batteries as a measure of immediate verbal recall. It involves a range of different mental activities including auditory attention and short-term retention. The test consists of two trials for each span length, each string consists of two to eight random number sequences that the examiner reads aloud at the rate of one number per second. The participants are required to repeat the number strings in reverse sequence. One point is awarded for each string recalled correctly; if neither list is repeated successfully, a score of zero is given and the test ended.</LI>
<LI>Letter Number Sequencing (<LINK REF="REF-Wechsler-1997" TYPE="REFERENCE">Wechsler 1997</LINK>). Chains of numbers and letters, from two to eight with three trials in each chain, are read to participants who are required to repeat first the numbers in given order then the letters in alphabetical order. One point is given for each chain recalled correctly.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Memory</HEADING>
<UL>
<LI>The Rey Auditory Verbal Learning Test (RAVLT) (<LINK REF="REF-Rey-1964" TYPE="REFERENCE">Rey 1964</LINK>) is an easily administered test lasting 10 to 15 minutes that allows comparison between retrieval efficacy and learning. It measures immediate memory span and both short and longer term retention of a 15-word list following interpolated activity. Scores range from 1 to 5.</LI>
<LI>Symbol Recall: requires recall of symbol-digit pairs from the Digit Symbol Coding test after completing the task.</LI>
<LI>Activity Recall tests ability to remember information that was not explicitly presented as part of a memory task. A recall memory task required the participants to rename the 13 tasks that they have been exposed to and one point was given for each name recalled correctly according to order.</LI>
<LI>Word learning test (<LINK REF="REF-Van-der-Elst-2006-a" TYPE="REFERENCE">Van der Elst 2006 a</LINK>): involves memorizing 15 commonly used monosyllabic words that are printed on cards and presented in a fixed sequence at 2 s intervals. The task is to recall the words immediately and 20 minutes after presentation of the cards. The score is the maximum and the total number of correctly repeated words in the immediate recall test and in the delayed recall test.</LI>
<LI>Scanning Memory Sets (SMS) (<LINK REF="REF-Kalra-1993" TYPE="REFERENCE">Kalra 1993</LINK>; <LINK REF="REF-Bryant-1998" TYPE="REFERENCE">Bryant 1998</LINK>): three numbers appeared on a screen for one minute and then disappeared. Then a single digit appeared on the screen. The task was to touch a yes or no button to indicate whether or not the number had been in the set. The subsequent set contained four numbers and the final set contained five. The total number of correct (sms-c) and incorrect (sms-ic) and the mean reaction time to the correct (sms-rti) and incorrect (sms-rti) responses was the total score.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Executive function</HEADING>
<P>Executive function is a higher order cognitive activity controlling other cognitive activities including planning strategies for performance and using feedback to adjust future planning (<LINK REF="REF-Lezak-1995" TYPE="REFERENCE">Lezak 1995</LINK>). The following measures were used for its assessment:<BR/>
</P>
<UL>
<LI>Stroop Test (<LINK REF="REF-Dodrill-1978" TYPE="REFERENCE">Dodrill 1978</LINK>). Dodrill's format of the Stroop test consists of one sheet containing 176 colour word names ("red", "orange", "green" and "blue") printed in a random order and in randomly assorted colours. In phase one of the task the participants are required to read the printed word name. The requirement in phase two is to report the colours in which the words are printed. The score is evaluated as the total time for phase one and the difference in time between phases one and two.</LI>
<LI>Self-Ordered Pointing Task (<LINK REF="REF-Spreen-1998" TYPE="REFERENCE">Spreen 1998</LINK>). This task assesses planning and organizing abilities as it relies on self-initiated responses (<LINK REF="REF-Petrides-1982" TYPE="REFERENCE">Petrides 1982</LINK>). It assesses capacity to initiate and execute a sequence of responses with constant monitoring of performance. The participant is required is to point to one item on each page of a sequence without repeating an item already indicated. The participants therefore need to memorize items previously selected and to develop a strategy for pointing to all items available.</LI>
<LI>Uses of Common Objects (<LINK REF="REF-Getzels-1962" TYPE="REFERENCE">Getzels 1962</LINK>) test requires participants to give as many uses as they can for objects that customarily have a single function associated with them. The scores are based on the number and originality of the uses suggested.</LI>
<LI>The Trail Making Test (<LINK REF="REF-Reitan-1985" TYPE="REFERENCE">Reitan 1985</LINK>) has two parts. In part A participants are presented with a sheet randomly printed with numbers 1 to 25. The requirement is to join the numbers in sequence by tracing. Scores are derived as the time in seconds taken to complete the task. Part B presents numbers from 1 to 13 and letters from A to L in random placement. The requirement is to join the number and letters in numerical and alphabetical order. Scores are calculated by the time taken in seconds to complete the task.</LI>
<LI>Verbal Fluency Task (<LINK REF="REF-Benton-1989" TYPE="REFERENCE">Benton 1989</LINK>; <LINK REF="REF-Benton-1994" TYPE="REFERENCE">Benton 1994</LINK>) comprises two parts, initial letter fluency and excluded letter fluency. In the first part, participants are asked to generate as many words as possible beginning with an allocated letter. The score is calculated as the number of words generated correctly in two trials of 60 seconds each. The excluded letter fluency task is to generate as many words as possible that do not contain the specified letter. The score is the number of correct words produced in two trials of 60 seconds each.</LI>
<LI>Verbal fluency test (<LINK REF="REF-Van-der-Elst-2006-b" TYPE="REFERENCE">Van der Elst 2006 b</LINK>). This test involves naming as many animals as possible in one minute. It measures word fluency or the ability to draw on one's encyclopaedic memory in a strategic manner.</LI>
<LI>Concept shifting test (<LINK REF="REF-Van-der-Elst-2006-b" TYPE="REFERENCE">Van der Elst 2006 b</LINK>). A timed test with four subtests testing flexibility in switching between two psychological concepts. Each subtest contained 16 circles (15 mm diameter) arranged in a large circle (16 cm diameter). For the first subtest, crossing off the circles in numerical and alphabetical order was required.</LI>
<LI>Letter digit substitution test (<LINK REF="REF-Van-der-Elst-2006-b" TYPE="REFERENCE">Van der Elst 2006 b</LINK>). A test to assess the speed of visual information processing. Nine different letters were assigned a unique number (1 to 9) in a key at the top of the form. A random series of letters in cells were presented and participants were instructed to add the corresponding digit to the letters. The score is the number of correctly corresponding digits in 90 seconds.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Verbal abilities</HEADING>
<P>Two batteries were used to assess verbal ability, Vocabulary (WAIS-III) (<LINK REF="REF-Earles-1995" TYPE="REFERENCE">Earles 1995</LINK>) and spot the word (<LINK REF="REF-Baddeley-1988" TYPE="REFERENCE">Baddeley 1988</LINK>).<BR/>
</P>
<UL>
<LI>Vocabulary (WAIS-III) (<LINK REF="REF-Earles-1995" TYPE="REFERENCE">Earles 1995</LINK>) evaluates an individual's ability to define the meanings of 15 words. The score is 0, 1, or 2 based on the accuracy, precision, and aptness of definition. Vocabulary scores peak at middle age and show a slow average decline in the sixth to seventh decades.</LI>
<LI>Spot- the-Word Task (<LINK REF="REF-Baddeley-1988" TYPE="REFERENCE">Baddeley 1988</LINK>). Two printed sheets each containing 60 real word paired with non-words, the participant's task being to identify the real word in each pair. Scores are calculated as the number of words identified correctly minus the number of errors (to correct for guessing).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mood</HEADING>
<UL>
<LI>The Center for Epidemiological Studies Depression Scale (CESD) (<LINK REF="REF-Radloff-1977" TYPE="REFERENCE">Radloff 1977</LINK>) is a short self-report test designed to assess depressive symptomatology in the general population. The components of the scale include depressive mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of appetite and sleep disturbance. There is a 1 to 4 point scale for each of 20 items with higher scores indicating more symptoms of depressive mood.</LI>
<LI>The Profile of Mood State Questionnaire (POMS) (<LINK REF="REF-McNair-1971" TYPE="REFERENCE">McNair 1971</LINK>) assesses six aspects of mood: tension-anxiety, depression-dejection, anger-hostility, vigour-activity, fatigue-inertia, and confusion-bewilderment. The score is on a five-point ranging from 1 (no symptoms) to 5 (extreme symptoms).</LI>
</UL>
<P>The following range of outcome measures were used in trials with cognitively impaired participants:</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary global measures</HEADING>
<UL>
<LI>Global Deterioration Scale (<LINK REF="REF-Reisberg-1982" TYPE="REFERENCE">Reisberg 1982</LINK>). This scale consists of a description of seven stages of dementia from 1 being normal to 7 where all verbal ability is lost. This scale has been shown to have a significant relation with anatomical brain changes as visualized on computerized tomographic scans (CT):</LI>
</UL>
<P>Stage 1: No cognitive decline. There is no complaint or evidence of memory deficits. In the Psychometric Concomitants questionnaire, the individual scores on at least 3 of the 5 subtests of the Guide Memory Test are average or above the standard for the subject's age and WAIS vocabulary score.<BR/>Stage 2: Very Mild Cognitive Decline. There are complaints of memory deficits, but no objective evidence of memory deficits in clinical interview. In the Psychometric Concomitants questionnaire, performance is below average for the patient's age and WAIS vocabulary score on 3 of the 5 Guide Memory subtests.<BR/>Stage 3: Mild Cognitive decline. There is objective evidence of memory and concentration deficits accompanied by mild to moderate anxiety. In the Psychometric Concomitants questionnaire performance is one standard deviation or more below average for the subject's age and WAIS vocabulary score on at least 3 of the 5 Guide Memory subtests.<BR/>Stage 4: There are deficits in many areas of cognition, in concentration, remembering recent events and there may be deficits in respondents' memories of their personal history. Orientation to time and person is preserved. In the Psychometric Concomitants evaluation, respondents make 3 or more errors on the Mental Status Questionnaire.<BR/>Stage 5: Moderately Severe Cognitive Decline. This represents the early phase of dementia. Some assistance is required with activities of daily living but subjects can manage toileting and eating. Disorientation in time or place occur frequently. Deficits are evident in the Mental Status Questionnaire.<BR/>Stage 6: Severe Cognitive Decline. In this middle phase of dementia, full assistance is required with activities daily living. Subjects make 5 to 10 errors on the Mental Status Questionnaire.<BR/>Stage 7: Very severe Cognitive Decline. All verbal abilities are lost and assistance is required in toileting and eating. Signs and symptoms of cortical and focal neurological damage may be present. Assessment of the patients on the Mental Status Questionnaire shows 10 errors.</P>
<UL>
<LI>Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>). This schedule provides clinical criteria for the listed categories of dementia - Alzheimer's disease, vascular dementia and dementia due to multiple aetiologies. The criteria include memory impairment and at least one of: aphasia, apraxia, agnosia, and disturbance in executive functioning. The cognitive deficits are required to cause significant impairment in social and occupational functioning, and the deficits do not occur exclusively during delirium and are not accounted for by depression.</LI>
</UL>
<UL>
<LI>Rosen scale (<LINK REF="REF-Rosen-1984" TYPE="REFERENCE">Rosen 1984</LINK>). This scale distinguishes between Alzheimer's dementia and vascular dementia in patients with known histological diagnosis. Scores ranging from 0 to 2 for Alzheimer's disease and 4 to 10 for vascular dementia. Features of primary importance are: abrupt onset, stepwise deterioration, history of stroke, focal neurological signs, and focal neurological symptoms. A feature of secondary importance is a history of hypertension.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cognitive function and memory measures</HEADING>
<UL>
<LI>The Mini Mental State Examination (<LINK REF="REF-Folstein-1975" TYPE="REFERENCE">Folstein 1975</LINK>) is the most widely used test of cognitive function. It is a short performance test (5 to 15 minutes) and has been validated for screening for dementia with a sensitivity of 69% and a specificity of 90% (<LINK REF="REF-Feher-1992" TYPE="REFERENCE">Feher 1992</LINK>). The test evaluates cognition in five areas: orientation, immediate recall, attention and calculation, delayed recall and language. Scores range from 0 (severe impairment) to 30 (normal). Scores below 24 (25 for well-educated subjects) are suggestive of dementia (<LINK REF="REF-Galasko-1990" TYPE="REFERENCE">Galasko 1990</LINK>).</LI>
<LI>Randt Memory Test (RMT) (<LINK REF="REF-Randt-1983" TYPE="REFERENCE">Randt 1983</LINK>) is a memory test for longitudinal assessment of mild and/or moderate memory storage and retrieval functions. It takes approximately 20 minutes and comprises five different parallel forms of acquisition, recall, and memory subtests. Scores are adjusted for age.</LI>
<LI>The Modified Telephone Interview for Cognitive Status (TICS-M) (<LINK REF="REF-Prince-1999" TYPE="REFERENCE">Prince 1999</LINK>) was developed to provide follow-up documentation on patients already examined in the clinic or research project. Validated as a sensitive and specific screening instrument for dementia, the test lasts less than 30 minutes and assesses orientation, concentration, immediate and delayed memory, naming, calculation, comprehension and reasoning. TICTS-m has several different versions, the version used in <LINK REF="STD-Clarke-2003" TYPE="STUDY">Clarke 2003</LINK> comprised 13 items with a maximum score of 39 points. It includes an effortful list-learning task with delayed recall.</LI>
<LI>Cognitive section of the Alzheimer's disease Scale (ADAS-Cog) (<LINK REF="REF-Rosen-1984" TYPE="REFERENCE">Rosen 1984</LINK>) comprises 11 individual tests, spoken language ability (0-5), comprehension of spoken language (0-5), recall of test instructions (O-5), word-finding (0-5), following instructions (0-5), naming objects (0-5), construction drawing (0-5), ideational praxis (0-5), orientation (0-8), word recall (0-10) and word recognition (0-2). The scores range from 0 to 70, a higher score indicating impairment.</LI>
<LI>Digit Symbol Substitution Test (DSST) (<LINK REF="REF-Wecshler-1981" TYPE="REFERENCE">Wecshler 1981</LINK>).</LI>
<LI>Prorated Verbal IQ. This is a measure of intellectual function. Items from the Information, Vocabulary, and Similarities subtests of the Wechsler Adult Intelligence Scale-revised was used <LINK REF="REF-Welchsler-1982" TYPE="REFERENCE">Welchsler 1982</LINK>.</LI>
<LI>Boston Naming Test <LINK REF="REF-Kaplan-1983" TYPE="REFERENCE">Kaplan 1983</LINK>. Object-naming test detected difficulties in confrontation naming.</LI>
<LI>Controlled Oral Word Association Test (<LINK REF="REF-Benton-1955" TYPE="REFERENCE">Benton 1955</LINK>). A measure of verbal fluency.</LI>
<LI>Logical Memory and Associated Learning subtests from the Wechsler Memory Scale. A measure of short-term verbal memory (<LINK REF="REF-Wechsler-1955" TYPE="REFERENCE">Wechsler 1955</LINK>).</LI>
<LI>Benton Visual Retention Test (<LINK REF="REF-Benton-1955" TYPE="REFERENCE">Benton 1955</LINK>). A measure of the visuospatial memory.</LI>
<LI>Trial Making Test A and B (<LINK REF="REF-Reitan-1992" TYPE="REFERENCE">Reitan 1992</LINK>). A measure of visual scanning, conceptual flexibility, and motor speed.</LI>
<LI>Finger tapping Test (<LINK REF="REF-Reitan-1974" TYPE="REFERENCE">Reitan 1974</LINK>). A measure of motor speed for both dominant and nondominant hands.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Activities of daily living and behaviour</HEADING>
<UL>
<LI>Bristol Activities of Daily Living Scale (<LINK REF="REF-Bucks-1996" TYPE="REFERENCE">Bucks 1996</LINK>). This 20-item scale uses a five-point severity grading for basic activities of daily living such as feeding, eating, dressing, toileting and instrumental activities of daily living (more complex tasks such as shopping, travelling and handling finances). It is an easy test that can be used by carers.</LI>
<LI>Social Behaviour (SB) subscale of the Nurses' Observation Scale for Geriatric patients (NOSGER) (<LINK REF="REF-Spiegel-1991" TYPE="REFERENCE">Spiegel 1991</LINK>). The NOSGER contains 30 items of behaviour, each rated a five-point scale according to frequency of occurrence. Item scores are summarized into six dimension scores (memory, instrumental activities of daily life, self-care, social behaviour, and disturbing behaviour).</LI>
</UL>
<P>
<BR/>Homocysteine level was assessed in <LINK REF="STD-Connelly-2008" TYPE="STUDY">Connelly 2008</LINK> and <LINK REF="STD-Pathansali-2006" TYPE="STUDY">Pathansali 2006</LINK> at baseline and at end point.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-07-23 12:39:13 +0100" MODIFIED_BY="Helen Collins">
<P>The included trials were of randomized, double-blind, and placebo-controlled design, but the methods of randomization to treatment and placebo were not reported in all. The numbers of drop-outs were small. Seven participants did not reach the endpoint of the treatment period in the <LINK REF="STD-Clarke-2003" TYPE="STUDY">Clarke 2003</LINK> trial but their treatment group was not specified. One woman withdrew from the folic acid group in <LINK REF="STD-Bryan-2002" TYPE="STUDY">Bryan 2002</LINK>. One participant dropped out from the placebo group in <LINK REF="STD-Fioravanti-1997" TYPE="STUDY">Fioravanti 1997</LINK>. In <LINK REF="STD-Connelly-2008" TYPE="STUDY">Connelly 2008</LINK>, 40 patients completed the study with no drop-outs due to side-effects reported during the study. <LINK REF="STD-Durga-2007" TYPE="STUDY">Durga 2007</LINK> reported that five participants allocated folic acid reported adverse events, compared with seven in the placebo group; five participants were lost to follow-up.<BR/>
<BR/>Two trials were multifactorial evaluating more than one intervention and allowing detection of their interactions. Disadvantages of this design with a large number of factors is that interactions become difficult to interpret and the number of participants apportionable to each treatment smaller.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-23 16:18:57 +0100" MODIFIED_BY="[Empty name]">
<P>Eight trials met the criteria for inclusion and seven (<LINK REF="STD-Bryan-2002" TYPE="STUDY">Bryan 2002</LINK>; <LINK REF="STD-Fioravanti-1997" TYPE="STUDY">Fioravanti 1997</LINK>; <LINK REF="STD-Clarke-2003" TYPE="STUDY">Clarke 2003</LINK>; <LINK REF="STD-Connelly-2008" TYPE="STUDY">Connelly 2008</LINK>; <LINK REF="STD-Durga-2007" TYPE="STUDY">Durga 2007</LINK>; <LINK REF="STD-Pathansali-2006" TYPE="STUDY">Pathansali 2006</LINK>; <LINK REF="STD-Eussen-2006" TYPE="STUDY">Eussen 2006</LINK>) provided sufficient data for analysis. <LINK REF="STD-Bryan-2002" TYPE="STUDY">Bryan 2002</LINK>, <LINK REF="STD-Eussen-2006" TYPE="STUDY">Eussen 2006</LINK>, <LINK REF="STD-Durga-2007" TYPE="STUDY">Durga 2007</LINK> , <LINK REF="STD-Pathansali-2006" TYPE="STUDY">Pathansali 2006</LINK> enrolled healthy elderly participants and in <LINK REF="STD-Durga-2007" TYPE="STUDY">Durga 2007</LINK> the high plasma homocysteine level ( &gt; 13 micmol/L) was an inclusion criteria for enrolment in the study. It was not possible to pool the data because the trials studied different populations, different doses of folic acid, assessed different outcomes, and in the case of two trials vitamin B12 was also given.</P>
<SUBSECTION>
<HEADING LEVEL="3">Effect of folic acid on healthy older people</HEADING>
<P>0.75 mg/day folic acid at five weeks - homocysteine level was not measured at baseline:<BR/>
</P>
<UL>
<LI>No statistically significant results in favour of folic acid on cognitive processing functions as measured by speed of processing tests were found. The Boxes Task showed WMD 2.12 (95% CI -11.28 to 15.52, P = 0.76), Digit-Symbol Coding WMD 2.19 (95% CI -7.40 to 11.78, P = 0.65), and Symbol Search Test WMD 1.59 (95% CI -1.55 to 4.73, P = 0.32).</LI>
<LI>There were no statistically significant differences between folic acid and placebo in any of the free recall tasks. Results were: Immediate Recall A WMD -0.06 (95% CI -6.87 to 6.75, P = 0.99); Immediate Recall B WMD -0.54 (95% CI -2.05 to 0.97, P = 0.48); Delayed Recall WMD -0.07 (95% CI -2.85 to 217, P = 0.79); Recognition A WMD 1.42 (95% CI -0.24 to 3.08, P = 0.09); Recognition B WMD 1.59 (95% CI -1.35 to 4.53, P = 0.29). No statistically significant differences between folic acid and placebo emerged in measures of working memory as assessed by Digit Span-Backwards (WMD -0.31, 95% CI -2.66 to 2.04, P = 0.80) or the Letter-Number Sequencing (WMD -050, 95% CI -2.78 to 1.78, P = 0.67).</LI>
<LI>There were no statistically significant differences between folic acid and placebo groups in Executive Function as assessed by the Stroop Test (WMD -0.09, 95% CI -0.44 to 0.26, P = 0.61), Trail Making Test A (WMD 2.29, 95% CI -11.40 to 15.89, P = 0.74), Trail Making Test B (WMD -5.21 95% CI -37.01 to 26.59, P = 0.75), Verbal Fluency Initial (WMD -3.44, 95% CI -11.20 to 4.32, P = 0.39) or Excluded Letter test (WMD 0.57, 95% CI -6.76 to 7.90, P = 0.88).</LI>
<LI>Verbal Ability Tests: the meta-analysis revealed no superiority of folic acid supplementation over placebo as assessed by the Vocabulary Task ( WMD -0.13, 95% CI -4.87 to 4.61, P = 0.96) and Spot the Word Test (WMD 0.87, 95% CI -7.92 to 9.66, P = 0.85).</LI>
<LI>Measures of mood revealed no statistically significant advantage of folic acid over placebo: total Profile of Mood States Questionnaire (POMS) WMD -3.14 (95% CI -23.56 to 17.28, P = 0.73); tension symptoms WMD 0.30 (95% CI -3.93 to 4.53, P = 0.89); depression WMD 0.59 (95% CI -5.45 to 6.63, P = 0.85); anger WMD 0.97 (95% CI -3.29 to 5.23, P = 0.66); activity WMD 3.13 (95% CI -2.26 to 8.52, P = 0.26); fatigue WMD -1.83 (95% CI -5.85 to 2.19, P =0.37); confusion WMD -0.05 (95% CI -3.05 to 2.95, P = 0.97).</LI>
</UL>
<P>There was no statistically significant difference between folic acid and placebo in depressive symptoms as assessed by the Center for Epidemiological Studies-Depression Scale (WMD -1.11, 95% CI -7.31 to 5.09, P = 0.73).</P>
<SUBSECTION>
<HEADING LEVEL="4">Effect of folic acid on healthy older people with normal folate levels</HEADING>
<P>5 mg/day folic acid for four weeks<BR/>
</P>
<UL>
<LI>There was no significant difference in psychomotor performance between the placebo and folic acid group in all the domains, except on the outcome<B> </B>Digit-Symbol Substitution reaction time DSS WMD 0.21(95% CI 0.01 to 0.41, P = 0.04) where the data was in favour of folic acid. The following results were nonsignificant:<B> </B>Four-Choice Reaction Time fixed FRCT (f-c) WMD -6.00 (95% CI -16.29 to 4.29, P = 0.25), Four-Choice Reaction Time fixed FRCT correct WMD 6.75 (-3.70 to 17.20); Four-Choice Reaction Time random correct FC RT (fc-i) random incorrect WMD<B> </B>-0.75 (95% CI -1.82 to 0.32, P = 0.17); FC RT random reaction time WMD -0.02 (95% CI -0.11 to 0.07, P = 0.63); Continuous Attention Test correct CAT WMD 1.94 (95% CI -1.00 to 4.88; P = 0.20); Continuous Attention Test incorrect CAT WMD -0.19 (95% CI -1.55 to 1.17, P = 0.78); Continuous Attention Test error index CAT WMD -0.04 (95% CI -0.11 to 0.03; P = 0.27); Digit-Symbol Substitution correct DSS WMD 0.66 (95% CI -0.49 to 1.8; P = 0.27); Digit-Symbol Substitution incorrect DSS WMD -0.66 (95% CI -1.81 to 0.49, P = 0.26); Scanning Memory Test SMS three digits correct WMD -0.58 (95% CI -1.60 to 0.44, P = 0.26); Scanning Memory Test SMS three digits reaction time WMD 0.04 (95% CI -0.05 to 0.13, P = 0.4); Scanning Memory Test SMS four digits correct WMD -0.01 (95% CI -1.69 to 1.67, P = 0.99); Scanning Memory Test SMS Reaction WMD -0.01 (95% -0.14 to 0.12, P = 0.88); Scanning Memory Test SMS five digits correct WMD 0.15 (95% CI -1.97 to 2.27, P = 0.89); Scanning Memory Test SMS five digits reaction time WMD 0.00 (95% CI -0.12 to 0.12, P = 1.00).</LI>
<LI>There was no significant benefit in favour of 5 mg/day of folic acid over placebo at week 4 in reducing the plasma homocysteine level WMD -1.60 (95% CI -4.28 to 1.08, P = 0.24)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Effect of folic acid on healthy older people with high plasma homocysteine level</HEADING>
<P>800 mcg/day folic acid for three years:</P>
<UL>
<LI>A statistically significant difference in favour of folic acid over placebo, illustrated in the global cognitive function domains at the end point of three years WMD 0.05 (95% CI 0.004 to 0.096 , P = 0.033).</LI>
</UL>
<UL>
<LI>Folic acid administration significantly improved memory storage over placebo; the results showed WMD 0.14 (95% CI 0.04 to 0.24, P = 0.006)</LI>
</UL>
<UL>
<LI>The three-year change in cognitive function was significantly better with folic acid than with placebo in the domains of information-processing speed; WMD 0.09 (95% CI 0.02 to 0.16, P = 0.016).</LI>
</UL>
<UL>
<LI>There were no statistically significant differences in sensorimotor speed, complex speed and word fluency assessment between folic acid and placebo: WMD 0.06 (95% CI 0.00 to 0.120, P = 0.07); WMD 0.04; (95% -0.05 to 0.13, P = 0.36) and WMD -0.06 (95% CI -0.18 to 0.06, P = 0.32) respectively.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Effect of folic acid with vitamin B12 on healthy older people</HEADING>
<P>400 mcg/day folic acid combined with 1000 mcg/day vitamin B12 for 24 weeks:</P>
<UL>
<LI>The combination of folic acid with vitamin B12 produced no improvement in cognitive function. There was no significant difference between folic acid with B12 and placebo with the complex figure of Rey WMD -0.5 (95% CI -5.33 to -4.33, P = 0.84).</LI>
<LI>There was no benefit in favour of folic acid with B12 for improving attention as assessed by using the digit span forward WMD -0.30 (95% CI -1.17 to -0.57, P = 0.50).</LI>
<LI>There was no statistically significant difference between placebo and folic acid with vitamin B12 on sensorimotor speed as measured by motor planning WMD 84 (95% CI -8.38 to -248.38, P = 32) or finger tapping WMD 3 (95% CI -11.50 to -125.50, P = 0.96), trial making test part A, WMD -9 (95% CI -34.41 to -16.41, P = 0.49).</LI>
<LI>Measures of memory: there was no significant difference between placebo and folic acid with B12 in 15-word learning (immediate recall) WMD 0.50 (95% CI -5.25 to -6.25, P = 0.86), (delayed recall) WMD 060 (95% CI -1.42 to -2.62, P = 0.56), word recognition WMD 0.08 (95% CI -1.62 to -0.02, P = 0.06).</LI>
<LI>There was no statistically significant difference between placebo and folic acid with vitamin B12 in executive function as assessed by: motor planning 3 WMD 35 (95% CI -247.33 to -317.33; P = 0.81); trail making test WMD 0.50 (95% CI -0.2 to -1.20, P = 0.16); no changes in the Stroop test from baseline for folic acid with Vitamin B12 arm; similarities WAIS WMD; Raven WMD 0.50 (95% CI -1.55 to 2.55, P = 0.63); word fluency, animals and number of nouns WMD -0.60 (95% CI -3.55 to 2.35; P = 0.39); word fluency, letter, number of nouns WMD -1.80 (95% CI -8.43 to 3.37, P = 0.39).</LI>
<LI>Effect on total homocysteine level: folic acid with B12 significantly reduced serum total homocysteine levels in comparison with placebo at both 12 and 24 weeks WMD -4.50 (95% CI -7.05 to 1.95, P = 0.0006) and WMD -5.90 (95% CI -8.43 to 3.37; P &lt; 0.0001) respectively.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effect of folic acid on patients with Alzheimer's dementia, vascular dementia and unclassified cognitive decline</HEADING>
<UL>
<LI>On the Mini Mental State Examination (MMSE), there was no statistically significant difference between 2 mg per day folic acid plus vitamin B12 1 mg per day for 12 weeks and placebo groups (WMD 0.39, 95% CI -0.43 to 1.21, P = 0.35).</LI>
<LI>There was no statistically significant benefit from 2 mg folic acid per day plus 1 mg vitamin B12 for 12 weeks compared with placebo on ADAS-Cog scales (WMD 0.41, 95% CI -1.25 to 2.07, P = 0.63).</LI>
<LI>No statistically significant difference was seen between 2 mg folic acid plus 1 mg vitamin B12 per day for 12 weeks and placebo for the Bristol Activity of Daily Living (BADL) (WMD -0.57, 95% CI -1.95 to 0.81, P = 0.42).</LI>
<LI>No statistically significant differences were found between 15 mg folic acid per day and placebo on any part of the Randt Memory Test (RMT) tests: acquisition and recall assessment WMD 5.47 (95% CI -10.05 to 20.99, P = 0.49); delayed recall WMD 7.38 (95% CI -8.58 to 23.34, P = 0.36); encoding subtest WMD 0.67 (95% CI -1.89 to 3.23, P = 0.61); Memory Index WMD 7.34 (95% CI -9.67 to 24.35, P = 0.40); Cognitive Efficiency Test WMD 0.57 (95% CI -1.97 to 3.11, P = 0.66); Attention Efficiency WMD 1.05 (95%, -0.17 to 2.27, P = 0.09). In comparison with placebo, 10 mg/day folic acid had no effect on memory at 10 weeks: WMS Logical Memory Subtest WMD -1.70 (95% CI -12.26 to 8.86, P = 0.72) and Associated Learning Subtest WMD -7.40 (95% CI -15.54 to 0.74, P = 0.07).</LI>
<LI>There was no effect of folic acid on language as assessed by WAIS-R: Pro-rated Verbal IQ: WMD -15.00 (95% CI -51.92 to 21.92, P = 0.43), Boston naming Test WMD -0.20 (-37.30 to 36.90, P = 0.99) and Controlled Oral Word Association Test WMD 8.30 (95% CI -36.94 to 53.54, P = 0.72).</LI>
<LI>Speed and Concentration measures: there were no differences between placebo and 10 mg/day folic acid at week 10 over placebo in measures of speed or concentration:Trial A WMD 31.50 (95% CI -574.18 to 637.18, P = 0.92), Trial B WMD175.00 (95% CI -354.94 to 704.94, P = 0.52) and Finger Tapping Test WMD 7.90 (95% CI -15.83 to 31.63, P = 0.51).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effect of folic acid on patients with Alzheimer's disease treated with cholinesterase inhibitors</HEADING>
<P>1 mg/day folic acid for 24 weeks:<BR/>
</P>
<UL>
<LI>The results revealed no statistically significant benefit of folic acid compared with placebo on the Mini-Mental State Examination (MMSE) WMD -0.13 (95% CI -1.96 to 1.70, P = 0.89) or Digit Symbol Substitution Test (DSST) WMD 0.26 (95% CI -4.12 to 4.46.1; P = 0.91).</LI>
<LI>On the Instrumental Activities of Daily Living (IADL) scale, 1 mg/day folic acid was significantly better than placebo: WMD 2.67 (95% CI 0.25 to 5.09; P = 0.03). On the Social Behaviour Subscale (SB) there was no difference between the treatment and control: WMD 1.38 (95% CI-1.13 to 3.89; P = 0.28). There was a significant benefit in favour of folic acid over placebo on the combined IADL/SB: WMD 4.01 (95% CI 0.50 to 7.52, P = 0.02).</LI>
<LI>Response to treatment with cholinesterase inhibitors was significantly better in the folic acid group than in the placebo group: 20/28 were classified as responders in the folic acid group compared with 8/21 in the placebo group: odds ratio: 4.06 (95% CI 1.22 to 13.53; P = 0.02).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effect of folic acid with or without vitamin B12 on healthy and cognitively impaired older people</HEADING>
<UL>
<LI>One meta-analysis of the effect folic acid on healthy people was performed regardless of the dose, duration and combination with vitamin B12. The results showed no benefit of folic acid on memory and word fluency: for memory immediate recall WMD 0.27 (95% CI -4.14 to 4.67, P = 0.91); delayed recall WMD 0.23 (95% CI -1.34 to 1.80, P = 0.77); word recognition WMD 0.46 (95% CI -0.81 to 1.73, P=0.48); verbal ability WMD -0.06 (95% CI -0.18 to 0.06, P = 0.31).</LI>
<LI>There was no statistically significant difference between folic acid with or without vitamin B12 on cognitive function as assessed by changes in MMSE in cognitively impairment and demented patients: WMD 0.30 (95% CI -0.45 to 1.05, P = 0.43).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effect of folic acid on serum homocysteine levels</HEADING>
<UL>
<LI>
<LINK REF="STD-Clarke-2003" TYPE="STUDY">Clarke 2003</LINK> was the only trial to present data on the efficacy of the vitamin supplements in lowering serum homocysteine levels. The dose of 2 mg folic acid plus 1 mg vitamin B12 significantly reduced serum homocysteine concentration (P &lt; 0.001).</LI>
<LI>In <LINK REF="STD-Durga-2007" TYPE="STUDY">Durga 2007</LINK>, the baseline plasma total homocysteine level in the folic acid group was 13 (11.6 to 14.7) mcmol/L compared with 10.1 (9.0 to 11.3) mcmol/L at three years. In the placebo group the values were 12.9 (11.4 to 14.8) mcmol/L at baseline compared with 13.4 (11.5 to 15.2) mcmol/L at the three-year end point. Data were given as only as median and interquartile ranges and therefore could not be used in meta-analysis.</LI>
<LI>In <LINK REF="STD-Connelly-2008" TYPE="STUDY">Connelly 2008</LINK>, there was no significant difference between placebo and folic acid 5 mg/day folic acid for 24 weeks in reducing blood total homocysteine levels: WMD -1.60 (95% CI -5.13 to 1.93; P = 0.37).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>In one trial only, <LINK REF="STD-Durga-2007" TYPE="STUDY">Durga 2007</LINK> with an intervention period of three years, were adverse events reported and no seriuos side effects were noted: five participants allocated to folic acid supplement reported adverse events of forgetfulness, sun allergies, weight gain, tinnitus, and dark urine. In the placebo group, seven participants reported having adverse effects in the form of muscle aches, headaches, weight gain, queasiness, bitter taste and skin irritations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Withdrawal</HEADING>
<P>The numbers of drop-outs were small: 17 participants in total across all the trials. Seven participants did not reach the endpoint of the treatment period in <LINK REF="STD-Clarke-2003" TYPE="STUDY">Clarke 2003</LINK> but their treatment group was not specified. One woman withdrew from the folic acid group in <LINK REF="STD-Bryan-2002" TYPE="STUDY">Bryan 2002</LINK>. One participant dropped out from the placebo group in <LINK REF="STD-Fioravanti-1997" TYPE="STUDY">Fioravanti 1997</LINK>. In <LINK REF="STD-Connelly-2008" TYPE="STUDY">Connelly 2008</LINK>, eight patients did not reach the end point, three owing to non-compliance, four were hospitalized with unrelated problems, and one participant proved intolerant to cholinesterase inhibitors.</P>
<P>There were no data on effects on caregiver burden or costs of treatment.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-07-23 15:48:07 +0100" MODIFIED_BY="[Empty name]">
<P>Eight trials of folic acid with or without vitamin B12 qualified for inclusion in this review. Four were performed on healthy elderly populations and four enrolled cognitively impaired and demented participants.</P>
<P>The review provides some evidence of benefit from dietary supplementation with folic acid, with or without vitamin B12, on cognitive function of healthy, cognitively impaired or demented older people. There are some limitations on the interpretation of these findings. The range of folic acid dosage in the reviewed studies was limited and may have been too low at 750 mcg or too high at 15 mg daily. The included trials were mostly of short duration. In one large study, <LINK REF="STD-Durga-2007" TYPE="STUDY">Durga 2007</LINK>,<B> </B>that lasted for three years, no attempt was made to measure the prevalence of dementia at baseline or during the trial.</P>
<P>The trials on healthy elderly people drew on different populations and used more than 50 different cognitive measures. In some cognitive tests greater improvement was seen in the placebo than in the treatment groups. It is possible that results may have been affected by learning from repetition, although attempts to reduce learning effects<B> </B>were made in<B> </B>
<LINK REF="STD-Pathansali-2006" TYPE="STUDY">Pathansali 2006</LINK>. In a selected group of older people with elevated levels of blood homocysteine, prolonged folic acid supplementation was associated with better memory performance tests, but no benefit was seen in measures of sensorimotor speed and verbal fluency. Restriction to older people with mild B12 deficiency limited the applicability of the trial by <LINK REF="STD-Pathansali-2006" TYPE="STUDY">Pathansali 2006</LINK>.<B> </B>The main aim of this trial was to assess the efficacy of vitamin B12 supplementation on cognitive function. This issue will be discussed in <LINK REF="REF-Malouf-2003-a" TYPE="REFERENCE">Malouf 2003 a</LINK>.</P>
<P>Participants with cognitive impairment or dementia were heterogeneous and some aetiological subgroups could be more susceptible than others to benefit from folic acid. Different degrees of metabolic deficiency of folic acid among participants may also affect results. If high blood homocysteine concentrations are relevant and precede clinical manifestations of dementia<B> </B>(<LINK REF="REF-Seshadri-2002" TYPE="REFERENCE">Seshadri 2002</LINK>), benefit may only emerge in very large studies of normal populations over long periods. In <LINK REF="STD-Connelly-2008" TYPE="STUDY">Connelly 2008</LINK>, there were some indications that folic acid supplementation improved general response to cholinesterase inhibitors by patients with Alzheimer's disease as determined by improved functional, though not cognitive measures.The number needed to treat (NNT) is four with a 95% confidence interval of 1.7 to 23.8 . This means that about one in every four AD patients will benefit from combined treatment of cholinesterase inhibitors and folic acid for six months. This suggests that folic acid might act synergistically with cholinesterase inhibitors in addition to the role of reducing<B> </B>homocysteine levels. However, no firm recommendations can be drawn from a pilot study of only 49 people with Alzheimer's disease treated only for six months.</P>
<P>Only two studies met the criteria for evaluation of folic acid supplementation (<LINK REF="STD-Connelly-2008" TYPE="STUDY">Connelly 2008</LINK>; <LINK REF="STD-Durga-2007" TYPE="STUDY">Durga 2007</LINK>). In both trials folic acid supplementation was associated with improvement in some domains of cognitive status. The two studies involved people with high blood homocysteine levels.</P>
<P>Given the plausible rationale for there being beneficial effects from folic acid at least among people with evidence of metabolic insufficiency, more trials seem necessary. The increasing dietary intakes of folic acid as a consequence of official and commercial fortification will make trials harder to design and implement. It also needs to be emphasised that without adequate trials the possibility of harm from high intakes of folic acid, an artificial substance, cannot be excluded.<BR/>
</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-07-23 15:49:21 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-07-23 15:48:57 +0100" MODIFIED_BY="[Empty name]">
<P>The findings of a single large study suggest a possible benefit from folic acid supplementation over long periods in preserving some aspects of cognitive function of healthy people with high homocysteine levels. The risks of malignancy with long term folate supplementation are unknown and folate supplementation may worsen cognitive function in the presence of low B12.  Until further safety data accrue, and the effect is replicated, the risk-benefit ratio remains unknown and practice should not change.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-07-23 15:49:21 +0100" MODIFIED_BY="[Empty name]">
<P>Because the risk-benefit ratio for cognitive function of folate supplementation may be unfavourable (as well as favourable), further large scale RCTs should be undertaken before recommending either population treatment with fortification of flour or folate supplementation.  Such RCTs should incorporate multiple dosing regimes, stratification by homocysteine and B12 levels and include careful follow-up of malignancy risk beyond the end of the treatment period. Future trialists should agree on the range of outcome measures assessed to ensure consistency across trials. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-07-23 13:20:09 +0100" MODIFIED_BY="Helen Collins">
<P>We thank Almudena Areosa Sastre for her work on the protocol and the first version of the review (selection of studies for inclusion and checking drafts). We thank Dr. Robert Clarke for providing original data from the VITAL trial and Dr Bryan for providing the data requested. We are also grateful to Corinne Cavender as consumer editor of the first version of the review. We wish to thank the following consumer editors for their comment on the latest update of this review: Ann E. Finfa, Morio Aihara and U. Hla Htay.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-07-23 11:39:49 +0100" MODIFIED_BY="Helen Collins">
<P>-RM- contact author, collection of studies, assessment of studies, data extraction and input into Revman, writing the review<BR/>-JGE- co-reviewer, assessment of studies, co-drafting of text<BR/>
</P>
<P>-Dymphna Hermans: original search and update searches; Vittoria Lutje, 2008 update search<BR/>-The review was peer reviewed anonymously in April 2008</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-03-19 11:15:08 +0000" MODIFIED_BY="Helen Collins">
<P>None</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-12-01 15:41:06 +0000" MODIFIED_BY="Helen Collins">
<P>This review and the following review on Vitamin B12 for cognition will be combined into a single review on Folate and B vitamins for the prevention and treatment of dementia. New searches will be run, and the reviewers anticipate completion of the combined updated review for issue 3/2009.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-23 15:54:46 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-07-23 15:54:46 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-07-23 15:54:46 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bryan-2002" NAME="Bryan 2002" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bryan J, Calvaresi E, Hughes D</AU>
<TI>Short term folate vitamin B12 or vitamin B6 supplementation slightly affects memory performance but not mood in women of various ages</TI>
<SO>Journal of Nutrition</SO>
<YR>2002</YR>
<VL>132</VL>
<NO>6</NO>
<PG>1345-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-2003" MODIFIED="2008-06-04 11:16:17 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 2003" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke R, Harrison G, Richards S, VITAL Trial Collaborative Group</AU>
<TI>Effect of vitamins and aspirin on markers of platelet activations oxidative stress and homocysteine in people at high risk of dementia</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2003</YR>
<VL>254</VL>
<NO>1</NO>
<PG>67-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Connelly-2008" MODIFIED="2008-07-23 13:26:57 +0100" MODIFIED_BY="Helen Collins" NAME="Connelly 2008" YEAR="">
<REFERENCE MODIFIED="2008-07-23 13:26:57 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Connelly PJ, Prentice NP, Cousland G, Bonham J</AU>
<TI>A randomised double-blind placeblo controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>2</NO>
<PG>155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Durga-2007" MODIFIED="2008-07-23 13:33:35 +0100" MODIFIED_BY="Helen Collins" NAME="Durga 2007" YEAR="">
<REFERENCE MODIFIED="2008-07-23 13:33:35 +0100" MODIFIED_BY="Helen Collins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Durga J, Van Boxtel MPV, Schouten EG, Kok FJ, Katan MB, Verhoef P</AU>
<TI>Effect of 3-year folic acid supplementation on cognition function in older adults in the FACIT trial a randomized double blind controlled trial</TI>
<SO>The Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<PG>208-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eussen-2006" MODIFIED="2008-07-23 15:54:46 +0100" MODIFIED_BY="[Empty name]" NAME="Eussen 2006" YEAR="">
<REFERENCE MODIFIED="2008-07-23 15:54:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eussen SJ, Groot LC, Joosten LW, Bloo RJ, Clarke R, et al</AU>
<TI>Effect of oral vitamin B12 with or without folic acid on cognitive function in older people with mild vitamin deficiency a randomized placebo controlled trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2006</YR>
<VL>84</VL>
<PG>361-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fioravanti-1997" NAME="Fioravanti 1997" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fioravanti M, Ferrario E, Massaia M, Cappa G, Rivolta G, Grossi E, Buckley AE</AU>
<TI>Low folate levels in the cognitive decline of elderly patients and efficacy of folate as a treatment for improving memory deficits</TI>
<SO>Archives of Gerontology and Geriatrics</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>1</NO>
<PG>1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pathansali-2006" NAME="Pathansali 2006" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pathansali R, Mangoni A, Creagh-Brown B, Lan Z, Ngow G, et al</AU>
<TI>Effects of folic acid supplementation on psychomotor performance and hemorheology in healthy elderly subjects</TI>
<SO>Archives of Gerontology and Geriatrics</SO>
<YR>2006</YR>
<VL>43</VL>
<PG>127-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sommer-2003" MODIFIED="2008-07-23 13:33:55 +0100" MODIFIED_BY="Helen Collins" NAME="Sommer 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-07-23 13:33:00 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sommer BR, Hoff AL, Costa M</AU>
<TI>Folic acid supplementation in dementia a preliminary report</TI>
<SO>Proceedings of the 11th Annual Meeting of the American Association for Geriatric Psychiatry, 1998 8-11 March, San Diego</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-23 13:33:55 +0100" MODIFIED_BY="Helen Collins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sommer BR, Hoff AL, Costa M</AU>
<TI>Folic acid supplementation in dementia: a preliminary report</TI>
<SO>Journal of Geriatric Psychiatry and Neurology</SO>
<YR>2003</YR>
<VL>16</VL>
<PG>156-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-07-23 13:35:40 +0100" MODIFIED_BY="Helen Collins">
<STUDY DATA_SOURCE="PUB" ID="STD-Brouwer-2000" MODIFIED="2008-07-23 13:34:22 +0100" MODIFIED_BY="Helen Collins" NAME="Brouwer 2000" YEAR="">
<REFERENCE MODIFIED="2008-07-23 13:34:22 +0100" MODIFIED_BY="Helen Collins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brouwer IA, Van Dusseldorp M, Thomas CMG, Duran M, Hautvast JGAJ, Eskes TK, et al</AU>
<TI>Low dose folic acid supplementation decreases plasma homocysteine concentrations a randomised trial</TI>
<SO>Indian Heart Journal</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>S52</NO>
<PG>S53-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cockle-2000" MODIFIED="2008-07-23 13:34:38 +0100" MODIFIED_BY="Helen Collins" NAME="Cockle 2000" YEAR="">
<REFERENCE MODIFIED="2008-07-23 13:34:38 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cockle SM, Haller J, Kimber S, Dawe RA, Hindmarch I</AU>
<TI>The influence of multivitamins on cognitive function and mood in the elderly</TI>
<SO>Aging and Mental Health</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>4</NO>
<PG>339-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jong-2001" NAME="Jong 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jong ND, Paw MC, Groot L, Rutten R, Swinkels DW, Kok FJ, Staveren WAV</AU>
<TI>Nutrient dense foods and exercise in frail elderly effects on B vitamins homocysteine methylmalonic acid and neuropsychological functioning</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2001</YR>
<VL>73</VL>
<PG>338-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewerin-2005" NAME="Lewerin 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewerin C, Matousek M, Steen G, Johansson B, Steen B, Nilson-Ehle H</AU>
<TI>Significant correlations of plasma homocysteine and serum methylmalonic acid with movement and cognitive performance in elderly subjects but no improvement from short-term vitamin therapy: a placebo-controlled randomized study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2005</YR>
<VL>81</VL>
<PG>1155-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McMahon-2006" NAME="McMahon 2006" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McMahon JA, Green TJ, Skeaff M, Knight RG, Mann JI, Williams SM</AU>
<TI>A controlled trial of homocysteine lowering and cognitive performance</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<PG>2764-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Passeri-1993" NAME="Passeri 1993" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Passeri M, Cucinotta D, Abate G, Senin U, Ventura A, Badiale MS, Diana R, Greca PL, Grazie L</AU>
<TI>Oral 5 methyltetrahydrofolic acid in senile organic mental disorders with depression results of a double blind multicenter study</TI>
<SO>Aging Clinical and Experimental Research</SO>
<YR>1993</YR>
<VL>5</VL>
<NO>1</NO>
<PG>63-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ralph-1974" NAME="Ralph 1974" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magnus RV, Cooper AJ</AU>
<TI>A controlled study of reactivan in geriatrics</TI>
<SO>Modern Geriatrics</SO>
<YR>1974</YR>
<VL>June</VL>
<PG>270-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stott-2005" NAME="Stott 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stott DJ, MacIntosh G, DO Lowe J, Rumley A, MacMahon AD, Langhorne P, et al</AU>
<TI>Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease</TI>
<SO>The American Journal of Clinical Nutrition</SO>
<YR>2005</YR>
<VL>82</VL>
<PG>1320-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tucker-2004" MODIFIED="2008-07-23 13:35:40 +0100" MODIFIED_BY="Helen Collins" NAME="Tucker 2004" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tucker KL, Olson B, Bakun P, Dallal GE, Selhub J, Rosenberg IH</AU>
<TI>Breakfast cereal fortified with folic acid, vitamin B6, and vitamin B12 increases vitamin concentrations and reduces homocysteine concentrations a randomized trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2004</YR>
<VL>79</VL>
<PG>805-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-23 13:35:40 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="OTHER">
<AU>Walker J, Christensen H</AU>
<TI>Beyond ageing: A study for the prevention of depression cognitive impairment and the improvement of knowledge about mental health</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-23 13:50:40 +0100" MODIFIED_BY="Helen Collins">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-23 13:50:40 +0100" MODIFIED_BY="Helen Collins">
<REFERENCE ID="REF-Abalan-1996" NAME="Abalan 1996" TYPE="JOURNAL_ARTICLE">
<AU>Abalan F, Zittoun J, Boutami C</AU>
<TI>Plasma red cell and cerebrospinal fluid folate in Alzheimer's disease</TI>
<SO>Encephale</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>430-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Antony-1995" NAME="Antony 1995" TYPE="BOOK">
<AU>Antony AC</AU>
<SO>Heamatology basic principles and practice</SO>
<YR>1995</YR>
<PG>552-86</PG>
<EN>2nd</EN>
<PB>Chirchill Livingstone</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1987" NAME="APA 1987" TYPE="BOOK">
<AU>Americam Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders</SO>
<YR>1987</YR>
<EN>3rd revised</EN>
<PB>APA</PB>
<CY>Washington</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders</SO>
<YR>1994</YR>
<PB>APA</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aronow-1997" NAME="Aronow 1997" TYPE="JOURNAL_ARTICLE">
<AU>Aronow WS, Ahn C, Schoenfed MR</AU>
<TI>Association between plasma homocysteine and extracranial carotid disease in older persons</TI>
<SO>American Journal of Cardiology</SO>
<YR>1997</YR>
<VL>79</VL>
<PG>1432</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baddeley-1988" NAME="Baddeley 1988" TYPE="JOURNAL_ARTICLE">
<AU>Baddeley A, Emslie H, Nimmo-Smith I</AU>
<TI>Estimating premorbid intelligence</TI>
<SO>Journal of Clinical Neuropsychology</SO>
<YR>1988</YR>
<VL>10</VL>
<PG>326</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benton-1955" MODIFIED="2008-06-04 13:50:15 +0100" MODIFIED_BY="[Empty name]" NAME="Benton 1955" TYPE="BOOK">
<AU>Benton AL</AU>
<SO>Revised Visual Retention Test</SO>
<YR>1955</YR>
<EN>5th</EN>
<PB>The Psychological Corporation, Harcourt, Brace and Jovanovich</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benton-1989" MODIFIED="2008-07-23 13:36:29 +0100" MODIFIED_BY="Helen Collins" NAME="Benton 1989" TYPE="BOOK">
<AU>Benton AL, Hamsher D</AU>
<SO>Multilingual Aphasia Examination</SO>
<YR>1989</YR>
<PB>Universty of Iowa</PB>
<CY>Iowa City, IA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benton-1994" MODIFIED="2008-06-04 13:42:48 +0100" MODIFIED_BY="[Empty name]" NAME="Benton 1994" TYPE="BOOK">
<AU>Benton AL, Hamsher K, Sivan AB</AU>
<SO>Multilingual aphasia examination</SO>
<YR>1994</YR>
<EN>3rd</EN>
<PB>AJA Associated</PB>
<CY>Iowa</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Botez-1979" NAME="Botez 1979" TYPE="BOOK">
<AU>Botez MT, Reynolds EH</AU>
<SO>Folic acid in neurology psychiatry and internal medicine</SO>
<YR>1979</YR>
<EN>Botez MT, Reynolds EH</EN>
<PB>Raven press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bottiglieri-1994" NAME="Bottiglieri 1994" TYPE="BOOK">
<AU>Bottiglieri T, Crellin R, Reynolds EH</AU>
<SO>Folate and Neuropsychiatry</SO>
<YR>1994</YR>
<PG>435-63</PG>
<EN>In Bailey</EN>
<PB>Marcel Dekker</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bottiglieri-2000" NAME="Bottiglieri 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bottiglieri T, Reynolds EH</AU>
<TI>Folate in CSF and age</TI>
<SO>Journal of Neurology, Neurosurgry and Psychiatry</SO>
<YR>2000</YR>
<VL>69</VL>
<PG>562</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Breteler-1994" NAME="Breteler 1994" TYPE="JOURNAL_ARTICLE">
<AU>Breteler MMB, Claus JJ, Grobbee DE</AU>
<TI>Cardiovascular disease and distribution of cognitive function in elderly people the Rotterdam study</TI>
<SO>British Medical Journal</SO>
<YR>1994</YR>
<VL>308</VL>
<PG>1604-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brocker-1986" NAME="Brocker 1986" TYPE="JOURNAL_ARTICLE">
<AU>Brocker P, Lebel C, Maurine H, Lods JC</AU>
<TI>Carences en folates chez les sujets ages interet de leir correction dans le traitment des troubles du comportement</TI>
<TO>Carences en folates chez les sujets ages interet de leir correction dans le traitment des troubles du comportement</TO>
<SO>Semaine Hopital. Paris</SO>
<YR>1986</YR>
<VL>27</VL>
<PG>2135-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bryant-1998" NAME="Bryant 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bryant CA, Farmer A, Tiplady J, Sherwood R, Swift CG, Jackson SH</AU>
<TI>Psychomotor performance: investigating the dose-response relationship for caffeine and theophylline in elderly volunteers</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1998</YR>
<VL>54</VL>
<PG>309-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bucks-1996" MODIFIED="2008-07-23 13:36:45 +0100" MODIFIED_BY="Helen Collins" NAME="Bucks 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bucks RS, Ashworth D, Wilcock GK, Siegfried K</AU>
<TI>Assessment of activities of daily living in dementia development of the Bristol activities of daily living scale</TI>
<SO>Age and Ageing</SO>
<YR>1996</YR>
<VL>25</VL>
<PG>113-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1983" NAME="Chalmers 1983" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC, Celano P, Sacks HS, Smith H</AU>
<TI>Bais in treatment assignment in controlled clinical trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<PG>1358-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chanarin-1979" NAME="Chanarin 1979" TYPE="BOOK">
<AU>Chanarin I</AU>
<SO>The Megaloblastic Anemias</SO>
<YR>1979</YR>
<PB>Blackwell Scientific Publications</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chanarin-1989" NAME="Chanarin 1989" TYPE="JOURNAL_ARTICLE">
<AU>Chanarin I, Deacon R, Lumb M, Perry J</AU>
<TI>Cobalamin folate interrelations</TI>
<SO>Blood Review</SO>
<YR>1989</YR>
<VL>3</VL>
<PG>211-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-1998" NAME="Clarke 1998" TYPE="JOURNAL_ARTICLE">
<AU>Clarke R, Smith AD, Jobst KA</AU>
<TI>Folate vitamin B12 and serum total homocysteine levels in confirmed Alzehimer's disease</TI>
<SO>Archives of Neurology</SO>
<YR>1998</YR>
<VL>55</VL>
<PG>1449-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2007" NAME="Clarke 2007" TYPE="JOURNAL_ARTICLE">
<AU>Clarke R, Sherliker P, Hin H, Nexo E, Hvas AM, Schneede J</AU>
<TI>Detection of vitamin B12 deficiency in older people by measuring vitamin B12 or the active fraction of vitamin B12, holotranscobalamin</TI>
<SO>Clinical Chemistry</SO>
<YR>2007</YR>
<VL>53</VL>
<PG>963-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cole-2007" MODIFIED="2008-07-23 13:37:03 +0100" MODIFIED_BY="Helen Collins" NAME="Cole 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS et al</AU>
<TI>Folic acid for the prevention of colorectal adenomas: a randomized clinical trial</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2007</YR>
<VL>297</VL>
<PG>2351-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooper-1986" NAME="Cooper 1986" TYPE="BOOK">
<AU>Cooper BA</AU>
<SO>Nutritional Pharmacological and Physiological Aspects /Folate nutrition in man and animals</SO>
<YR>1986</YR>
<EN>Blakley R</EN>
<PB>Blakley RL, Whitehead VM</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corrada-2005" MODIFIED="2008-07-23 13:38:23 +0100" MODIFIED_BY="Helen Collins" NAME="Corrada 2005" TYPE="JOURNAL_ARTICLE">
<AU>Corrada M, Kawas CH, Hallfrisch J, Muller D, Brookmeyer R</AU>
<TI>Reduced risk of Alzheimer's disease with high folate intake: the Baltimore Longitudinal Study of Aging</TI>
<SO>Alzheimer Disease and Associated Disorders</SO>
<YR>2005</YR>
<VL>1</VL>
<PG>11-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dodrill-1978" NAME="Dodrill 1978" TYPE="JOURNAL_ARTICLE">
<AU>Dodrill CB</AU>
<TI>A neuropsychological battery for epilepsy</TI>
<SO>Epilepsia</SO>
<YR>1978</YR>
<VL>19</VL>
<PG>611-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Earles-1995" MODIFIED="2008-07-23 13:38:47 +0100" MODIFIED_BY="Helen Collins" NAME="Earles 1995" TYPE="JOURNAL_ARTICLE">
<AU>Earles JL, Salthouse TA</AU>
<TI>Interrelations of age health and speed</TI>
<SO>Journals of Gerontology B. Psychology and Social Sciences</SO>
<YR>1995</YR>
<VL>50B</VL>
<PG>33-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebly-1998" NAME="Ebly 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ebly EM, Schaefer JP, Campbell NRC</AU>
<TI>Folate status vascular disease and cognition in elderly Canadians</TI>
<SO>Age and Ageing</SO>
<YR>1998</YR>
<VL>27</VL>
<PG>485-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feher-1992" NAME="Feher 1992" TYPE="JOURNAL_ARTICLE">
<AU>Feher EP, Mahurin RK, Doody RS, Cooke N, Sims J, Prizzolo FJ.</AU>
<TI>Establishing the limits of the mini mental state examination of subtests</TI>
<SO>Archives of Neurology</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>1</NO>
<PG>87-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferri-2005" MODIFIED="2008-05-13 15:25:38 +0100" MODIFIED_BY="[Empty name]" NAME="Ferri 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ferri PC, Prince M, Brayne C, Brodaty H, Fratiglioni H, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y et al,</AU>
<TI>Global prevalence of dementia: a Delphi consensus study</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<PG>2112-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Folstein-1975" NAME="Folstein 1975" TYPE="JOURNAL_ARTICLE">
<AU>Folstein MF, Folstein SE, McHugh PR</AU>
<TI>Mini mental state, a practical method for grading cognitive state of patients for the clinician</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1975</YR>
<VL>313</VL>
<PG>1419-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galasko-1990" NAME="Galasko 1990" TYPE="JOURNAL_ARTICLE">
<AU>Galasko D, Klauber MR, Hofstetter CR</AU>
<TI>The Mini Mental State examination in the early diagnosis of Alzheimer's disease</TI>
<SO>Archives of Neurology</SO>
<YR>1990</YR>
<VL>47</VL>
<PG>49-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Getzels-1962" NAME="Getzels 1962" TYPE="BOOK">
<AU>Getzels JW, Jackson PW</AU>
<SO>Creativity and Intelligence</SO>
<YR>1962</YR>
<PB>Wiley</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gospe-1995" NAME="Gospe 1995" TYPE="JOURNAL_ARTICLE">
<AU>Gospe SM, Gietzen DW, Summers PJ, Lunetta JM, Miller JW, Selhub J</AU>
<TI>Behavioral and neurochemical changes in folate deficient mice</TI>
<SO>Journal of Physiology and Behavior</SO>
<YR>1995</YR>
<VL>58</VL>
<PG>935-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gottfries-1998" NAME="Gottfries 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gottfries CG, Lehman W, Regland B</AU>
<TI>Early diagnosis of cognitive impairment in the elderly with the focus on Alzheimer's disease</TI>
<SO>Journal of Neural Transmission</SO>
<YR>1998</YR>
<VL>105</VL>
<PG>773-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hassing-1999" NAME="Hassing 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hassing L, Wahlin A, Winblad B</AU>
<TI>Further evidence for the effects of vitamin B12 and folate status on episodic memory functioning a population based study of very old adults</TI>
<SO>Biological Psychiatry</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>11</NO>
<PG>1472-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herbert-1985" NAME="Herbert 1985" TYPE="JOURNAL_ARTICLE">
<AU>Herbert V</AU>
<TI>Megaloblastic anemias</TI>
<SO>Laboratory Investigation</SO>
<YR>1985</YR>
<VL>52</VL>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herbet-1961" MODIFIED="2008-07-23 13:42:26 +0100" MODIFIED_BY="Helen Collins" NAME="Herbet 1961" TYPE="JOURNAL_ARTICLE">
<AU>Herbet V</AU>
<TI>Experimental nutritional folate deficiency in men</TI>
<SO>Transactions of the Association of American Physicians</SO>
<YR>1961</YR>
<VL>75</VL>
<PG>307-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2008-07-22 17:14:23 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]</TI>
<SO>The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirsch-2002" NAME="Hirsch 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch S, Maza P, Barrera G, Gattas V, Petermann M, Bunout D</AU>
<TI>The Chilean folic acid fortification program reduces serum homocysteine levels and masks vitamin B12 deficiency in elderly people</TI>
<SO>Journal of Nutrition</SO>
<YR>2002</YR>
<VL>132</VL>
<PG>289-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hofman-1997" NAME="Hofman 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hofman A, Ott A, Breteler MMB</AU>
<TI>Atherosclerosis apolipoprotein E and the prevalence of dementia and Alzheimer's disease in the Rotterdam Study</TI>
<SO>The Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>151-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICD_x002d_10-1992" NAME="ICD-10 1992" TYPE="BOOK">
<AU>World Health Organizition</AU>
<SO>The ICD-10 classification of mental and behavioural disorders clinical description and diagnostic guidelines</SO>
<YR>1992</YR>
<PB>World Health Organisation, Division of Mental Health</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacques-1999" NAME="Jacques 1999" TYPE="JOURNAL_ARTICLE">
<AU>Jacques PF, Selhub J, Bostom A, Peter WF, Wilson P et al</AU>
<TI>The effect of folic acid fortification on plasma and total homocysteine concentrations</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<PG>1449-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jorm-1987" NAME="Jorm 1987" TYPE="JOURNAL_ARTICLE">
<AU>Jorm AF, Korten AE, Henderson AS</AU>
<TI>The prevalence of dementia a quantitative integration of the literature</TI>
<SO>Acta Psychiatrica Scandanavica</SO>
<YR>1987</YR>
<VL>76</VL>
<PG>465-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kalra-1993" NAME="Kalra 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kalra L, Jakson SH, Swift CG</AU>
<TI>Assessment of changes in psychomotor performance in elderly subjects</TI>
<SO>British Journal of Pharmacology</SO>
<YR>1993</YR>
<VL>36</VL>
<PG>383-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1983" MODIFIED="2008-06-04 13:38:57 +0100" MODIFIED_BY="[Empty name]" NAME="Kaplan 1983" TYPE="BOOK">
<AU>Kaplan E, Goodglass H, Weintraub S</AU>
<SO>The Boston Naming Test</SO>
<YR>1983</YR>
<PB>Lea and Febiger</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keane-1998" NAME="Keane 1998" TYPE="JOURNAL_ARTICLE">
<AU>Keane EM, O'Broin S, Kelleher B, Coakley D, Walsh JB</AU>
<TI>Use of folic acid fortified milk in the elderly population</TI>
<SO>Gerontology</SO>
<YR>1998</YR>
<VL>44</VL>
<PG>336-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kruman-2002" NAME="Kruman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kruman Inna I, Kumaravel TS, Lohani A</AU>
<TI>Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of alzheimer's disease</TI>
<SO>Journal of Neuroscience</SO>
<YR>2002</YR>
<VL>22</VL>
<PG>1752-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-La-Rue-1997" NAME="La Rue 1997" TYPE="JOURNAL_ARTICLE">
<AU>La Rue A, Koehler Km, Wayne SJ, Chiulli SJ, Haaland KY, Garry PJ</AU>
<TI>Nutritional status and cognitive functioning in a normally aging sample a 6 year reassessment</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1997</YR>
<VL>65</VL>
<PG>20-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levitt-1989" NAME="Levitt 1989" TYPE="JOURNAL_ARTICLE">
<AU>Levitt AJ, Joffe RT</AU>
<TI>Folate vitamin B12 and life course of depressive illness</TI>
<SO>Biological Psychiatry</SO>
<YR>1989</YR>
<VL>25</VL>
<PG>867-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lezak-1995" NAME="Lezak 1995" TYPE="BOOK">
<AU>Lezak MD</AU>
<SO>Neuropsychological Assessment</SO>
<YR>1995</YR>
<EN>Third ed</EN>
<PB>Oxford University Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malouf-2003-a" NAME="Malouf 2003 a" NOTES="&lt;p&gt;Malouf R, Areosa Sastre A. Vitamin B12 for cognition (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley &amp;amp; Sons, Ltd. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Malouf R, Areosa Sastre A</AU>
<TI>Vitamin B12 for cognition</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons</PB>
<CY>Chicester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marcus-1998" NAME="Marcus 1998" TYPE="JOURNAL_ARTICLE">
<AU>Marcus EL, Berry EM</AU>
<TI>Refused to eat in the elderly</TI>
<SO>Nutrition Reviews</SO>
<YR>1998</YR>
<VL>56</VL>
<PG>163-171</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mason-2007" MODIFIED="2008-07-23 13:43:28 +0100" MODIFIED_BY="Helen Collins" NAME="Mason 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mason JB, Dickstein A, Jacques PF, Haggarty P, Selhub J, Dallal G et al</AU>
<TI>A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis</TI>
<SO>Cancer Epidemiology Biomarkers and Prevention</SO>
<YR>2007</YR>
<VL>16</VL>
<PG>1325-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayer-1996" NAME="Mayer 1996" TYPE="JOURNAL_ARTICLE">
<AU>Mayer EL, Jacobsen DW, Robinson K</AU>
<TI>Homocysteine and coronary atherosclerosis</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1996</YR>
<VL>27</VL>
<PG>517</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCaddon-1998" NAME="McCaddon 1998" TYPE="JOURNAL_ARTICLE">
<AU>McCaddon A, Davis G, Hudson P, Tandy S, Cattell H</AU>
<TI>Total serum homocysteine in senile dementia of Alzheimer type</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1998</YR>
<VL>13</VL>
<PG>235-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKhann-1984" NAME="McKhann 1984" TYPE="JOURNAL_ARTICLE">
<AU>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM</AU>
<TI>Clinical diagnosis of Alzheimer&#8217;s disease report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer&#8217;s disease</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>4</VL>
<PG>939-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McNair-1971" NAME="McNair 1971" TYPE="BOOK">
<AU>McNair PM</AU>
<SO>Profile of mood states manual</SO>
<YR>1971</YR>
<PB>Education and Industrial Testing Service</PB>
<CY>San Diego, CA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meindok-1970" NAME="Meindok 1970" TYPE="JOURNAL_ARTICLE">
<AU>Meindok H, Dvorsky R</AU>
<TI>Serum folate and vitamin B12 levels in the elderly</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1970</YR>
<VL>18</VL>
<PG>317-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morris-2005" MODIFIED="2008-07-23 13:43:53 +0100" MODIFIED_BY="Helen Collins" NAME="Morris 2005" TYPE="JOURNAL_ARTICLE">
<AU>Morris MC, Evans DA, Bienias JL, et al</AU>
<TI>Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons</TI>
<SO>Archives of Neurology</SO>
<YR>2005</YR>
<VL>62</VL>
<PG>641-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morris-2007" MODIFIED="2008-06-30 09:09:22 +0100" MODIFIED_BY="[Empty name]" NAME="Morris 2007" TYPE="JOURNAL_ARTICLE">
<AU>Morris MS, Jacques PF, Rosenberg IH, Selhub J</AU>
<TI>Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2007</YR>
<VL>85</VL>
<PG>193-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2006a" MODIFIED="2008-07-23 13:44:49 +0100" MODIFIED_BY="Helen Collins" NAME="NICE 2006a" TYPE="OTHER">
<AU>NICE</AU>
<TI>Donepezil, galantamine, revastigmine and memantine for the treatment of Alzheimer's disease</TI>
<SO>www.nice.org/uk</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nygard-1997" NAME="Nygard 1997" TYPE="JOURNAL_ARTICLE">
<AU>Nygard O, Nordrehauge JE, Refsum H</AU>
<TI>Plasma homocysteine levels and mortality in patients with coronary artery disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<PG>230</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ortega-1996" NAME="Ortega 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ortega RM, Manas LR, Andres P, Gaspar MJ, Agudo FR et al</AU>
<TI>Functional and psychic deterioration in elderly people may be aggravated by folate deficiency</TI>
<SO>Journal of Nutrition</SO>
<YR>1996</YR>
<VL>126</VL>
<PG>1992-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perry-1995" NAME="Perry 1995" TYPE="JOURNAL_ARTICLE">
<AU>Perrt IJ, Refsum H, Morris RW</AU>
<TI>Protictive study of serum total homocysteine concentaration and risk of stroke in middle aged British men</TI>
<SO>The Lancet</SO>
<YR>1995</YR>
<VL>346</VL>
<PG>1395</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petrides-1982" NAME="Petrides 1982" TYPE="JOURNAL_ARTICLE">
<AU>Petrides M, Milner B</AU>
<TI>Deficts on subject ordered tasks after frontal and temporal lobe lesions in man</TI>
<SO>Neuropsychologia</SO>
<YR>1982</YR>
<VL>20</VL>
<PG>249-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prince-1999" NAME="Prince 1999" TYPE="JOURNAL_ARTICLE">
<AU>Prince M, MacDonald AM, Sham PC, Richards M, Quraishi S, Horn I</AU>
<TI>The development and validation of a telephone administered cognitive test battery (TACT)</TI>
<SO>The International Journal of Methods in Psychiatric Research</SO>
<YR>1999</YR>
<VL>8</VL>
<PG>49-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Radloff-1977" NAME="Radloff 1977" TYPE="JOURNAL_ARTICLE">
<AU>Radloff LS</AU>
<TI>The CES-D scale a self report depression scale for research in the general population</TI>
<SO>Applied Psychological Measurement</SO>
<YR>1977</YR>
<VL>1</VL>
<NO>3</NO>
<PG>385-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Randt-1983" NAME="Randt 1983" TYPE="BOOK">
<AU>Randt CT, Brown ER</AU>
<SO>Randt memory test administration manual</SO>
<YR>1983</YR>
<PB>Life Science Associates</PB>
<CY>Bayport, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ravaglia-2005" MODIFIED="2008-05-13 12:30:33 +0100" MODIFIED_BY="[Empty name]" NAME="Ravaglia 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ravaglia G, Forti P, Maioli F, et al</AU>
<TI>Homocysteine and folate as risk factors for dementia and Alzheimer disease</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2005</YR>
<VL>82</VL>
<PG>636-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reisberg-1982" NAME="Reisberg 1982" TYPE="JOURNAL_ARTICLE">
<AU>Reisberg B, Ferris SH, de Leon MJ, Crook T</AU>
<TI>The global deterioration scale for the assessment of primary degenerative dementia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1982</YR>
<VL>139</VL>
<PG>1136-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reitan-1974" MODIFIED="2008-06-04 13:58:13 +0100" MODIFIED_BY="[Empty name]" NAME="Reitan 1974" TYPE="BOOK">
<AU>Reitan RM, Davidson LA</AU>
<SO>Clinical neuropsychology: Current status and applications</SO>
<YR>1974</YR>
<PB>Hemisphere</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reitan-1985" MODIFIED="2008-07-23 13:45:39 +0100" MODIFIED_BY="Helen Collins" NAME="Reitan 1985" TYPE="BOOK">
<AU>Reitan RM, Wolfson D</AU>
<SO>The Halstead Reitan Neuropsychological Test Battery</SO>
<YR>1985</YR>
<PB>Neuropsychology Press</PB>
<CY>Tucson, AZ</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reitan-1992" MODIFIED="2008-06-04 13:53:49 +0100" MODIFIED_BY="[Empty name]" NAME="Reitan 1992" TYPE="BOOK">
<AU>Reitan RM</AU>
<SO>Trial making test : Manual for administration and scoring</SO>
<YR>1992</YR>
<PB>Reitan Neuropsychological Laboratory</PB>
<CY>Tucson</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Renvall-1989" NAME="Renvall 1989" TYPE="JOURNAL_ARTICLE">
<AU>Renvall MJ, Spindler AA, Ramsdell JW</AU>
<TI>Nutritional status of free living Alzheimer's patients</TI>
<SO>American Journal of Medical Science</SO>
<YR>1989</YR>
<VL>298</VL>
<PG>20-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rey-1964" NAME="Rey 1964" TYPE="BOOK">
<AU>Rey A</AU>
<TI>Psychological clinical examination</TI>
<SO>L'examen clinique en psychologie</SO>
<YR>1964</YR>
<PB>Presses Universitaires de France</PB>
<CY>Paris, France</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reynolds-1976" NAME="Reynolds 1976" TYPE="JOURNAL_ARTICLE">
<AU>Reynolds EH</AU>
<TI>Neurological aspects of folate and vitamin B12 metabolism</TI>
<SO>Clinics in Haematology</SO>
<YR>1976</YR>
<VL>5</VL>
<PG>661-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosen-1984" MODIFIED="2008-07-23 13:45:54 +0100" MODIFIED_BY="Helen Collins" NAME="Rosen 1984" TYPE="JOURNAL_ARTICLE">
<AU>Rosen WG, Mohs RC, Davis KL</AU>
<TI>A new rating scale for Alzheimer's disease</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1984</YR>
<VL>141</VL>
<PG>1356-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenberg-1985" NAME="Rosenberg 1985" TYPE="JOURNAL_ARTICLE">
<AU>Rosenberg IH, Zimmerman J, Selhub J</AU>
<TI>Folate transport</TI>
<SO>Chemioterapia</SO>
<YR>1985</YR>
<VL>4</VL>
<PG>354</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-07-23 13:46:05 +0100" MODIFIED_BY="Helen Collins" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman D</AU>
<TI>Empirical evidence of bias</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Selhub-1993" MODIFIED="2008-07-23 13:46:27 +0100" MODIFIED_BY="Helen Collins" NAME="Selhub 1993" TYPE="JOURNAL_ARTICLE">
<AU>Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH</AU>
<TI>Vitamin status and intake as primary determinants of homocysteinemia in an elderly population</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1993</YR>
<VL>270</VL>
<NO>22</NO>
<PG>2693-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Senti-1985" NAME="Senti 1985" TYPE="JOURNAL_ARTICLE">
<AU>Snti</AU>
<TI>Analysis of folate data from the second national health examination study (NHANESII)</TI>
<SO>Journal of Niutrition</SO>
<YR>1985</YR>
<VL>115</VL>
<NO>11</NO>
<PG>1398-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seshadri-2002" NAME="Seshadri 2002" TYPE="JOURNAL_ARTICLE">
<AU>Seshadri S, Beiser A, Selhub J, Jacques P, Jacques PF, Rosenberg IH</AU>
<TI>Plasma homocysteine as a risk factor for dementia and Alzheimer's disease</TI>
<SO>The New Engalnd Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<PG>476-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shane-1985" NAME="Shane 1985" TYPE="JOURNAL_ARTICLE">
<AU>Shane B, Stokstad ELB</AU>
<TI>Vitamin B12 folate interrelationships</TI>
<SO>Annual Review of Nutrition</SO>
<YR>1985</YR>
<VL>5</VL>
<PG>115-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Small-1997" NAME="Small 1997" TYPE="JOURNAL_ARTICLE">
<AU>Small GW, Rabins PV, Barry PP</AU>
<TI>Diagnosis and treatment of Alzheimer disease and related disorders</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1997</YR>
<VL>278</VL>
<PG>1363-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2002" MODIFIED="2008-07-23 13:46:57 +0100" MODIFIED_BY="Helen Collins" NAME="Smith 2002" TYPE="BOOK">
<AU>Smith PG</AU>
<SO>Clinical Pharmacology and Drug Therapy</SO>
<YR>2002</YR>
<EN>3rd</EN>
<PB>Oxford Textbook</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2008" MODIFIED="2008-07-22 16:39:27 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2008" TYPE="JOURNAL_ARTICLE">
<AU>Smith DA</AU>
<TI>The worldwide challenge of the dementias: a role for B vitamins and homocysteine?</TI>
<SO>Food and Nutrition Bulletin</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>2</NO>
<PG>S143-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sneath-1973" NAME="Sneath 1973" TYPE="JOURNAL_ARTICLE">
<AU>Sneath P, Chanarin I, Hodkinson HM, McPherson CK, Reynolds EH</AU>
<TI>Folate status in a geriatric population and its relation to dementia</TI>
<SO>Age and Ageing</SO>
<YR>1973</YR>
<VL>2</VL>
<PG>177-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Snowdon-2000" NAME="Snowdon 2000" TYPE="JOURNAL_ARTICLE">
<AU>Snowdon DA, Tully CL, Smith CD, Riley KP, Markesbery WR</AU>
<TI>Serum folate and the severity of atrophy of the neocortex in Alzheimer disease finding from the nun study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>4</NO>
<PG>993-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spiegel-1991" MODIFIED="2008-05-14 10:12:57 +0100" MODIFIED_BY="[Empty name]" NAME="Spiegel 1991" TYPE="JOURNAL_ARTICLE">
<AU>Spiegel R, Brunner C, Ermini-Funfschilling D, et al</AU>
<TI>A new behavioural assessment scale for geriatric out and in patients the NOSGER (Nurses' Observation scale for geriatric patients)</TI>
<SO>Journal of The American Geriatrics Society</SO>
<YR>1991</YR>
<VL>39</VL>
<NO>4</NO>
<PG>339-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spreen-1998" MODIFIED="2008-07-23 13:47:25 +0100" MODIFIED_BY="Helen Collins" NAME="Spreen 1998" TYPE="BOOK">
<AU>Spreen O, Strauss E</AU>
<SO>A compendium of neuropsychological test administration</SO>
<YR>1998</YR>
<EN>2nd</EN>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stabler-1986" NAME="Stabler 1986" TYPE="JOURNAL_ARTICLE">
<AU>Stabler SP, Marcell PD, Podell ER</AU>
<TI>Assay of methylmalonic acid in the serum of patients with cobalamin deficiency using capillary gas chromatography mass spectrometry</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1986</YR>
<VL>77</VL>
<NO>5</NO>
<PG>1606-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stabler-1988" NAME="Stabler 1988" TYPE="JOURNAL_ARTICLE">
<AU>Stabler SP, Marcell PD, Podell ER</AU>
<TI>Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography mass spectrometry</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1988</YR>
<VL>81</VL>
<PG>466</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stehouwer-1998" NAME="Stehouwer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Stehouwer CDA, Weijenberg MP, Van den Berg M</AU>
<TI>Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men a ten year follow up</TI>
<SO>Arteriosclerosis Thrombosis and Vascular Biology</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>1895-901</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ueland-1993" NAME="Ueland 1993" TYPE="JOURNAL_ARTICLE">
<AU>Ueland PM, Refsum H, Stabler SP, Malinow MR, Anderson A, Allen RH</AU>
<TI>Total homocysteine in plasma or serum methods and clinical applications</TI>
<SO>Clinical Chemistry</SO>
<YR>1993</YR>
<VL>39</VL>
<PG>1764-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-der-Elst-2006-a" MODIFIED="2008-07-23 13:48:42 +0100" MODIFIED_BY="Helen Collins" NAME="Van der Elst 2006 a" TYPE="JOURNAL_ARTICLE">
<AU>Van der Elst W, van Boxtel Mp, Van Breukelen GJ, Jolles J</AU>
<TI>Rey's verbal learning test: normative data for 1855 healthy participants ages 24-81 years and the influence of age, sex, education and mood of presentation</TI>
<SO>Journal of the International Neuropsychological Society</SO>
<YR>2005</YR>
<VL>11</VL>
<PG>290-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-der-Elst-2006-b" MODIFIED="2008-07-23 13:49:47 +0100" MODIFIED_BY="Helen Collins" NAME="Van der Elst 2006 b" TYPE="JOURNAL_ARTICLE">
<AU>Van der Elst W, Boxtel MP, Breukelen GJ, Jolles J</AU>
<TI>The concept shifting test: adult normative data</TI>
<SO>Psychological Assessment</SO>
<YR>2006</YR>
<VL>18</VL>
<PG>424-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wahlin-1996" NAME="Wahlin 1996" TYPE="JOURNAL_ARTICLE">
<AU>Wahlin A, Hill RD, Winblad B</AU>
<TI>Effects of serum vitamin B12 and folate status on episodic memeory performance in very old age a population based study</TI>
<SO>Psychology and Aging</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>487-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2001" NAME="Wang 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L</AU>
<TI>Vitamin B12 and folate in relation to the development of Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>9</NO>
<PG>1188-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wechsler-1955" MODIFIED="2008-06-04 13:46:09 +0100" MODIFIED_BY="[Empty name]" NAME="Wechsler 1955" TYPE="BOOK">
<AU>Wechsler D, Stone CP</AU>
<SO>Wechsler Memory Scale manual</SO>
<YR>1955</YR>
<PB>The Psychological Corporation, Harcourt, Brace and Jovanovich</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wechsler-1997" MODIFIED="2008-07-23 13:50:31 +0100" MODIFIED_BY="Helen Collins" NAME="Wechsler 1997" TYPE="BOOK">
<AU>Wechsler D</AU>
<SO>Wechsler adult intelligence scale</SO>
<YR>1997</YR>
<EN>3rd</EN>
<PB>The Psychological Corporation/Harcourt Brace</PB>
<CY>San Antonio, TX</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wecshler-1981" MODIFIED="2008-07-23 13:50:40 +0100" MODIFIED_BY="Helen Collins" NAME="Wecshler 1981" TYPE="BOOK">
<AU>Wecshler D</AU>
<SO>Wecshler Adult Intelligence Scale Revised</SO>
<YR>1981</YR>
<PB>The psychological Corporation</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Welchsler-1982" MODIFIED="2008-06-04 13:35:29 +0100" MODIFIED_BY="[Empty name]" NAME="Welchsler 1982" TYPE="BOOK">
<AU>Wechsler D</AU>
<SO>Wechsler Adult Intelligence Scale-Revised manual</SO>
<YR>1982</YR>
<PB>The Psychological Corporation, Harcourt, Brace and Jovanovich</PB>
<CY>New-York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitehead-1995" NAME="Whitehead 1995" TYPE="JOURNAL_ARTICLE">
<AU>Whitehead AS, Gallagher PM, Mills JM, Kirke P, Burke H, Molloy AM, Weir DG, Shields DC, Scott JM</AU>
<TI>A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>1995</YR>
<VL>88</VL>
<PG>763-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Malouf-2003-b" NAME="Malouf 2003 b" TYPE="COCHRANE_REVIEW">
<AU>Malouf R, Grimley Evans J, Areosa Sastre A</AU>
<TI>Folic acid with or without vitamin B12 for cognition and dementia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-07-23 16:15:10 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-07-23 16:15:10 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-05-13 10:58:20 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Bryan-2002">
<CHAR_METHODS>
<P>35 days, randomized, double-blind, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Australia<BR/>221 women were enrolled<BR/>75 elderly participants <BR/>aged 65-92 years<BR/>40 of the elderly group assigned randomly 19 to folic group and 21 to placebo group.<BR/>Selection criteria: healthy women and English as a first language.<BR/>Exclusion criteria:<BR/>* Smoking<BR/>*On hormone replacement therapy (HRT).<BR/>* On medication that could affect mental performance.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 11:56:32 +0100" MODIFIED_BY="[Empty name]">
<P>1- placebo<BR/>2- 750 microgram of folate /day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-13 10:58:20 +0100" MODIFIED_BY="Helen Collins">
<P>* Speed of processing:<BR/>1-Boxes test<BR/>2-Digit Symbol Coding<BR/>3-Symbol Search</P>
<P>*Working Memory:<BR/>1-Digit Span Backwards<BR/>2-Letter Number Sequencing</P>
<P>*Free Recall:<BR/>1-Immediate Recall<BR/>2-Delayed Recall<BR/>3-Recognition</P>
<P>*Incidental Recall:<BR/>1-Digit Symbol<BR/>2-Symbol Position<BR/>3-Activity</P>
<P>*Verbal ability</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>One participant dropped from the folic acid group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 14:08:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clarke-2003">
<CHAR_METHODS>
<P>12 weeks 2x2x2 factorial design randomized, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 14:08:26 +0100" MODIFIED_BY="[Empty name]">
<P>Country: England<BR/>149 participants<BR/>Aged 56-89<BR/>Inclusion criteria:<BR/>1-Clinical diagnosis of dementia using DSM IV and MMSE score between 12 and 26 or<BR/>2-MIC with TICS-M score below 27<BR/>Exclusion criteria:<BR/>1-Frontal lobe dementia, Huntington's disease, normal pressure hydrocephalus<BR/>2-Taken any of the study treatments.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1-placebo<BR/>2-81 mg aspirin<BR/>3-2 mg folic acid<BR/>4-1 mg B12<BR/>5-500 mg vitamin E<BR/>6-200 mg vitamin C</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1-MMSE<BR/>2-DSM IV<BR/>3-TICS-M<BR/>4-Homocysteine levels<BR/>5-Folate levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>seven participants dropped from the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-13 11:46:33 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Connelly-2008">
<CHAR_METHODS>
<P>6 months randomized, double-blind placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-13 11:46:25 +0100" MODIFIED_BY="Helen Collins">
<P>Country: Scotland<BR/>75 patients with AD</P>
<P>Inclusion criteria:<BR/>1-Unable to perform significantly in the study protocol<BR/>2-Cerebrovascular comorbid condition<BR/>3-conditions that interacts with folate or B12 metabolism<BR/>4-Usage of ChI primarily for hallucination or delusion<BR/>5-Taking folic acid or B12<BR/>6-AD based on NINCDS-ADRDA criteria<BR/>7-Were treated according to NICE 2001<BR/>8-Scoring 0 or 1 on MHI scale</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-13 11:46:33 +0100" MODIFIED_BY="Helen Collins">
<P>1-placebo<BR/>2-1 mg folic acid/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1-MMSE<BR/>2-DSST<BR/>3-IADL<BR/>4-SB of NOSGER<BR/>5-HCy level</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 13:17:08 +0100" MODIFIED_BY="[Empty name]">
<P>All patients were on ChI</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-06 11:56:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Durga-2007">
<CHAR_METHODS>
<P>3-year randomized, double-blind, placebo controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-06 11:56:59 +0100" MODIFIED_BY="[Empty name]">
<P>Country: The Netherlands<BR/>818 elderly aged 50-70 years<BR/>Exclusion criteria:<BR/>1-total plasma homocysteine &lt; 13 mcm/l<BR/>2-homocysteine level &gt; 26 mcm/l<BR/>3-serum B12 &lt; 200pmol/l<BR/>3-renal or theroid disease<BR/>4-use of medications that interact with folic acid<BR/>5-intestinal disease<BR/>6-using vitamin B supplements<BR/>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1-placebo<BR/>2-800 mcg/day folic acid<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1-word learning test<BR/>2-concept shifting test<BR/>3-stroop colour-word test<BR/>4-verbal fluency test<BR/>5-letter digit substitution test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-23 13:21:49 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Eussen-2006">
<CHAR_METHODS>
<P>6 months randomized double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-23 13:21:47 +0100" MODIFIED_BY="Helen Collins">
<P>Country: The Netherlands<BR/>195 elderly were enrolled<BR/>Inclusion criteria:<BR/>1-Free-living or in elderly homes<BR/>2- Age &lt; 70 years</P>
<P>Exclusion criteria:<BR/>1-Current use of B12 injection<BR/>2-current use of high-dose multivitamins<BR/>3-gastrointestinal surgery<BR/>4-suffering from stoma, anaemia, dementia, life-threatening disease, visual/hearing problems</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-23 13:21:49 +0100" MODIFIED_BY="Helen Collins">
<P>1-placebo<BR/>2-1000 mcg B12<BR/>3-1000 mcg B12 + 400 mcg folic acid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 13:17:55 +0100" MODIFIED_BY="[Empty name]">
<P>1-MMSE<BR/>2-CRD<BR/>3-GDS<BR/>4-tHcy<BR/>5-MMA<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-23 13:22:28 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Fioravanti-1997">
<CHAR_METHODS>
<P>60 days, randomized, double-blind, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-23 13:22:28 +0100" MODIFIED_BY="Helen Collins">
<P>Country: Italy<BR/>30 participants<BR/>Aged 70-90<BR/>16 in the treatment group<BR/>14 in the placebo group<BR/>Inclusion criteria:<BR/>1-Low folate level &lt; 3 ng/ml<BR/>2-Very mild to moderate severity cognitive decline according to the (GDS) and MMSE score.</P>
<P>Exclusion criteria:<BR/>1-Gastrointestinal, endocrinal, cardiovascular, renal disorders<BR/>2-Depression<BR/>3-24&lt;MMSE&lt;16<BR/>4-Vitamin supplement<BR/>5-Alcohol consumption less than 55 g/d of alcohol</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 13:18:11 +0100" MODIFIED_BY="[Empty name]">
<P>1-placebo<BR/>2-15 mg/day of folic acid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1-Randt Memory Test (RMT)<BR/>2-Acquisition and recall<BR/>3-Delayed Recall<BR/>4-Memory Index<BR/>5-Encoding<BR/>6-Cognitive Efficiency<BR/>7-Attention Efficiency</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>One patient dropped from the placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-23 13:22:57 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Pathansali-2006">
<CHAR_METHODS>
<P>4-week randomized double-blind placebo controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-23 13:22:57 +0100" MODIFIED_BY="Helen Collins">
<P>Country: UK<BR/>24 healthy participants were enrolled</P>
<P>Inclusion criteria:<BR/>1-age&gt;65 years<BR/>2-no previous history of vascular disease, hypertension, diabetes or smoking<BR/>3-MMSE &gt; 27<BR/>4-no folic acid or vitamin B12 deficiency<BR/>5-normal renal function<BR/>6-not on vitamin supplement or any medication that affects folic acid levels</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-06 12:39:43 +0100" MODIFIED_BY="[Empty name]">
<P>1-placebo<BR/>2-5 mg/day folic acid/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1-CAT<BR/>2-FCRT<BR/>3-DSS<BR/>4-SMS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-23 16:15:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sommer-2003">
<CHAR_METHODS MODIFIED="2008-07-23 15:56:53 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-23 16:08:04 +0100" MODIFIED_BY="[Empty name]">
<P>11 patients with (AD, vascular and frontotemporal, and other dementia)</P>
<P>Inclusion criteria:</P>
<P>1-Age 65 years and over</P>
<P>2-Demented based on DSM-III-R</P>
<P>3-Serum folates between 2 and 5 mcg/L, red blood cell folic acid levels between 127 and 452 mcg/L, and normal vitamin B12 levels (above 200 ng/L)</P>
<P>
<BR/>
</P>
<P>Exclusion criteria:</P>
<P>1-Patients with seizure disorder </P>
<P>2-Patients with major depression or need for antidepressant medication </P>
<P>3-On oral multivitamins supplements refrained for at least 1 month prior to the study</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-23 16:15:10 +0100" MODIFIED_BY="[Empty name]">
<P>1-placebo <BR/>2-10 mg folic acid for10 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-23 16:01:56 +0100" MODIFIED_BY="[Empty name]">
<P>1-Prorated Verbal IQ</P>
<P>2-Boston Naming Test</P>
<P>3-Controlled Oral Word Association Test</P>
<P>4-Logical Memory and Associate Learning subtests</P>
<P>5-Benton Visual Retention Test</P>
<P>6-Trail Making Test (Trails A and B)</P>
<P>7-Finger Tapping Test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-23 15:57:36 +0100" MODIFIED_BY="[Empty name]">
<P>Folic acid group performed worse on the Learning associated Task</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>GDS: Global Deterioration Scale<BR/>MMSE: Mini Mental State Examination<BR/>RMT: Randt Memory Test<BR/>DSST: Digit Symbol Substitution Test<BR/>SB: Social behaviour<BR/>NOSGER: Nurses Observation Scale for Geriatric Patients<BR/>CDR: Clinical Dementia Rating<BR/>tHcy: total homocysteine<BR/>MMA: Methylmalonic acid<BR/>holo TC: holotranscobalamin<BR/>CAT: Continuous Attention Test<BR/>FCRT: Four-Choice Reaction Time<BR/>SMS: Scanning Memory Sets<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-07-23 13:25:49 +0100" MODIFIED_BY="Helen Collins" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Brouwer-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Younger age participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-23 13:25:32 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Cockle-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-23 13:25:32 +0100" MODIFIED_BY="Helen Collins">
<P>Multivitamin intervention study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-23 13:25:34 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Jong-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-23 13:25:34 +0100" MODIFIED_BY="Helen Collins">
<P>Multivitamin intervention study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lewerin-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention confounded by cyanocobalamin and vitamin B6</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McMahon-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention confounded with vitamins B12 and B6</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Passeri-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not placebo-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-23 13:25:43 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Ralph-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-23 13:25:43 +0100" MODIFIED_BY="Helen Collins">
<P>The intervention is the combination of vitamin B1, B6, B12 and vitamin C</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-23 13:25:48 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Stott-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-23 13:25:48 +0100" MODIFIED_BY="Helen Collins">
<P>The intervention is fortified cereal with folic acid, vitamin B12, vitamin B6 and riboflavin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-23 13:25:49 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Tucker-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-23 13:25:49 +0100" MODIFIED_BY="Helen Collins">
<P>The intervention is fortified cereal with folic acid, vitamin B12 and vitamin B6</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-07-23 16:10:43 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-07-23 16:10:33 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 13:23:54 +0100" MODIFIED_BY="Helen Collins" RESULT="YES" STUDY_ID="STD-Bryan-2002">
<DESCRIPTION>
<P>randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-06 14:08:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clarke-2003">
<DESCRIPTION>
<P>Using a telephone randomization system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 13:24:14 +0100" MODIFIED_BY="Helen Collins" RESULT="YES" STUDY_ID="STD-Connelly-2008">
<DESCRIPTION>
<P>Allocation sequence generated by using a computer programme.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 13:24:22 +0100" MODIFIED_BY="Helen Collins" RESULT="YES" STUDY_ID="STD-Durga-2007">
<DESCRIPTION>
<P>Allocation to treatment or placebo using blocks of sizes of four and six.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 13:24:30 +0100" MODIFIED_BY="Helen Collins" RESULT="YES" STUDY_ID="STD-Eussen-2006">
<DESCRIPTION>
<P>Randomization was stratified according to MMA concentration at screening, age, sex, and MMSE score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-06 12:51:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fioravanti-1997">
<DESCRIPTION>
<P>The randomization method was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 13:24:42 +0100" MODIFIED_BY="Helen Collins" RESULT="YES" STUDY_ID="STD-Pathansali-2006">
<DESCRIPTION>
<P>Allocation sequence was generated by using a computer program</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 16:10:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sommer-2003">
<DESCRIPTION>
<P>Randomized method was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-07-23 16:10:43 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-06 11:39:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bryan-2002">
<DESCRIPTION>
<P>Identical capsules in colour and shape were administrated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-23 13:21:09 +0100" MODIFIED_BY="Helen Collins" RESULT="YES" STUDY_ID="STD-Clarke-2003">
<DESCRIPTION>
<P>Identical blister packs for each participant for both placebo and treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-06 11:46:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Connelly-2008">
<DESCRIPTION>
<P>Identical capsules were supplied.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-06 11:55:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Durga-2007">
<DESCRIPTION>
<P>capsules were indistinguishable in appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-06 12:38:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eussen-2006">
<DESCRIPTION>
<P>Double-blind. The capsules were identical in appearance, smell, and taste.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-06 12:51:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fioravanti-1997">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-23 13:24:50 +0100" MODIFIED_BY="Helen Collins" RESULT="YES" STUDY_ID="STD-Pathansali-2006">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-23 16:10:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sommer-2003">
<DESCRIPTION>
<P>Double-blind </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2008-05-06 11:36:21 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>New Item</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-05-13 11:49:23 +0100" MODIFIED_BY="Helen Collins">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-05-13 11:49:23 +0100" MODIFIED_BY="Helen Collins" NO="1">
<TITLE MODIFIED="2008-05-13 11:43:15 +0100" MODIFIED_BY="Helen Collins">Baseline characteristics of included studies</TITLE>
<TABLE COLS="9" ROWS="9">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Participant number</P>
</TH>
<TH>
<P>Age range</P>
</TH>
<TH>
<P>Females proportion</P>
</TH>
<TH>
<P>Diagnosis</P>
</TH>
<TH>
<P>MMSE range</P>
</TH>
<TH>
<P>ADAS-Cog range</P>
</TH>
<TH>
<P>Homocysteine levels</P>
</TH>
<TH>
<P>Folic acid levels</P>
</TH>
</TR>
<TR>
<TD>
<P>Bryan 2002</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>65-92</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD>
<P>healthy</P>
</TD>
<TD>
<P>Not assessed</P>
</TD>
<TD>
<P>Not assessed</P>
</TD>
<TD>
<P>Not assessed</P>
</TD>
<TD>
<P>Not assessed</P>
</TD>
</TR>
<TR>
<TD>
<P>Connelly 2008</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>Mean 76.27 (SD = 6.23)</P>
</TD>
<TD>
<P>29%</P>
</TD>
<TD>
<P>AD patients</P>
</TD>
<TD>
<P>Mean 23.49 (SD = 3.53)</P>
</TD>
<TD>
<P>Not assessed</P>
</TD>
<TD>
<P>Mean 18.39 (SD = 4.62)</P>
</TD>
<TD>
<P>Not assessed</P>
</TD>
</TR>
<TR>
<TD>
<P>Durga 2007</P>
</TD>
<TD>
<P>818</P>
</TD>
<TD>
<P>50-70</P>
</TD>
<TD>
<P>28%</P>
</TD>
<TD>
<P>healthy</P>
</TD>
<TD>
<P>28-30</P>
</TD>
<TD>
<P>Not assessed</P>
</TD>
<TD>
<P>13.0 (11.2-14.7) µmol/L</P>
</TD>
<TD>
<P>12 (10-15) nmol/L</P>
</TD>
</TR>
<TR>
<TD>
<P>Eussen 2006</P>
</TD>
<TD>
<P>195</P>
</TD>
<TD>
<P>&gt;70</P>
</TD>
<TD>
<P>76%</P>
</TD>
<TD>
<P>healthy, with vitamin B12 deficiency</P>
</TD>
<TD>
<P>Mean 26.7± 3</P>
</TD>
<TD>
<P>Not assessed</P>
</TD>
<TD>
<P>15.3 ± 5.5 µmol/L</P>
</TD>
<TD>
<P>RBC 616 ± 218 nmol/L</P>
</TD>
</TR>
<TR>
<TD>
<P>Fioravanti 1997</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>70-90</P>
</TD>
<TD>
<P>83%</P>
</TD>
<TD>
<P>mild to moderate cognitive impairment, not demented with folic acid &lt;3 ng/ml</P>
</TD>
<TD>
<P>16-24</P>
</TD>
<TD>
<P>Not assessed</P>
</TD>
<TD>
<P>Not assessed</P>
</TD>
<TD>
<P>Blood folate 2.28 (0.6) ng/ml</P>
</TD>
</TR>
<TR>
<TD>
<P>Pathansali 2006</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>73 (5.6)</P>
</TD>
<TD>
<P>87%</P>
</TD>
<TD>
<P>healthy</P>
</TD>
<TD>
<P>&lt;27</P>
</TD>
<TD>
<P>Not assessed</P>
</TD>
<TD>
<P>11.2±2 µmol/L</P>
</TD>
<TD>
<P>6.3 ± 2.5 µmol/</P>
</TD>
</TR>
<TR>
<TD>
<P>Sommer 1998</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>76.7±4.1</P>
</TD>
<TD>
<P>15%</P>
</TD>
<TD>
<P>Demented</P>
</TD>
<TD>
<P>16-27</P>
</TD>
<TD>
<P>Not assessed</P>
</TD>
<TD>
<P>Not assessed</P>
</TD>
<TD>
<P>127-452 mcg/L (RBC)</P>
</TD>
</TR>
<TR>
<TD>
<P>VITAL 2003</P>
</TD>
<TD>
<P>149</P>
</TD>
<TD>
<P>56-89</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>84 AD,11 mixed dementia, 47 MCI, 4 unclassified</P>
</TD>
<TD>
<P>10-26</P>
</TD>
<TD>
<P>5-55</P>
</TD>
<TD>
<P>5.7-130.2 µmol/ (range)</P>
</TD>
<TD>
<P>1.7-30.5 nmol/l (range)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-07-23 14:37:23 +0100" MODIFIED_BY="Helen Collins">
<COMPARISON ID="CMP-001" MODIFIED="2008-07-23 13:52:32 +0100" MODIFIED_BY="Helen Collins" NO="1">
<NAME>Folic acid (1mg/day) vs placebo for cognitive impairment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.6976370010371902" CI_START="-1.9576370010371904" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.13" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2008-07-23 13:51:27 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.88912424950432" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="0.13941243137757106">
<NAME>Mini Mental State Examination MMSE (changes from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6976370010371902" CI_START="-1.9576370010371904" EFFECT_SIZE="-0.13" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.22" ORDER="166" SD_1="3.3" SD_2="2.67" SE="0.9324849923025921" STUDY_ID="STD-Connelly-2008" TOTAL_1="23" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.641040396720937" CI_START="-4.121040396720938" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2599999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2008-07-23 13:51:43 +0100" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9074011031623863" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="0.11631726481267446">
<NAME>DDST ( changes from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.641040396720937" CI_START="-4.121040396720938" EFFECT_SIZE="0.2599999999999998" ESTIMABLE="YES" MEAN_1="3.26" MEAN_2="3.0" ORDER="167" SD_1="7.89" SD_2="6.42" SE="2.2352657657375468" STUDY_ID="STD-Connelly-2008" TOTAL_1="23" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.093967786340887" CI_START="0.24603221365911354" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.67" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2008-07-23 13:51:53 +0100" MODIFIED_BY="Helen Collins" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.03085793276849403" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="2.1588999112160665">
<NAME>IADL ( changes from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.093967786340887" CI_START="0.24603221365911354" EFFECT_SIZE="2.67" ESTIMABLE="YES" MEAN_1="0.61" MEAN_2="-2.06" ORDER="6" SD_1="3.6" SD_2="4.17" SE="1.2367409837429846" STUDY_ID="STD-Connelly-2008" TOTAL_1="23" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.892886275294972" CI_START="-1.1328862752949722" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.38" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2008-07-23 13:52:04 +0100" MODIFIED_BY="Helen Collins" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.28176985393036047" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="1.0763520519239498">
<NAME>SB ( changes from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.892886275294972" CI_START="-1.1328862752949722" EFFECT_SIZE="1.38" ESTIMABLE="YES" MEAN_1="0.82" MEAN_2="-0.56" ORDER="169" SD_1="3.52" SD_2="4.46" SE="1.2821083933767652" STUDY_ID="STD-Connelly-2008" TOTAL_1="23" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.516094926012551" CI_START="0.5039050739874491" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.01" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2008-07-23 13:52:14 +0100" MODIFIED_BY="Helen Collins" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.02498367177367251" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="2.2416551017185675">
<NAME>IADL/SB ( changes from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.516094926012551" CI_START="0.5039050739874491" EFFECT_SIZE="4.01" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="-2.61" ORDER="170" SD_1="5.34" SD_2="5.94" SE="1.788856812506852" STUDY_ID="STD-Connelly-2008" TOTAL_1="23" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9052438185940277" CI_START="0.005182303850950936" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.09936575052854123" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.27995056126845924" LOG_CI_START="-2.2854771268726473" LOG_EFFECT_SIZE="-1.002763282802094" METHOD="MH" MODIFIED="2008-07-23 13:52:23 +0100" MODIFIED_BY="Helen Collins" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.12547197935324497" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="21" WEIGHT="100.0" Z="1.5322044962688932">
<NAME>Completers</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours folic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9052438185940277" CI_START="0.005182303850950936" EFFECT_SIZE="0.09936575052854123" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.27995056126845924" LOG_CI_START="-2.2854771268726473" LOG_EFFECT_SIZE="-1.002763282802094" ORDER="171" O_E="0.0" SE="1.5069449230859502" STUDY_ID="STD-Connelly-2008" TOTAL_1="28" TOTAL_2="21" VAR="2.2708830012145205" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="13.53257901788567" CI_START="1.219568437633891" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="4.0625" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="1.1313805716531067" LOG_CI_START="0.08620617632075506" LOG_EFFECT_SIZE="0.6087933739869308" METHOD="MH" MODIFIED="2008-07-23 13:52:32 +0100" MODIFIED_BY="Helen Collins" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.02241385889665361" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="21" WEIGHT="99.99999999999999" Z="2.283280364252671">
<NAME>Treatment responders</NAME>
<GROUP_LABEL_1>1mg/day folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours folic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.53257901788567" CI_START="1.219568437633891" EFFECT_SIZE="4.0625" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="1.1313805716531067" LOG_CI_START="0.08620617632075506" LOG_EFFECT_SIZE="0.6087933739869308" ORDER="172" O_E="0.0" SE="0.6139406135149205" STUDY_ID="STD-Connelly-2008" TOTAL_1="28" TOTAL_2="21" VAR="0.3769230769230769" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-07-23 13:53:12 +0100" MODIFIED_BY="Helen Collins" NO="2">
<NAME>Folic acid (10mg/day) vs placebo for cognitive impairment and dementia</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2008-07-23 13:32:13 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Language: WAIS-R:Pro-rated Verbal IQ (changes from baseline at week 10)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2008-07-23 13:32:13 +0100" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Boston Naming Test (changes from baseline at week 10)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2008-07-23 13:32:13 +0100" MODIFIED_BY="Helen Collins" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Controlled Oral Word Association Test (changes from baseline at week 10)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2008-07-23 13:32:13 +0100" MODIFIED_BY="Helen Collins" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="14.997272575695195" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>WMS:Logical Memory Subtest (changes from baseline at week 10)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2008-07-23 13:32:13 +0100" MODIFIED_BY="Helen Collins" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="34.75" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>WMS: Associated Learning Subtest (changes from baseline at week 10 )</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2008-07-23 13:32:13 +0100" MODIFIED_BY="Helen Collins" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Speed/Concentration:Trial A (changes from baseline at week 10)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2008-07-23 13:53:12 +0100" MODIFIED_BY="Helen Collins" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="677.93" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Speed/Concentration: Trial B (changes from baseline at week 10)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2008-07-23 13:32:13 +0100" MODIFIED_BY="Helen Collins" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="25.67" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Fingger Tapping Test (changes from baseline at week 10)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-07-23 13:55:06 +0100" MODIFIED_BY="Helen Collins" NO="3">
<NAME>Folic acid (15mg/day) vs placebo for cognitive impairment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="20.993329086148748" CI_START="-10.05332908614875" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.47" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2008-07-23 13:53:34 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4897929829374803" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.6906381315461706">
<NAME>Randt Memory Test - acquisition and recall (change from baseline at 9 weeks)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="20.993329086148748" CI_START="-10.05332908614875" EFFECT_SIZE="5.47" ESTIMABLE="YES" MEAN_1="4.25" MEAN_2="-1.22" ORDER="157" SD_1="17.39" SD_2="23.87" SE="7.920211396022982" STUDY_ID="STD-Fioravanti-1997" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="23.335216070477255" CI_START="-8.575216070477257" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.38" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2008-07-23 13:53:54 +0100" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.36463377913759565" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.9065708757570548">
<NAME>Randt Memory Test - delayed recall (change from baseline at 9 weeks)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="23.335216070477255" CI_START="-8.575216070477257" EFFECT_SIZE="7.38" ESTIMABLE="YES" MEAN_1="7.38" MEAN_2="0.0" ORDER="158" SD_1="17.83" SD_2="24.56" SE="8.140565947297993" STUDY_ID="STD-Fioravanti-1997" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="24.349544156445052" CI_START="-9.669544156445053" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.34" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2008-07-23 13:54:12 +0100" MODIFIED_BY="Helen Collins" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.3976819424866799" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.8457684411885299">
<NAME>Randt Memory Test - memory index (change from baseline at 9 weeks)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="24.349544156445052" CI_START="-9.669544156445053" EFFECT_SIZE="7.34" ESTIMABLE="YES" MEAN_1="6.81" MEAN_2="-0.53" ORDER="159" SD_1="18.53" SD_2="26.46" SE="8.678498324772375" STUDY_ID="STD-Fioravanti-1997" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.2342591646286722" CI_START="-1.8942591646286724" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.67" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2008-07-23 13:54:32 +0100" MODIFIED_BY="Helen Collins" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6085759089515012" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="13" UNITS="" WEIGHT="100.00000000000001" Z="0.5121073126132304">
<NAME>Randt Memory Test - encoding (change from baseline at 9 weeks)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.2342591646286727" CI_START="-1.8942591646286728" EFFECT_SIZE="0.67" ESTIMABLE="YES" MEAN_1="0.46" MEAN_2="-0.21" ORDER="160" SD_1="2.72" SD_2="4.03" SE="1.3083195328359203" STUDY_ID="STD-Fioravanti-1997" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.1082683240781463" CI_START="-1.968268324078146" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5700000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2008-07-23 13:54:51 +0100" MODIFIED_BY="Helen Collins" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6598396939236628" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.4401345045321679">
<NAME>Randt Memory Test - cognitive efficiency (change from baseline at 9 weeks)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.1082683240781463" CI_START="-1.968268324078146" EFFECT_SIZE="0.5700000000000001" ESTIMABLE="YES" MEAN_1="0.63" MEAN_2="0.06" ORDER="161" SD_1="3.16" SD_2="3.7" SE="1.2950586562302586" STUDY_ID="STD-Fioravanti-1997" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.2681384785067853" CI_START="-0.1681384785067852" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.05" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2008-07-23 13:55:06 +0100" MODIFIED_BY="Helen Collins" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.09113666385017094" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="1.689432047405433">
<NAME>Randt Memory Test - attention efficiency (change from baseline at 9 weeks)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.2681384785067853" CI_START="-0.1681384785067852" EFFECT_SIZE="1.05" ESTIMABLE="YES" MEAN_1="1.12" MEAN_2="0.07" ORDER="162" SD_1="1.67" SD_2="1.66" SE="0.6215106441318851" STUDY_ID="STD-Fioravanti-1997" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-07-23 13:57:54 +0100" MODIFIED_BY="Helen Collins" NO="4">
<NAME>Folic acid (2 mg/day) + vitamin B12 (1mg/day) for mild cognitive impairment or dementia</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.2142059386479422" CI_START="-0.4342059386479424" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.38999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2008-07-23 13:57:08 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.35370796578001595" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="0.9274210705452425">
<NAME>MMSE (change from baseline at 12 weeks)</NAME>
<GROUP_LABEL_1>Folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2142059386479422" CI_START="-0.4342059386479424" EFFECT_SIZE="0.38999999999999996" ESTIMABLE="YES" MEAN_1="0.04" MEAN_2="-0.35" ORDER="163" SD_1="2.58" SD_2="2.36" SE="0.42052096117539584" STUDY_ID="STD-Clarke-2003" TOTAL_1="72" TOTAL_2="66" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.0663196242048887" CI_START="-1.2463196242048888" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.41000000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2008-07-23 13:57:27 +0100" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6275606264808548" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="61" UNITS="" WEIGHT="100.0" Z="0.48516314237789765">
<NAME>ADAS-Cog (change from baseline at 12 weeks)</NAME>
<GROUP_LABEL_1>Folic acid+ B12</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid+ B12</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.0663196242048887" CI_START="-1.2463196242048888" EFFECT_SIZE="0.41000000000000003" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="-0.14" ORDER="164" SD_1="4.63" SD_2="5.04" SE="0.8450765612377199" STUDY_ID="STD-Clarke-2003" TOTAL_1="72" TOTAL_2="61" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.812227183039392" CI_START="-1.9522271830393918" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.57" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2008-07-23 13:57:54 +0100" MODIFIED_BY="Helen Collins" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4189490394140464" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="65" UNITS="" WEIGHT="100.0" Z="0.8082459127531081">
<NAME>BADL (change from baseline at 12 weeks)</NAME>
<GROUP_LABEL_1>Folic acid+ B12</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid+ B12</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.812227183039392" CI_START="-1.9522271830393918" EFFECT_SIZE="-0.57" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.17" ORDER="165" SD_1="4.08" SD_2="4.08" SE="0.7052309093137545" STUDY_ID="STD-Clarke-2003" TOTAL_1="69" TOTAL_2="65" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-07-23 14:03:02 +0100" MODIFIED_BY="Helen Collins" NO="5">
<NAME>Folic acid( 400 mcg/day) + vitamin B12 (1000 mcg/day) in healthy elderly with mild B12 deficiency</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.325883593960666" CI_START="-5.325883593960666" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2008-07-23 13:58:10 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8390819700688341" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="0.20306788864456282">
<NAME>Constuction complex figure of Rey ( change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.325883593960666" CI_START="-5.325883593960666" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.5" ORDER="199" SD_1="13.0" SD_2="11.16" SE="2.4622307511906443" STUDY_ID="STD-Eussen-2006" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5701305581227631" CI_START="-1.1701305581227632" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2008-07-23 13:58:27 +0100" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.49920050532372073" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="0.6757482424597935">
<NAME>Attention digit span forward ( change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5701305581227631" CI_START="-1.1701305581227632" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.2" ORDER="200" SD_1="2.26" SD_2="2.33" SE="0.4439523200355935" STUDY_ID="STD-Eussen-2006" TOTAL_1="51" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="248.3770068321832" CI_START="-80.37700683218321" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="84.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2008-07-23 13:58:42 +0100" MODIFIED_BY="Helen Collins" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.3165457565628649" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="1.0015815342680303">
<NAME>Sensomotor speed motor planning ( change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="248.37700683218324" CI_START="-80.37700683218324" EFFECT_SIZE="84.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="-55.0" ORDER="201" SD_1="375.9" SD_2="437.17" SE="83.86736089477566" STUDY_ID="STD-Eussen-2006" TOTAL_1="44" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="125.49836927597126" CI_START="-119.49836927597126" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2008-07-23 13:58:52 +0100" MODIFIED_BY="Helen Collins" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9617164362984288" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="0.047999756963079315">
<NAME>Sensomotor speed, finger tapping ( change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="125.49836927597126" CI_START="-119.49836927597126" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="-17.0" MEAN_2="-20.0" ORDER="202" SD_1="317.0" SD_2="284.82" SE="62.50031645592611" STUDY_ID="STD-Eussen-2006" TOTAL_1="44" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="16.412391909118757" CI_START="-34.41239190911875" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.05" MODIFIED="2008-07-23 13:59:06 +0100" MODIFIED_BY="Helen Collins" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.4875964404114115" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="56" UNITS="" WEIGHT="99.99999999999999" Z="0.694136778778814">
<NAME>Sensomotor speed trial making test (change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.412391909118757" CI_START="-34.41239190911875" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="1.9" ORDER="203" SD_1="71.37" SD_2="58.92" SE="12.965744324675587" STUDY_ID="STD-Eussen-2006" TOTAL_1="48" TOTAL_2="56" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.24547225012708" CI_START="-5.24547225012708" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.06" MODIFIED="2008-07-23 13:59:22 +0100" MODIFIED_BY="Helen Collins" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.8645650653754289" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="0.17056596039574493">
<NAME>Memory 15 words learning, immediate recall ( change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid +B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid+B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.24547225012708" CI_START="-5.24547225012708" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="5.7" ORDER="204" SD_1="15.0" SD_2="15.14" SE="2.9314172584020075" STUDY_ID="STD-Eussen-2006" TOTAL_1="50" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.6214683671373438" CI_START="-1.4214683671373436" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2008-07-23 13:59:36 +0100" MODIFIED_BY="Helen Collins" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.5607387000340505" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="55" UNITS="" WEIGHT="100.0" Z="0.5817446415891077">
<NAME>Memory, delayed recall (change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid+B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.6214683671373438" CI_START="-1.4214683671373436" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.0" ORDER="205" SD_1="5.6" SD_2="4.9" SE="1.0313803636609795" STUDY_ID="STD-Eussen-2006" TOTAL_1="50" TOTAL_2="55" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0695337545504089" CI_START="-2.8695337545504085" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.08" MODIFIED="2008-07-23 13:59:53 +0100" MODIFIED_BY="Helen Collins" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.3704520262456594" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="55" UNITS="" WEIGHT="100.0" Z="0.8956269888802767">
<NAME>Memory 15 learning word, recognition ( change from baseline at week 24 )</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0695337545504089" CI_START="-2.8695337545504085" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.7" ORDER="206" SD_1="4.6" SD_2="5.68" SE="1.004882625438957" STUDY_ID="STD-Eussen-2006" TOTAL_1="50" TOTAL_2="55" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.318393325233464" CI_START="-3.9183933252334633" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.09" MODIFIED="2008-07-23 14:00:03 +0100" MODIFIED_BY="Helen Collins" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.9241710609227848" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="52" UNITS="" WEIGHT="100.0" Z="0.09518100044166858">
<NAME>Memory, complex figure of Rey, immediate recall ( change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.318393325233464" CI_START="-3.9183933252334633" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="3.0" ORDER="207" SD_1="10.32" SD_2="10.04" SE="2.101259695442786" STUDY_ID="STD-Eussen-2006" TOTAL_1="43" TOTAL_2="52" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.6010225594766956" CI_START="-4.601022559476696" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.10" MODIFIED="2008-07-23 14:00:15 +0100" MODIFIED_BY="Helen Collins" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.8111362894819144" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="0.23896040025565626">
<NAME>Memory, complex figure of Rey, delayed recall ( change from baseline at week 24 )</NAME>
<GROUP_LABEL_1>folica acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid + B12</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.6010225594766956" CI_START="-4.601022559476696" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.4" ORDER="208" SD_1="10.33" SD_2="9.64" SE="2.092396896996597" STUDY_ID="STD-Eussen-2006" TOTAL_1="43" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.01899610676180441" CI_START="-1.6189961067618044" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.11" MODIFIED="2008-07-23 14:00:22 +0100" MODIFIED_BY="Helen Collins" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.055555809529802255" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="1.9145038354719184">
<NAME>Memory, digit span backward (change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.01899610676180441" CI_START="-1.6189961067618044" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="0.6" ORDER="209" SD_1="1.83" SD_2="2.47" SE="0.4178628348387732" STUDY_ID="STD-Eussen-2006" TOTAL_1="51" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="317.33376101880384" CI_START="-247.33376101880384" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="35.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.12" MODIFIED="2008-07-23 14:00:30 +0100" MODIFIED_BY="Helen Collins" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.8080283483091484" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="0.2429703738276384">
<NAME>Executive function, motor planing ( change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid +B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="317.33376101880384" CI_START="-247.33376101880384" EFFECT_SIZE="35.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="-22.0" ORDER="210" SD_1="514.0" SD_2="846.0" SE="144.05048421594302" STUDY_ID="STD-Eussen-2006" TOTAL_1="43" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1974416662477905" CI_START="-0.19744166624779047" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.13" MODIFIED="2008-07-23 14:00:42 +0100" MODIFIED_BY="Helen Collins" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.1599886849322888" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="54" UNITS="" WEIGHT="100.0" Z="1.4051096166110821">
<NAME>Excutive function, trial making test ( change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid +B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1974416662477905" CI_START="-0.19744166624779047" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="-0.1" ORDER="211" SD_1="2.23" SD_2="1.0" SE="0.3558441235395759" STUDY_ID="STD-Eussen-2006" TOTAL_1="46" TOTAL_2="54" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.14" MODIFIED="2008-07-23 14:01:08 +0100" MODIFIED_BY="Helen Collins" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="54" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Excutive function, stroop test ( change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.7" ORDER="212" SD_1="0.0" SD_2="1.16" SE="0.0" STUDY_ID="STD-Eussen-2006" TOTAL_1="43" TOTAL_2="54" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.0211695419835727" CI_START="-1.0211695419835727" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.15" MODIFIED="2008-07-23 14:01:24 +0100" MODIFIED_BY="Helen Collins" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.5194267563304966" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="0.6442293020093945">
<NAME>Excutive function , similarities (change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid + B12</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.0211695419835727" CI_START="-1.0211695419835727" EFFECT_SIZE="0.5000000000000001" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="0.6" ORDER="213" SD_1="3.82" SD_2="4.17" SE="0.776121170583931" STUDY_ID="STD-Eussen-2006" TOTAL_1="50" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.549529138105586" CI_START="-1.5495291381055858" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.16" MODIFIED="2008-07-23 14:01:41 +0100" MODIFIED_BY="Helen Collins" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.6325435753016706" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="0.4781498218541264">
<NAME>Excutive function, Raven (change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid+ B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.549529138105586" CI_START="-1.5495291381055858" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.0" ORDER="214" SD_1="4.96" SD_2="5.65" SE="1.0456973466206574" STUDY_ID="STD-Eussen-2006" TOTAL_1="47" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.349560073368411" CI_START="-3.5495600733684114" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.17" MODIFIED="2008-07-23 14:01:56 +0100" MODIFIED_BY="Helen Collins" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.6901170696879111" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="0.3986961992542366">
<NAME>Executive function, word fluency, animals, numbers of nouns (changes from baselien at week 24)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.349560073368411" CI_START="-3.5495600733684114" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.9" ORDER="215" SD_1="7.63" SD_2="7.85" SE="1.5049052414402329" STUDY_ID="STD-Eussen-2006" TOTAL_1="50" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.3123932206971016" CI_START="-5.912393220697101" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.18" MODIFIED="2008-07-23 14:02:10 +0100" MODIFIED_BY="Helen Collins" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.39095937210877707" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="55" UNITS="" WEIGHT="100.0" Z="0.8578788512772785">
<NAME>Executive function, word fluency, letters, numbers of nouns (changes from baselien at week 24)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.3123932206971016" CI_START="-5.912393220697101" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="2.3" ORDER="216" SD_1="10.2" SD_2="11.3" SE="2.0981983613653794" STUDY_ID="STD-Eussen-2006" TOTAL_1="50" TOTAL_2="55" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.94518086961122" CI_START="-7.05481913038878" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.19" MODIFIED="2008-07-23 14:02:21 +0100" MODIFIED_BY="Helen Collins" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="5.559617470620137E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="54" UNITS="" WEIGHT="100.0" Z="3.4522357475411907">
<NAME>Homocysteine (mcmo/L) (changes from baseline at week 12)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid + B12</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.94518086961122" CI_START="-7.05481913038878" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="-4.8" MEAN_2="-0.3" ORDER="7" SD_1="5.16" SD_2="7.9" SE="1.3035031003328974" STUDY_ID="STD-Eussen-2006" TOTAL_1="49" TOTAL_2="54" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3.3680699062238544" CI_START="-8.431930093776145" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.8999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.20" MODIFIED="2008-07-23 14:03:02 +0100" MODIFIED_BY="Helen Collins" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="4.943229620806973E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="54" UNITS="" WEIGHT="100.0" Z="4.567182773810305">
<NAME>Homocysteine (mcmol/L) (change from baseline at week 24)</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid + B12</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.3680699062238544" CI_START="-8.431930093776145" EFFECT_SIZE="-5.8999999999999995" ESTIMABLE="YES" MEAN_1="-5.6" MEAN_2="0.3" ORDER="218" SD_1="3.46" SD_2="8.8" SE="1.29182480583709" STUDY_ID="STD-Eussen-2006" TOTAL_1="51" TOTAL_2="54" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2008-07-23 14:05:03 +0100" MODIFIED_BY="Helen Collins" NO="6">
<NAME>Folic acid (800 mcg/day) vs placebo in healthy elderly</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.09578789392767625" CI_START="0.004212106072323758" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.05" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2008-07-23 14:04:05 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.03233340544635272" Q="0.0" RANDOM="NO" SCALE="0.08" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="405" TOTAL_2="413" UNITS="" WEIGHT="100.0" Z="2.1402643978732603">
<NAME>Global cognitive function (changes from baseline to 3-year)</NAME>
<GROUP_LABEL_1>800 mcg/d folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.09578789392767625" CI_START="0.004212106072323758" EFFECT_SIZE="0.05" ESTIMABLE="YES" MEAN_1="0.067" MEAN_2="0.017" MODIFIED="2008-06-09 11:13:37 +0100" MODIFIED_BY="[Empty name]" ORDER="219" SD_1="0.338" SD_2="0.33" SE="0.023361599646139066" STUDY_ID="STD-Durga-2007" TOTAL_1="405" TOTAL_2="413" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.23936678693146857" CI_START="0.04063321306853135" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.13999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2008-07-23 14:04:16 +0100" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.005754790918721368" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="405" TOTAL_2="413" UNITS="" WEIGHT="99.99999999999999" Z="2.761435347857756">
<NAME>Memory (change from baseline to 3-year)</NAME>
<GROUP_LABEL_1>800 mcg/d folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.23936678693146857" CI_START="0.04063321306853135" EFFECT_SIZE="0.13999999999999996" ESTIMABLE="YES" MEAN_1="0.48" MEAN_2="0.34" ORDER="220" SD_1="0.72" SD_2="0.73" SE="0.05069827186380012" STUDY_ID="STD-Durga-2007" TOTAL_1="405" TOTAL_2="413" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.12445141025666259" CI_START="-0.004451410256662576" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.060000000000000005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" MODIFIED="2008-07-23 14:04:27 +0100" MODIFIED_BY="Helen Collins" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.06806189161622743" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="405" TOTAL_2="413" UNITS="" WEIGHT="100.0" Z="1.8245968335541074">
<NAME>Sensorimotor speed (change from baseline at 3-year)</NAME>
<GROUP_LABEL_1>800 mcg/d folc acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.12445141025666259" CI_START="-0.004451410256662576" EFFECT_SIZE="0.060000000000000005" ESTIMABLE="YES" MEAN_1="-0.04" MEAN_2="-0.1" ORDER="221" SD_1="0.45" SD_2="0.49" SE="0.03288397683072091" STUDY_ID="STD-Durga-2007" TOTAL_1="405" TOTAL_2="413" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.12576674699269516" CI_START="-0.04576674699269517" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.039999999999999994" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.04" MODIFIED="2008-07-23 14:04:41 +0100" MODIFIED_BY="Helen Collins" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.3606693611256795" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="405" TOTAL_2="413" UNITS="" WEIGHT="100.0" Z="0.9140903920289695">
<NAME>Complex speed (change from baseline at 3-year)</NAME>
<GROUP_LABEL_1>800 mcg/d folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.12576674699269516" CI_START="-0.04576674699269517" EFFECT_SIZE="0.039999999999999994" ESTIMABLE="YES" MEAN_1="-0.02" MEAN_2="-0.06" ORDER="222" SD_1="0.65" SD_2="0.6" SE="0.04375934847232516" STUDY_ID="STD-Durga-2007" TOTAL_1="405" TOTAL_2="413" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.514090744428422E-31" CI_END="0.15990244742254545" CI_START="0.02009755257745456" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09000000000000001" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-006.05" MODIFIED="2008-07-23 14:04:53 +0100" MODIFIED_BY="Helen Collins" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.011620283511775992" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="405" TOTAL_2="413" UNITS="" WEIGHT="99.99999999999999" Z="2.523470423607974">
<NAME>Information processing (change from baseline at 3-year)</NAME>
<GROUP_LABEL_1>800 mcg/d folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.15990244742254545" CI_START="0.020097552577454547" EFFECT_SIZE="0.09" ESTIMABLE="YES" MEAN_1="-0.07" MEAN_2="-0.16" ORDER="223" SD_1="0.51" SD_2="0.51" SE="0.03566516934695078" STUDY_ID="STD-Durga-2007" TOTAL_1="405" TOTAL_2="413" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.04815184143237557" CI_START="-0.18815184143237557" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.07" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" MODIFIED="2008-07-23 14:05:03 +0100" MODIFIED_BY="Helen Collins" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.24556210667057743" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="405" TOTAL_2="413" UNITS="" WEIGHT="100.0" Z="1.1611962814505015">
<NAME>Word fluency (change from baseline at 3-year)</NAME>
<GROUP_LABEL_1>800mcg/d folic cid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.04815184143237557" CI_START="-0.18815184143237557" EFFECT_SIZE="-0.07" ESTIMABLE="YES" MEAN_1="-0.0020" MEAN_2="0.068" MODIFIED="2008-06-09 11:17:56 +0100" MODIFIED_BY="[Empty name]" ORDER="224" SD_1="0.864" SD_2="0.86" SE="0.060282659459225896" STUDY_ID="STD-Durga-2007" TOTAL_1="405" TOTAL_2="413" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2008-07-23 14:05:24 +0100" MODIFIED_BY="Helen Collins" NO="7">
<NAME>Folic acid (0.75 mg/day) vs placebo in healthy older women</NAME>
<CONT_OUTCOME CHI2="1.5154545114136302" CI_END="1.5173310783541893" CI_START="-1.337065498459863" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0901327899471631" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2008-07-23 14:05:24 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="0.8239005290468024" P_Q="0.8239005290468024" P_Z="0.9014903454144303" Q="1.5154545114136302" RANDOM="NO" SCALE="15.54" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="105" UNITS="" WEIGHT="500.0" Z="0.12377889152300629">
<NAME>Cognitive processing (change from baseline at 5 weeks)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.521368645202784" CI_START="-11.281368645202782" DF="0.0" EFFECT_SIZE="2.12" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.01" NO="1" P_CHI2="1.0" P_Z="0.7565212719545366" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.00000000000001" Z="0.31005218625280506">
<NAME>Speed of processing - boxes</NAME>
<CONT_DATA CI_END="15.521368645202784" CI_START="-11.281368645202782" EFFECT_SIZE="2.12" ESTIMABLE="YES" MEAN_1="6.89" MEAN_2="4.77" ORDER="173" SD_1="20.72" SD_2="21.93" SE="6.837558623990578" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.781687189896715" CI_START="-7.401687189896716" DF="0.0" EFFECT_SIZE="2.19" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.02" NO="2" P_CHI2="1.0" P_Z="0.6545109954158708" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.4475042858636989">
<NAME>Speed of processing - digit symbol coding</NAME>
<CONT_DATA CI_END="11.781687189896715" CI_START="-7.401687189896716" EFFECT_SIZE="2.19" ESTIMABLE="YES" MEAN_1="5.71" MEAN_2="3.52" ORDER="174" SD_1="16.22" SD_2="14.0" SE="4.893807878897123" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.733415070484556" CI_START="-1.5534150704845557" DF="0.0" EFFECT_SIZE="1.5899999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.03" NO="3" P_CHI2="1.0" P_Z="0.32149636386099945" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.9913876040997358">
<NAME>Speed of processing - symbol search</NAME>
<CONT_DATA CI_END="4.733415070484556" CI_START="-1.5534150704845557" EFFECT_SIZE="1.5899999999999999" ESTIMABLE="YES" MEAN_1="1.45" MEAN_2="-0.14" ORDER="175" SD_1="4.45" SD_2="5.56" SE="1.6038126696609798" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.0408877618438908" CI_START="-2.660887761843891" DF="0.0" EFFECT_SIZE="-0.30999999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.04" NO="4" P_CHI2="1.0" P_Z="0.7960590113451439" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.258450805295299">
<NAME>Working memory - digit span backwards</NAME>
<CONT_DATA CI_END="2.0408877618438908" CI_START="-2.660887761843891" EFFECT_SIZE="-0.30999999999999994" ESTIMABLE="YES" MEAN_1="0.17" MEAN_2="0.48" ORDER="176" SD_1="3.41" SD_2="4.08" SE="1.199454571812234" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.780032600904299" CI_START="-2.780032600904299" DF="0.0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.05" NO="5" P_CHI2="1.0" P_Z="0.6673334826785831" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="99.99999999999999" Z="0.42981051756950756">
<NAME>Working memory - letter number sequencing</NAME>
<CONT_DATA CI_END="1.780032600904299" CI_START="-2.780032600904299" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="0.22" MEAN_2="0.72" ORDER="177" SD_1="2.8" SD_2="4.39" SE="1.163303315208292" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.044688692030785" CI_END="1.177380726607506" CI_START="-0.5750277426214102" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.30117649199304786" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.02" NO="2" P_CHI2="0.5430000818259544" P_Q="0.5430000818259544" P_Z="0.5005047628109046" Q="4.044688692030785" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="108" TOTAL_2="126" UNITS="" WEIGHT="600.0" Z="0.6736957594780717">
<NAME>Memory (change from baseline at 5 weeks)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.754878535972862" CI_START="-6.8748785359728615" DF="0.0" EFFECT_SIZE="-0.06000000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.01" NO="1" P_CHI2="1.0" P_Z="0.9862323527434919" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.01725604329580551">
<NAME>Immediate recall - RAVLT 1-5</NAME>
<CONT_DATA CI_END="6.754878535972862" CI_START="-6.8748785359728615" EFFECT_SIZE="-0.06000000000000005" ESTIMABLE="YES" MEAN_1="3.23" MEAN_2="3.29" ORDER="178" SD_1="11.61" SD_2="9.83" SE="3.477042736360338" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9695964431142226" CI_START="-2.049596443114223" DF="0.0" EFFECT_SIZE="-0.54" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.02" NO="2" P_CHI2="1.0" P_Z="0.4832395879064618" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.701101646389841">
<NAME>Immediate recall - RAVLT B</NAME>
<CONT_DATA CI_END="0.9695964431142226" CI_START="-2.049596443114223" EFFECT_SIZE="-0.54" ESTIMABLE="YES" MEAN_1="-0.78" MEAN_2="-0.24" ORDER="179" SD_1="2.22" SD_2="2.59" SE="0.7702164198024691" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.13774488195054" CI_START="-2.2777448819505404" DF="0.0" EFFECT_SIZE="-0.07000000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.03" NO="3" P_CHI2="1.0" P_Z="0.950448381040205" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.06214371961156586">
<NAME>Delayed recall - RAVLT 6</NAME>
<CONT_DATA CI_END="2.13774488195054" CI_START="-2.2777448819505404" EFFECT_SIZE="-0.07000000000000006" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.57" ORDER="180" SD_1="3.37" SD_2="3.66" SE="1.126421148227697" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.17008668141485" CI_START="-2.8500866814148496" DF="0.0" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.04" NO="4" P_CHI2="1.0" P_Z="0.7906366642177687" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.00000000000001" Z="0.2654839610431296">
<NAME>Delayed recall - RAVLT 7</NAME>
<CONT_DATA CI_END="2.17008668141485" CI_START="-2.8500866814148496" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="YES" MEAN_1="0.66" MEAN_2="1.0" ORDER="181" SD_1="2.86" SD_2="4.99" SE="1.2806800029052028" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.080650142914388" CI_START="-0.24065014291438858" DF="0.0" EFFECT_SIZE="1.42" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.05" NO="5" P_CHI2="1.0" P_Z="0.09375008045945654" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="99.99999999999999" Z="1.6759393120350676">
<NAME>Recognition - RAVLT A</NAME>
<CONT_DATA CI_END="3.080650142914388" CI_START="-0.24065014291438858" EFFECT_SIZE="1.42" ESTIMABLE="YES" MEAN_1="0.56" MEAN_2="-0.86" ORDER="182" SD_1="2.5" SD_2="2.79" SE="0.8472860501587707" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.529949606370776" CI_START="-1.3499496063707757" DF="0.0" EFFECT_SIZE="1.59" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.06" NO="6" P_CHI2="1.0" P_Z="0.289145210369985" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="1.059998691360448">
<NAME>Recognition - RAVLT B</NAME>
<CONT_DATA CI_END="4.529949606370776" CI_START="-1.3499496063707757" EFFECT_SIZE="1.59" ESTIMABLE="YES" MEAN_1="1.11" MEAN_2="-0.48" ORDER="183" SD_1="4.03" SD_2="5.32" SE="1.500001851850709" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9613253997543894" CI_END="0.2532714708640976" CI_START="-0.441888048050867" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09430828859338466" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.03" NO="3" P_CHI2="0.915602562926129" P_Q="0.915602562926129" P_Z="0.5948686442119647" Q="0.9613253997543894" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="105" UNITS="" WEIGHT="500.0" Z="0.5317940531840842">
<NAME>Executive function (change from baseline at 5 weeks)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.25845456877813" CI_START="-0.43845456877813005" DF="0.0" EFFECT_SIZE="-0.09" ESTIMABLE="YES" I2="0.0" ID="CMP-007.03.01" NO="1" P_CHI2="1.0" P_Z="0.6126980145926206" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.506225988734047">
<NAME>Stroop</NAME>
<CONT_DATA CI_END="0.25845456877813" CI_START="-0.43845456877813005" EFFECT_SIZE="-0.09" ESTIMABLE="YES" MEAN_1="0.03" MEAN_2="0.12" ORDER="184" SD_1="0.5" SD_2="0.61" SE="0.1777862101174793" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.980833398206101" CI_START="-11.400833398206103" DF="0.0" EFFECT_SIZE="2.29" ESTIMABLE="YES" I2="0.0" ID="CMP-007.03.02" NO="2" P_CHI2="1.0" P_Z="0.7430373530280494" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.3278337697970106">
<NAME>Trail making test : Test A</NAME>
<CONT_DATA CI_END="15.980833398206101" CI_START="-11.400833398206103" EFFECT_SIZE="2.29" ESTIMABLE="YES" MEAN_1="3.44" MEAN_2="1.15" ORDER="185" SD_1="23.05" SD_2="20.12" SE="6.985247436278242" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="26.587796048226075" CI_START="-37.007796048226076" DF="0.0" EFFECT_SIZE="-5.21" ESTIMABLE="YES" I2="0.0" ID="CMP-007.03.03" NO="3" P_CHI2="1.0" P_Z="0.7481074417407609" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.32113585306247516">
<NAME>Trail making test: Test B</NAME>
<CONT_DATA CI_END="26.587796048226075" CI_START="-37.007796048226076" EFFECT_SIZE="-5.21" ESTIMABLE="YES" MEAN_1="-9.5" MEAN_2="-4.29" ORDER="186" SD_1="40.48" SD_2="60.13" SE="16.223663444350525" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.324367161452317" CI_START="-11.204367161452318" DF="0.0" EFFECT_SIZE="-3.44" ESTIMABLE="YES" I2="0.0" ID="CMP-007.03.04" NO="4" P_CHI2="1.0" P_Z="0.38519657264651064" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.8683613186520986">
<NAME>Verbal fluency - initial letter</NAME>
<CONT_DATA CI_END="4.324367161452317" CI_START="-11.204367161452318" EFFECT_SIZE="-3.44" ESTIMABLE="YES" MEAN_1="-0.11" MEAN_2="3.33" ORDER="187" SD_1="13.22" SD_2="11.21" SE="3.961484610276849" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.902909636986905" CI_START="-6.762909636986906" DF="0.0" EFFECT_SIZE="0.5699999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-007.03.05" NO="5" P_CHI2="1.0" P_Z="0.8789097413668756" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.15235145753778576">
<NAME>Verbal fluency - excluded letter</NAME>
<CONT_DATA CI_END="7.902909636986905" CI_START="-6.762909636986905" EFFECT_SIZE="0.5699999999999998" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-2.57" ORDER="188" SD_1="11.68" SD_2="11.61" SE="3.7413491752031978" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03855527745096741" CI_END="4.264285620601713" CI_START="-4.073998168058747" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09514372627148344" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.04" NO="4" P_CHI2="0.8443324167089985" P_Q="0.8443324167089985" P_Z="0.9643239435280466" Q="0.03855527745096741" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="42" UNITS="" WEIGHT="200.0" Z="0.044728215439403404">
<NAME>Verbal ability (change from baseline at 5 weeks)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.606266153427656" CI_START="-4.866266153427656" DF="0.0" EFFECT_SIZE="-0.13000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.01" NO="1" P_CHI2="1.0" P_Z="0.9570971675611329" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="99.99999999999999" Z="0.05379666381413356">
<NAME>Vocabulary</NAME>
<CONT_DATA CI_END="4.606266153427656" CI_START="-4.866266153427656" EFFECT_SIZE="-0.13000000000000003" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="-0.15" ORDER="189" SD_1="7.56" SD_2="7.48" SE="2.4165067270555576" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.656516956978383" CI_START="-7.916516956978383" DF="0.0" EFFECT_SIZE="0.87" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.02" NO="2" P_CHI2="1.0" P_Z="0.8461238056041647" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.19406650836718373">
<NAME>Spot the word</NAME>
<CONT_DATA CI_END="9.656516956978383" CI_START="-7.916516956978383" EFFECT_SIZE="0.87" ESTIMABLE="YES" MEAN_1="1.44" MEAN_2="0.57" ORDER="190" SD_1="14.95" SD_2="12.7" SE="4.482999190947032" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.541544643018568" CI_END="1.7393086083532967" CI_START="-1.5312451601682036" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10403172409254659" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.05" NO="5" P_CHI2="0.9239363926952633" P_Q="0.9239363926952633" P_Z="0.9007710283193324" Q="2.541544643018568" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="144" TOTAL_2="168" UNITS="" WEIGHT="800.0" Z="0.12468740580478169">
<NAME>Mood Measures (change from baseline at 5 weeks)</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>folic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.092403377167621" CI_START="-7.312403377167621" DF="0.0" EFFECT_SIZE="-1.11" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.01" NO="1" P_CHI2="1.0" P_Z="0.7257678023302359" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.35076080843889706">
<NAME>CESD - depression</NAME>
<CONT_DATA CI_END="5.092403377167621" CI_START="-7.312403377167621" EFFECT_SIZE="-1.11" ESTIMABLE="YES" MEAN_1="-1.06" MEAN_2="0.05" ORDER="191" SD_1="9.28" SD_2="10.48" SE="3.16454966830584" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="17.280521379049205" CI_START="-23.560521379049206" DF="0.0" EFFECT_SIZE="-3.14" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.02" NO="2" P_CHI2="1.0" P_Z="0.7631266041075464" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.3013775602110664">
<NAME>POMS: total</NAME>
<CONT_DATA CI_END="17.280521379049205" CI_START="-23.560521379049206" EFFECT_SIZE="-3.14" ESTIMABLE="YES" MEAN_1="-6.29" MEAN_2="-3.15" ORDER="192" SD_1="35.27" SD_2="28.78" SE="10.418824805008496" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.62717695803085E-34" CI_END="4.526336198600935" CI_START="-3.9263361986009357" DF="0.0" EFFECT_SIZE="0.3" ESTIMABLE="YES" I2="100.0" ID="CMP-007.05.03" NO="3" P_CHI2="0.0" P_Z="0.88935134111768" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.13912504063369618">
<NAME>POMS - Tension/anxiety</NAME>
<CONT_DATA CI_END="4.526336198600935" CI_START="-3.9263361986009357" EFFECT_SIZE="0.29999999999999993" ESTIMABLE="YES" MEAN_1="-0.65" MEAN_2="-0.95" ORDER="193" SD_1="7.46" SD_2="5.72" SE="2.156333602013984" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.631976810837001" CI_START="-5.451976810837001" DF="0.0" EFFECT_SIZE="0.5900000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.04" NO="4" P_CHI2="1.0" P_Z="0.8482194306580058" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.19139079594025085">
<NAME>POMS - Depression/dejection</NAME>
<CONT_DATA CI_END="6.631976810837001" CI_START="-5.451976810837001" EFFECT_SIZE="0.5900000000000001" ESTIMABLE="YES" MEAN_1="-0.71" MEAN_2="-1.3" ORDER="194" SD_1="10.59" SD_2="8.29" SE="3.082697875315742" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.234939619095422" CI_START="-3.2949396190954223" DF="0.0" EFFECT_SIZE="0.97" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.05" NO="5" P_CHI2="1.0" P_Z="0.6557662868924667" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.4457659978330672">
<NAME>POMS - Anger/hostility</NAME>
<CONT_DATA CI_END="5.234939619095422" CI_START="-3.2949396190954223" EFFECT_SIZE="0.97" ESTIMABLE="YES" MEAN_1="-0.23" MEAN_2="-1.2" ORDER="195" SD_1="5.28" SD_2="8.18" SE="2.176029586633592" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.524707089971347" CI_START="-2.2647070899713473" DF="0.0" EFFECT_SIZE="3.13" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.06" NO="6" P_CHI2="1.0" P_Z="0.2554681579406425" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="1.1371678145444877">
<NAME>POMS - Vigour/activity</NAME>
<CONT_DATA CI_END="8.524707089971347" CI_START="-2.2647070899713473" EFFECT_SIZE="3.13" ESTIMABLE="YES" MEAN_1="2.53" MEAN_2="-0.6" ORDER="196" SD_1="9.51" SD_2="7.32" SE="2.752452153470221" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.1944055943390532" CI_START="-5.854405594339053" DF="0.0" EFFECT_SIZE="-1.83" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.07" NO="7" P_CHI2="1.0" P_Z="0.3727973939632728" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.8912456778098097">
<NAME>POMS - Fatigue/inertia</NAME>
<CONT_DATA CI_END="2.1944055943390532" CI_START="-5.854405594339053" EFFECT_SIZE="-1.83" ESTIMABLE="YES" MEAN_1="-1.53" MEAN_2="0.3" ORDER="197" SD_1="6.98" SD_2="5.63" SE="2.0533058903546446" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.9501313332231582" CI_START="-3.0501313332231588" DF="0.0" EFFECT_SIZE="-0.050000000000000044" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.08" NO="8" P_CHI2="1.0" P_Z="0.9739420248755293" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="0.03266463642500594">
<NAME>POMS - Confusion/bewilderment</NAME>
<CONT_DATA CI_END="2.9501313332231582" CI_START="-3.0501313332231588" EFFECT_SIZE="-0.050000000000000044" ESTIMABLE="YES" MEAN_1="-0.65" MEAN_2="-0.6" ORDER="198" SD_1="5.08" SD_2="4.37" SE="1.5307073787517584" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2008-07-23 14:36:00 +0100" MODIFIED_BY="Helen Collins" NO="8">
<NAME>Folic acid (5 mg/day) vs placebo in healthy elderly</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.294078399922375" CI_START="-16.294078399922377" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.01" MODIFIED="2008-07-23 14:06:09 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2532947225566279" Q="0.0" RANDOM="NO" SCALE="24.15" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.1423833635587042">
<NAME>Four-Choice Reaction Time (FCRT) fixed correct (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.294078399922375" CI_START="-16.294078399922377" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="-0.83" MEAN_2="5.17" ORDER="225" SD_1="14.0" SD_2="11.62" SE="5.252177326277804" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.31205925896309517" CI_START="-0.31205925896309517" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.02" MODIFIED="2008-07-23 14:06:17 +0100" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Four-Choice Reaction Time (FCRT) fixed incorrect (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.31205925896309517" CI_START="-0.31205925896309517" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.17" MEAN_2="0.17" ORDER="226" SD_1="0.39" SD_2="0.39" SE="0.15921683328090658" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.7777898331617076E-33" CI_END="0.11945970718585786" CI_START="-0.05945970718585786" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.029999999999999995" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-008.03" MODIFIED="2008-07-23 14:06:25 +0100" MODIFIED_BY="Helen Collins" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.5110092111844878" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.6572670690061992">
<NAME>Four-Choice Reaction Time (FCRT) fixed reaction time (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.11945970718585786" CI_START="-0.05945970718585786" EFFECT_SIZE="0.03" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-0.03" ORDER="227" SD_1="0.05" SD_2="0.15" SE="0.04564354645876384" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="17.195737723403397" CI_START="-3.6957377234033952" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="6.75" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.04" MODIFIED="2008-07-23 14:06:33 +0100" MODIFIED_BY="Helen Collins" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.20532627422027971" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.2665220251514118">
<NAME>Four-Choice Reaction Time (FCRT) random correct (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="17.195737723403397" CI_START="-3.6957377234033952" EFFECT_SIZE="6.75" ESTIMABLE="YES" MEAN_1="1.17" MEAN_2="-5.58" ORDER="228" SD_1="14.6" SD_2="11.3" SE="5.329555953985911" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3181504022856494" CI_START="-1.8181504022856494" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.75" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.05" MODIFIED="2008-07-23 14:06:41 +0100" MODIFIED_BY="Helen Collins" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.16876424111904656" Q="0.0" RANDOM="NO" SCALE="4.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.376185399789733">
<NAME>Four-Choice Reaction Time (FCRT) random incorrect (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3181504022856494" CI_START="-1.8181504022856494" EFFECT_SIZE="-0.75" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="0.25" MODIFIED="2008-06-05 14:37:58 +0100" MODIFIED_BY="[Empty name]" ORDER="229" SD_1="0.8" SD_2="1.71" SE="0.5449847092656209" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.06745970718585786" CI_START="-0.11145970718585785" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.022" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.06" MODIFIED="2008-07-23 14:06:51 +0100" MODIFIED_BY="Helen Collins" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.6298088956018456" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.4819958506045462">
<NAME>Four-Choice Reaction Time (FCRT) random reaction time (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.06745970718585786" CI_START="-0.11145970718585785" EFFECT_SIZE="-0.022" ESTIMABLE="YES" MEAN_1="-0.0020" MEAN_2="0.02" MODIFIED="2008-06-05 14:40:42 +0100" MODIFIED_BY="[Empty name]" ORDER="230" SD_1="0.05" SD_2="0.15" SE="0.04564354645876384" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.07" MODIFIED="2008-07-23 14:07:13 +0100" MODIFIED_BY="Helen Collins" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Four-Choice Reaction Time (FCRT) transform correct (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.08" MEAN_2="0.0" ORDER="231" SD_1="0.28" SD_2="0.0" SE="0.0" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.30532483384403214" CI_START="-0.14532483384403216" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.08" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.08" MODIFIED="2008-07-23 14:07:22 +0100" MODIFIED_BY="Helen Collins" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.4865093433774611" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.6958714496234264">
<NAME>Four-Choice Reaction Time (FCRT) transform reaction time (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.30532483384403214" CI_START="-0.14532483384403216" EFFECT_SIZE="0.08" ESTIMABLE="YES" MEAN_1="0.06" MEAN_2="-0.02" ORDER="232" SD_1="0.25" SD_2="0.31" SE="0.1149637624065369" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.09" MODIFIED="2008-07-23 14:07:38 +0100" MODIFIED_BY="Helen Collins" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Four-Choice Reaction Time (FCRT) transform incorrect (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-0.8" MEAN_2="0.0" ORDER="233" SD_1="0.29" SD_2="0.0" SE="0.0" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.879695526299821" CI_START="-0.999695526299822" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.94" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.10" MODIFIED="2008-07-23 14:07:56 +0100" MODIFIED_BY="Helen Collins" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.19585770634295055" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.293443520252479">
<NAME>Continuous Attention Test (CAT) correct ( changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.879695526299821" CI_START="-0.999695526299822" EFFECT_SIZE="1.94" ESTIMABLE="YES" MEAN_1="0.67" MEAN_2="-1.27" ORDER="234" SD_1="2.15" SD_2="4.73" SE="1.4998722167793719" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1705524500077098" CI_START="-1.5505524500077097" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.11" MODIFIED="2008-07-23 14:33:56 +0100" MODIFIED_BY="Helen Collins" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.7843095566497005" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.27370731430493545">
<NAME>Countinous Attention Test (CAT) incorrect ( changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1705524500077098" CI_START="-1.5505524500077097" EFFECT_SIZE="-0.18999999999999995" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-0.81" ORDER="235" SD_1="2.01" SD_2="1.32" SE="0.694172168845741" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.03089364304182344" CI_START="-0.11089364304182345" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.04" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.12" MODIFIED="2008-07-23 14:34:09 +0100" MODIFIED_BY="Helen Collins" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.26878643392225265" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.1058616262018193">
<NAME>Countinous Attention Test (CAT) error index (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.03089364304182344" CI_START="-0.11089364304182345" EFFECT_SIZE="-0.04" ESTIMABLE="YES" MEAN_1="-0.02" MEAN_2="0.02" ORDER="236" SD_1="0.06" SD_2="0.11" SE="0.036170890690351176" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.8063415888145133" CI_START="-0.48634158881451317" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.66" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.13" MODIFIED="2008-07-23 14:34:19 +0100" MODIFIED_BY="Helen Collins" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.2591347036915078" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.1284387153171203">
<NAME>Digit-symbol substitution (DSS) correct (change from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8063415888145133" CI_START="-0.48634158881451317" EFFECT_SIZE="0.66" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="-0.33" ORDER="237" SD_1="1.61" SD_2="1.23" SE="0.5848789048455529" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.4139995193397598" CI_START="0.006000480660240226" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.21000000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.14" MODIFIED="2008-07-23 14:34:37 +0100" MODIFIED_BY="Helen Collins" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.04363140075754271" Q="0.0" RANDOM="NO" SCALE="0.37" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="99.99999999999999" Z="2.0176147379440983">
<NAME>Digit-symbol substitution (DSS) reaction time correct (change from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4139995193397598" CI_START="0.006000480660240226" EFFECT_SIZE="0.21000000000000002" ESTIMABLE="YES" MEAN_1="0.05" MEAN_2="-0.16" ORDER="238" SD_1="0.2" SD_2="0.3" SE="0.10408329997330663" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.48634158881451317" CI_START="-1.8063415888145133" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.66" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.15" MODIFIED="2008-07-23 14:34:52 +0100" MODIFIED_BY="Helen Collins" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.2591347036915078" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.1284387153171203">
<NAME>Digit-symbol substitution (DSS) incorrect (change from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.48634158881451317" CI_START="-1.8063415888145133" EFFECT_SIZE="-0.66" ESTIMABLE="YES" MEAN_1="-0.33" MEAN_2="0.33" ORDER="239" SD_1="1.61" SD_2="1.23" SE="0.5848789048455529" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.4384271606685549" CI_START="-1.598427160668555" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.58" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.16" MODIFIED="2008-07-23 14:35:09 +0100" MODIFIED_BY="Helen Collins" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.26433205031202966" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.1162105204332762">
<NAME>Scanning Memory Sets (SMS) three digits correct (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4384271606685549" CI_START="-1.598427160668555" EFFECT_SIZE="-0.58" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="0.5" ORDER="240" SD_1="1.08" SD_2="1.44" SE="0.5196152422706632" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.13279692985073735" CI_START="-0.05279692985073734" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.04" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.17" MODIFIED="2008-07-23 14:35:25 +0100" MODIFIED_BY="Helen Collins" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.39820017938383423" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.8448400125705154">
<NAME>Scanning Memory Sets (SMS) three digits reaction time correct (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.13279692985073735" CI_START="-0.05279692985073734" EFFECT_SIZE="0.04" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="-0.02" ORDER="241" SD_1="0.1" SD_2="0.13" SE="0.047346242371139304" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.6721565264505358" CI_START="-1.6921565264505358" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.009999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.18" MODIFIED="2008-07-23 14:35:18 +0100" MODIFIED_BY="Helen Collins" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.9907036616638841" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.00000000000001" Z="0.011651495884724295">
<NAME>Scanning Memory Sets (SMS) four digits correct (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6721565264505358" CI_START="-1.6921565264505358" EFFECT_SIZE="-0.009999999999999995" ESTIMABLE="YES" MEAN_1="0.08" MEAN_2="0.09" ORDER="242" SD_1="2.27" SD_2="1.92" SE="0.8582588964486959" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.11562640376005771" CI_START="-0.13562640376005772" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.01" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.19" MODIFIED="2008-07-23 14:35:33 +0100" MODIFIED_BY="Helen Collins" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.8760209689820685" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.1560152902477031">
<NAME>Scanning Memory Sets (SMS) four digits reaction time (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.11562640376005771" CI_START="-0.13562640376005772" EFFECT_SIZE="-0.01" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.01" ORDER="243" SD_1="0.18" SD_2="0.13" SE="0.06409628174343138" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.2654298449378896" CI_START="-1.9654298449378897" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1499999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.20" MODIFIED="2008-07-23 14:35:42 +0100" MODIFIED_BY="Helen Collins" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="0.8894688828096441" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.13897629287235466">
<NAME>Scanning Memory Sets (SMS) five digits correct (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.2654298449378896" CI_START="-1.9654298449378897" EFFECT_SIZE="0.1499999999999999" ESTIMABLE="YES" MEAN_1="1.25" MEAN_2="1.1" ORDER="244" SD_1="3.36" SD_2="1.64" SE="1.0793207740673452" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.11609099030186865" CI_START="-0.11609099030186865" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.21" MODIFIED="2008-07-23 14:35:50 +0100" MODIFIED_BY="Helen Collins" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Scanning Memory Sets (SMS) five digits reaction time (changes from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.11609099030186865" CI_START="-0.11609099030186865" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.01" MEAN_2="-0.01" ORDER="245" SD_1="0.15" SD_2="0.14" SE="0.05923118547972287" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.083105270160861" CI_START="-4.283105270160862" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.22" MODIFIED="2008-07-23 14:36:00 +0100" MODIFIED_BY="Helen Collins" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.24249491453915784" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.168773514084327">
<NAME>Homocysteine level mcom/L (change from baseline at week 4)</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours folic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.083105270160861" CI_START="-4.283105270160862" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-0.4" MODIFIED="2008-06-05 15:01:14 +0100" MODIFIED_BY="[Empty name]" ORDER="246" SD_1="3.11" SD_2="3.58" SE="1.3689564151815303" STUDY_ID="STD-Pathansali-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2008-07-23 14:37:11 +0100" MODIFIED_BY="Helen Collins" NO="9">
<NAME>Folic acid with or without vitamin B12 in healthy people</NAME>
<CONT_OUTCOME CHI2="0.015098696586492292" CI_END="4.671556136553937" CI_START="-4.139625360005979" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2659653882739784" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2008-07-23 14:36:16 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="0.9022046972060561" P_Q="1.0" P_Z="0.9058117577941185" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="77" UNITS="" WEIGHT="100.0" Z="0.11832297004771263">
<NAME>Memory, immediate recall</NAME>
<GROUP_LABEL_1>folic acid +B12</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid +B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.754878535972862" CI_START="-6.8748785359728615" EFFECT_SIZE="-0.06000000000000005" ESTIMABLE="YES" MEAN_1="3.23" MEAN_2="3.29" ORDER="247" SD_1="11.61" SD_2="9.83" SE="3.477042736360338" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="41.791894951075285"/>
<CONT_DATA CI_END="6.274473875463843" CI_START="-5.274473875463843" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="5.7" ORDER="248" SD_1="15.0" SD_2="15.3" SE="2.946214277921511" STUDY_ID="STD-Eussen-2006" TOTAL_1="50" TOTAL_2="56" WEIGHT="58.208105048924715"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3277337120905485" CI_END="1.8027203154240945" CI_START="-1.3390403436837002" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.23183998587019722" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.02" MODIFIED="2008-07-23 14:36:34 +0100" MODIFIED_BY="Helen Collins" NO="2" P_CHI2="0.5669967622510295" P_Q="1.0" P_Z="0.7723798978004015" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="77" UNITS="" WEIGHT="100.00000000000001" Z="0.2892632964669579">
<NAME>Memory, delayed recall</NAME>
<GROUP_LABEL_1>folic acid +B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid +B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.17008668141485" CI_START="-2.8500866814148496" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="YES" MEAN_1="0.66" MEAN_2="1.0" ORDER="249" SD_1="2.86" SD_2="4.99" SE="1.2806800029052028" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="39.16595894997903"/>
<CONT_DATA CI_END="2.6140477754293623" CI_START="-1.414047775429362" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.0" ORDER="250" SD_1="5.6" SD_2="4.9" SE="1.0275942779132239" STUDY_ID="STD-Eussen-2006" TOTAL_1="50" TOTAL_2="56" WEIGHT="60.834041050020986"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.115386795318277" CI_END="1.72556844599672" CI_START="-0.8135998254151429" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4559843102907886" ESTIMABLE="YES" I2="67.9012570284122" I2_Q="0.0" ID="CMP-009.03" MODIFIED="2008-07-23 14:36:50 +0100" MODIFIED_BY="Helen Collins" NO="3" P_CHI2="0.07755635004278838" P_Q="1.0" P_Z="0.481469276950226" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="76" UNITS="" WEIGHT="100.0" Z="0.7039413935243829">
<NAME>Memory, word recognition</NAME>
<GROUP_LABEL_1>folic acid +B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.080650142914388" CI_START="-0.24065014291438858" EFFECT_SIZE="1.42" ESTIMABLE="YES" MEAN_1="0.56" MEAN_2="-0.86" ORDER="251" SD_1="2.5" SD_2="2.79" SE="0.8472860501587707" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="58.44759958149951"/>
<CONT_DATA CI_END="1.0695337545504089" CI_START="-2.8695337545504085" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.7" ORDER="252" SD_1="4.6" SD_2="5.68" SE="1.004882625438957" STUDY_ID="STD-Eussen-2006" TOTAL_1="50" TOTAL_2="55" WEIGHT="41.55240041850049"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.16978683752524504" CI_END="0.057186615823235525" CI_START="-0.1783019815546197" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.060557682865692096" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.04" MODIFIED="2008-07-23 14:37:11 +0100" MODIFIED_BY="Helen Collins" NO="4" P_CHI2="0.918610220031441" P_Q="1.0" P_Z="0.3134356218831288" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="473" TOTAL_2="490" UNITS="" WEIGHT="100.0" Z="1.0080392743051452">
<NAME>Verbal ability</NAME>
<GROUP_LABEL_1>folic acid + B12</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid+B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.166266153427656" CI_START="-4.306266153427656" EFFECT_SIZE="0.43000000000000005" ESTIMABLE="YES" MEAN_1="0.28" MEAN_2="-0.15" ORDER="253" SD_1="7.56" SD_2="7.48" SE="2.4165067270555576" STUDY_ID="STD-Bryan-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="0.061802718058196454"/>
<CONT_DATA CI_END="0.057874715261547235" CI_START="-0.17787471526154724" EFFECT_SIZE="-0.06" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.06" ORDER="254" SD_1="0.86" SD_2="0.86" SE="0.060141265957603274" STUDY_ID="STD-Durga-2007" TOTAL_1="405" TOTAL_2="413" WEIGHT="99.77884243302009"/>
<CONT_DATA CI_END="2.349560073368411" CI_START="-3.5495600733684114" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.9" ORDER="255" SD_1="7.63" SD_2="7.85" SE="1.5049052414402329" STUDY_ID="STD-Eussen-2006" TOTAL_1="50" TOTAL_2="56" WEIGHT="0.15935484892171434"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2008-07-23 14:37:23 +0100" MODIFIED_BY="Helen Collins" NO="10">
<NAME>Folic acid with or without vitamin B12 for cognitive impairment and dementia</NAME>
<CONT_OUTCOME CHI2="0.2584181480571635" CI_END="1.0534576924747563" CI_START="-0.4492196814852209" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3021190054947677" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.01" MODIFIED="2008-07-23 14:37:23 +0100" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="0.6112090371181682" P_Q="1.0" P_Z="0.4306286077837309" Q="0.0" RANDOM="NO" SCALE="2.2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="84" UNITS="" WEIGHT="100.0" Z="0.7881164381338117">
<NAME>MMSE</NAME>
<GROUP_LABEL_1>folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours folic acid + B12</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2142059386479422" CI_START="-0.4342059386479424" EFFECT_SIZE="0.38999999999999996" ESTIMABLE="YES" MEAN_1="0.04" MEAN_2="-0.35" ORDER="257" SD_1="2.58" SD_2="2.36" SE="0.42052096117539584" STUDY_ID="STD-Clarke-2003" TOTAL_1="72" TOTAL_2="66" WEIGHT="83.0998087489938"/>
<CONT_DATA CI_END="1.6976370010371902" CI_START="-1.9576370010371904" EFFECT_SIZE="-0.13" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.22" ORDER="256" SD_1="3.3" SD_2="2.67" SE="0.9324849923025921" STUDY_ID="STD-Connelly-2008" TOTAL_1="23" TOTAL_2="18" WEIGHT="16.900191251006213"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>THF: Tetra Hydro Folate<BR/>Met: Methionine<BR/>SAMe: S-Adenosylmethionine<BR/>PC: Phosphatidyl Choline<BR/>PE: Phosphatidyl Ethanolamine<BR/>
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiYAAAGQCAIAAAAV1zzkAABzgUlEQVR42uydd1wUx///P7HFXrFX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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2008-07-23 14:38:27 +0100" MODIFIED_BY="Helen Collins"/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>